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Abstract 
Glycolipids from the cell wall of Gram-positive bacteria have been the topic of my PhD. 
It is well known that many bacterial glycolipids (e.g. LPS, TDMs and PIMs) have 
profound immunological effects, and therefore the characterisation, biological testing 
and synthesis of gram-positive bacterial glycolipids is of interest. The first part of this 
thesis includes a description of the extraction and characterisation of glycolipids from 
gut bacteria including Bifidobacterium and Lactobacillus genus and the second part 
focussed on the chemical synthesis of Streptococcus sp. DSM 8747 glycolipids and 
lipoteichoic acid analogues (LTA).  
Members of the genus Lactobacillus are common in the gut microbiota and are often 
used as probiotics. As lactobacilli are known to have benefits to human health, 
compounds on its surface are of high interest. To date, the structures of the glycolipids 
from L. plantarum have not been conclusively assigned. Thus, for the first time, the full 
characterisation of the four principal glycolipids of the L. plantarum cell wall was 
reported using sugar, linkage and FAME analysis, as well as ESI-MS/MS and 1D- and 
2D-NMR spectroscopy. The major glycolipids were identified as: α-D-Glcp-diglyceride, 
α-D-Galp-(1→2)-α-D-Glcp-diglyceride, β-D-Glcp-(1→6)-α-D-Galp-(1→2)-6-O-acyl-α-
D-Glcp-diglyceride and β-D-Glcp-(1→6)-α-D-Galp-(1→2)-α-D-Glcp-diglyceride. These 
glycolipids showed weak activation of murine bone marrow macrophages in an initial 
biological screen. 
After having identified the structures of the glycolipids from L. plantarum, the 
glycolipids from Bifidobacterium, a dominant member of the gut microbiota in infants, 
were extracted. Bifidobacteria are considered to be important in the development of a 
healthy immune system and they are believed to exhibit anticancerous properties, 
alleviate the symptoms of irritable bowel syndrome, and are thought to reduce atopic 
disease. Despite this, the chemical nature of immunomodulatory compounds on the 
surface of bifidobacteria has not been well documented. Thus, glycolipids were 
extracted from B. longum subsp. infantis, fractionated chromatographically and 
iv 
 
analyzed using NMR spectroscopy, constituent sugar and linkage analysis, and fatty 
acid analysis. These analyzes revealed a novel glycolipid, containing an unprecedented 
mixed acetal moiety and a galactofuranose moiety as a head group. However, like L. 
plantarum glycolipids, bifidobacterial glycolipids were shown only to induce little 
macrophage activity when tested. 
Having successfully characterised a novel glycolipid present in bifidobacteria, 
analogues of this glycolipid as well as poly(glycerophosphate) lipotechoic acids 
analogues (LTAs) were then synthesised. Much debate still remains about the role of 
LTAs during Gram-positive bacterial infection. This is partly due to differences in the 
biological activities of extracted versus synthesised LTAs and highlights the need for 
structurally defined non-contaminated LTAs when investigating the effect of these 
glycolipids on the innate immune response. An efficient synthesis of the core 
lipoteichoic acid (LTA) anchor of the Streptococcus species DSM 8747, and derivatives 
thereof, was achieved. These Streptococcus glycolipids contain a galactofuranose 
moiety and thus have similarities to the novel glycolipid that was found in 
bifidobacteria. The syntheses, which commence with readily available D-galactose, are 
short (7-9 steps), convergent, and high-yielding (33-37% overall yield). In total 11 
different targets were synthesised. The biological activity of these compounds was also 
investigated, with several analogues (particularly the sn-1,2-di-acylglycerol LTA 
anchors) found to induce macrophage activation.  
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Glycoglycerolipid nomenclature
a
 
The sn (for stereospecifically numbered) notation system will be used in this thesis in 
order to simplify glycerol nomenclature. As glycerol is prochiral, depending on the 
substitution on the primary hydroxyls, the S or R prefix used in the Cahn-Ingold-Prelog 
designation often changes, causing confusion.
1
 
In order to determine the stereospecific numbering, the following convention is used: 
the glycerol unit is drawn in the Fischer projection with the secondary hydroxyl to the 
left. IUPAC has defined the sn numbering as explained in the subsequent quote. 
“Esters, ethers and glucose derivatives of glycerol are designated by a prefix, denoting 
the substituent, preceded by a locant. The carbon atoms of glycerol are numbered 
stereospecifically, with carbon atom 1 at the top of the formula shown below. To 
differentiate this numbering system from others that have been used, the glycerol is 
always accompanied by the prefix “sn” in systematic and abbreviated names.”b 
 
 
 
 
 
                                                 
a
 Adapted from 1. Nomenclature of Lipids. In Biochemical Nomenclature and Related Documents, 2nd 
Edition, Liébecq, C., Ed. Portland Press: London, 1992; p 10. 
b
 Quoted from: http://www.chem.qmul.ac.uk/iupac/misc/glylp.html 
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Chapter 1 
 
Introduction 
 
1.1 Gram-Positive and Gram-Negative Bacteria 
Bacteria are prokaryotic organisms populating most environments on earth. They need 
to survive a large range of environments (high or low temperature, pH etc.) and thus 
their cell walls need to be equipped to tolerate harsh exterior conditions.
2
 Some bacteria 
are pathogenic while others are beneficial and the study of their surface components is 
important in order to understand the mechanisms involved in their beneficial/pathogenic 
effects.
3,4
 The surface components of bacteria can be classified using Gram staining.
5
 
Gram-positive bacteria possess a thick peptidoglycan (PG) layer which stains a dark 
violet colour, whereas Gram-negative bacteria stain pink due to the counterstain 
(saffranin). Both Gram-positive and Gram-negative bacteria can have beneficial and 
pathogenic effects that can be related to the surface components. The introduction will 
focus on Gram-positive bacteria and their beneficial effects. In Section 1.2 and 1.3 the 
Gram-negative and Gram-positive cell walls will be examined. Then, the specific Gram-
positive structural components and the biosynthesis of these components will be 
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considered. Finally, published chemical synthese of structural components and the 
biological activity of some structures will be discussed. 
1.2 Gram-Negative Bacteria 
The Gram-negative cell wall consists of two phospholipid membranes sandwiching a 
thin PG layer (Figure 1.1).
6
 The latter usually contains alternating repeating units of N-
acetylmuramic acid (NAM) and N-acetylglucosamine (NAG). PG and smaller 
molecules such as amino acids, peptides, mono- and oligosaccharides, are situated in the 
periplasmic place (between both membranes).
7
 The two membranes are composed of 
phospholipids and proteins. The cell wall components are synthesised in the inner 
membrane or cytoplasmic membrane.
6
 Small molecules such as small saccharides 
diffuse through the outer membrane, while bigger molecules such as proteins are 
blocked out.
8
 The outer membrane also anchors lipopolysaccharides (LPS), antigenic 
endotoxins, that help solidify the outer membrane and protect it against bile salts and 
other noxious compounds.
6,7
 This membrane is covalently attached to the PG layer with 
a lipoprotein. Often, the outer membrane is covered by a proteineous capsular layer (A-
layer).
9
 
1.3 Gram-Positive Bacteria 
The Gram-positive cell wall is distinguished from the Gram-negative cell wall by 
having only a single phospholipid membrane and a PG layer that is much thicker 
(Figure 1.2). The thick PG strengthens the cell structure as a major constituent of the 
cell wall and protects the cell against osmotic pressure.
10
 The amino sugars present in 
the peptidoglycan layer are highly conserved between bacteria. Differences between the 
peptide compositions are observed between strains and species. In contrast to Gram-
negative bacteria containing LPS, Gram-positive bacteria usually possess lipoteichoic 
acids (LTAs) that are anchored in the phospholipid layer. Some Gram-positive bacteria 
also hold wall teichoic acids (WTAs), polymers of ribitol phosphates and/or glycerol 
phosphates, which are not present in Gram-negative bacteria. These WTAs are 
3 
 
covalently attached to the NAM and are interwoven in the PG layer. LTA is believed to 
promote autolysis at the septum during binary fission while WTA would be involved in 
autolysis inhibition in the rest of the cell.
11,12
 Capsular polysaccharides (CPS) are 
attached to different surface structures on the PG such as the peptides or NAG. They are 
believed to play a role in the structural stability of the cell.
11
 In contrast to CPS, 
exopolysaccharides (EPS) can also be produced in some bacteria as a slime, and are 
believed to have a protective function against the environment such as preventing 
dessication and phage attack, and to be involved in cell adhesion.
13
 Finally, the 
phospholipid bilayer, containing proteins and glycolipids, holds the cytoplasm from the 
exterior of the cell, keeping ions and other molecules from diffusing.
14
  
1.4 Gram-Positive Cell Wall Components and 
Biosynthetic Pathways 
The structure of Gram-positive cell wall components is often strain/species specific.
14
 In 
the next section, a general review of the component structures excluding proteins and 
the peptidoglycan layer will be presented. As the literature on Gram-positive bacteria is 
abundant (SciFinder
®
 ca. 25727 hits), only examples of the components, extracted in 
specific bacteria, will be given. Also, the sections on EPS/CPS, WTA and 
phosphoglycerolipids are important in order to understand how all the components are 
related and why the decision of choosing glycolipids and LTAs for extraction and 
synthesis was made. However, as the other components are beyond the scope of this 
work, the overview will be less extensive.  
1.4.1 Capsular Polysaccharides and Exopolysaccharides 
CPS and EPS are two types of glycan repeating units found in Gram-positive bacteria. 
These polysaccharides have an organised structure, and they can be very diverse. For 
example, 93 different CPS were detected for S. pneumonia.
15
 Although these 
polysaccharides are very diverse, each individual polymer has an organised structure of 
distinct repeating units. CPS can be liberated after phosphodiester cleavage from the 
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cell wall, whereas EPS are released as a slime, therefore the distinction between these 
polysaccharides is not always apparent during isolation.
16,17
 Furthermore, the CPS and 
EPS biosynthetic pathways have been found to be similar, adding to the confusion.
15
 
 
Figure 1.1 Gram-negative bacterial cell wall. 
 
Figure 1.2 Gram-positive bacterial cell wall. 
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Both CPS and EPS fall into two general classes of polysaccharides: homo- and hetero-
polysaccharides. Homopolysaccharides, consisting of a single type of sugar residue are 
usually synthesised extracellularly with glucansucrases or fuctansucrases.
18
 In contrast, 
heteropolysaccharides, that comprise several different sugar residues, are synthesised 
intra- and extracellularly. First, the repeating unit is synthesised intracellularly and 
transferred to undecaprenol, in the cell membrane, by a glycosyl-1-phosphate 
transferase (GTF). Additional monosaccharides are added to this structure with specific 
GTFs and the oligosaccharides are transported outside the cell with a flipase to be 
subsequently polymerised with a polymerase.
15,18
 EPS are then released while CPS are 
covalently attached to the PG. 
1.4.1.1 Extraction and Analysis 
As both polysaccharides have different locations, they are obtained for analysis or 
biological testing in different ways. EPS are usually precipitated in 60% ethanol from 
the bacterial culture supernatant while CPS first needs to be released from the cell wall 
with pepsin, trypsin and N-acetylmuramidase before extraction with trichloroacetic acid 
(TCA). The analysis of both polysacchararides is similar and involves constituent sugar 
and glycosyl linkage analysis, NMR and MS. Previous analyzes showed that the EPS 
composition as well as the amount of EPS differ depending on the strain, species and 
media.
19
 Figure 1.3 shows an example of an EPS precipitated with ethanol from L. 
rhamnosus growth medium.
20
  
1.4.2 Wall Teichoic Acids 
WTAs are polymers of poly(alditol phosphates) and/or poly(saccharides phosphates) 
that are covalently bound to the PG layer. In this document, the teichoic acids (WTAs 
and LTAs) are segregated according to their differences in structure (The glycerol 
stereochemistry differs between WTAs and LTAs), anchoring (LTAs are anchored in 
the membrane while WTAs are covalently bound to the cell surface) and biosynthetic 
pathway (the WTA pathway utilises undecaprenol as membrane anchor before transfer 
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while the LTA pathway doesn’t utilise undecaprenol). Interestingly, WTA is considered 
a virulence factor, as it was found to be essential for colonisation.
21,22
 
In the first step of the biosynthetic pathway of S. pneumonia WTA, poly(prenyl 
phosphate) (Prenol-P), anchored in the cell membrane, is coupled successively to NAG 
and N-acetylmannosamine (ManNAc).
15
 Then sn-glycerol 3-phosphate is polymerised 
on ManNAc and the glycerol moieties are partially glucosylated. Alanines are also 
partially transferred from the LTA to the glycerol catalysed by an ATP-binding cassette 
transporter (ABC).
21,23
 The WTA is finally covalently coupled to the PG layer on the 
NAM moiety (O-6).
14
 
 
Figure 1.3 Repeating unit of an L. Rhamnosus exopolysaccharide.
20
 
1.4.2.1 Extraction and Analysis 
WTAs are usually extracted after LTA extraction. Here, the pellet remaining from 
previous LTA extraction can be re-extracted using TCA/water (10%, v/v). Further 
purification steps are then required to obtain pure WTAs (e.g. anion exchange 
chromatography with DEAE-sephadex).
24
 In Figure 1.4, Streptococcus pneumonia 
WTA is represented as an example.
24
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Figure 1.4 Teichoic acid from Streptococcus pneumonia.
24
 
1.4.3 Fatty Acids 
Fatty acids are carboxylic acids containing long aliphatic chains and they are often 
attached to phospholipids, glycoglycerolipids or LTAs as part of the membrane and thus 
are usually not found as free fatty acids in the cell. Although most bacteria are known to 
incorporate exogenous fatty acids in their membranes,
25
 bacteria also utilise fatty acids 
which are de novo biosynthesised, even though these fatty acids require much more 
energy for their synthesis. The fatty acid biosynthetic pathway adapted from Chan and 
Vogel for the Gram-negative bacteria Escherichia coli is believed to be similar to 
Gram-positive bacteria (Figure 1.5).
26
 First, Apo-Acyl carrier protein (Apo-ACP) is 
converted into an acceptor thiol (holo-ACP) through ACP synthase. The coupling of 
HCO3
-
 1 and acetyl-CoA 2 is catalysed by acetyl-CoA carboxylase and malonyl-CoA 3 
is obtained. Holo-APC is then transferred to malonyl-CoA 3 by a Malonyl-CoA-ACP 
transacetylase (FabD). The next step involves β-oxoacyl synthase III (FabH) for the 
combination of malonyl-ACP 4 and acetyl-CoA 2 to form β-oxobutyryl-ACP 5 in a first 
step designed as “a” (pink pathway). Step “b” represents the reduction of ketone 5 into 
alcohol 6 and is made by the β-oxoacyl reductase (FabG) with NADPH. Alkene 7 is 
obtained by dehydration with a β-hydroxyacetyl dehydratase (FabZ, step c). Here, cis-
product 9 is obtained if FabA is present (step f, blue pathway). However, when FabZ is 
present, trans-product 7 results (black pathway). In the blue pathway, the hydrogenation 
step is omitted as the enzyme doesn’t hydrogenate the cis products. Then elongated 
compound 10 is formed as the molecule is further elongated with FabB and acid 4. 
After this, elongated 10 re-enters the black cycle (step h). Finally, hydrogenation of 
8 
 
alkene 7 with NADH and an enoyl-reductase (FabI) gives hydrogenated product 8 (step 
d). This intermediate can then be extended with malonyl-ACP 4 and β-oxoacyl synthase 
(FabF). The four last steps (elongation, reduction, deshydratation and hydrogenation) 
can be repeated until the chain reaches a proper length for being introduced into the 
membrane with acyltransferases. This length is controlled by enzymes present in the 
different bacteria. Here, a range of fatty acid chain lengths are introduced into the lipids. 
The vast range of fatty acids in the microbiome is due to the effect of the enzyme’s 
substrate specificity in each species.
27
  
1.4.3.1 Extraction and Analysis 
Usually, fatty acid analysis involves a simple transesterification from the cell biomass 
using sodium methoxide and methanol, and then treatment with HCl in MeOH before 
injection in the gas chromatograph (GC) and gas-chromatograph mass-spectrometer 
(GC-MS).
28
 In bacteria, fatty acid analysis usually shows a mixture of different fatty 
acid chain lengths between C12 to C20, saturated or monounsaturated.
29
 Examples of 
fatty acids found in bacteria are presented in Figure 1.6. 
9 
 
 
Figure 1.5 Fatty acid biosynthesis in E. coli.
26
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Figure 1.6 Fatty acids examples. 
1.4.4 Glycolipids and Phospholipids 
Glycoglycerolipids are neutral lipids with single sugars or short oligosaccharides. They 
are related to phospholipids and LTAs through their biosynthetic pathway. The 
Staphylococcus aureus biosynthetic pathway is similar to most Gram-positive bacteria 
pathways (Figure 1.7).
30-32
  
In the first biosynthetic step, glycerol is selectively phosphated by the action of a 
glycerol kinase Figure 1.7. The phosphate is transferred from adenosine triphosphate 
(ATP) to the C-3 of the glycerol to give sn-glycerol 3-phosphate 11 and release 
adenosine diphosphate (ADP) to be recycled. Subsequently, two acyl groups are 
transferred from an acylated acyl carrier protein (Acyl-ACP) to sn-glycerol 3-phosphate 
with acyltransferases. Following this step, the coenzyme cytidine triphosphate (CTP) 
reacts with 3-phosphatidic acid (PA) 12 to form cytidine diphosphate diacylglycerol 
(CDP-DAG). In a first instance, CDP-DAG can be the precursor for phosphatidylserine 
(PS) and phosphatidylethanolamine (PE) after the elimination of CO2. Also, 
phosphatidyl glycerophosphate 13 can be formed following the reaction of CDP-DAG 
with sn-glycerol 3-phosphate via the action of phosphatidylglycerolphosphate synthase. 
Phosphatidyl glycerol 14 is obtained after the elimination of a phosphate via the action 
of phosphatidylglycerolphosphate phosphatase, and used to either build cardiolipin 
11 
 
(Figure 1.7) or to introduce sn-glycerol 1-phosphate to the glycosyldiglyceride (Figure 
1.8). 
Monoglucosyldiglyceride 15 is generated via YpfP enzyme which adds a first glucose 
residue to DAG via an activated form of glucose (UDP-Glc) and UDP is released 
(Figure 1.8). This step is repeated to form a diglucosyldiglyceride 16, which then enters 
the membrane to act as an anchor for LTA. The condensation of diglucosyldiglyceride 
16 with phosphatidyl glycerol 14 to release DAG, is catalysed via LTA polymerase 
(LtaS) and thus form the lipoteichoic acid 17.
33
 The LTA phosphoglycerol chain is then 
further elongated with multiple units of sn-glycerol 1-phosphate from phosphatidyl-
glycerol 14.
34
 From there the LTA can be alanylated which requires a D-alanine-D-
alanyl carrier protein ligase (AMP) and a D-alanyl-carrier protein (Dcp).
35
 
 
Figure 1.7 LTA biosynthetic pathway for S. aureus, from glycerol to phosphatidyl 
glycerol 14.
30,32
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Figure 1.8 LTA biosynthetic pathway for Staphylococcus aureus, from 
phosphatidyl glycerol 14 to the LTAs 17.
30,32
 
1.4.4.1 Phosphoglycerolipids 
Most of the research on lipids has focussed on phosphoglycerolipids
36
 as the 
phosphoglycerolipids are a major part of bacterial membranes (phospholipid layer). The 
major phospholipids found in Gram-positive bacterial membranes are phosphatidyl 
glycerol and phosphatidylethanolamine (PE). Although PE (Figure 1.9) is not found in 
all Gram-positive bacteria, it can form a significant part of the cell wall and cardiolipin 
(CL) can also be present.
29,37
 An example of phosphoglycerolipid cell wall composition 
13 
 
was published by Golfine et al.
38
 They detected PE (35%), phosphatidyl glycerol (48%), 
CL (11%) and glucosaminyl phosphatidylglycerol (6%) in the membrane of Bacillus 
megaterium. 
 
Figure 1.9 Phosphatidylethanolamine (PE). 
1.4.4.1.1 Extraction and Analysis 
For analysis purposes, phospholipids are extracted with CHCl3/MeOH/H2O and purified 
using silica gel chromatography. Usually, their analysis involves the comparison of 
standards with LC/MS spectra. 
39
 
1.4.4.2 Glycoglycerolipids 
Bacterial glycoglycerolipids have been widely studied.
40
 They are usually composed of 
carbohydrate residues for which the anomeric center is glycosidically bound to the 3-
position of sn-1,2-diglycerides. To determine the complete structure of such 
compounds, the nature of the constituent sugars, the linkage between the residues, the 
linkage between the saccharide and the glycerol, the location and identification of the 
fatty acids and the stereochemistry of the sugar must be known. There are major 
differences in how the chemical analyzes are performed today compared to how they 
were conducted in the past. This is discussed in more detail in the next section. 
Glycoglycerolipids are neutral lipids such as monoglycosyldiglyceride (MGDG) and 
diglycosyldiglyceride (DGDG), and are mostly found in bacteria lacking PE. As 
glycoglycerolipids usually don’t form bilayer structures, they are believed to provide 
nonleaky discontinuity in the membrane. Other biological functions such as membrane 
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fusion for cell division and the integration of non-lipid components into the membrane 
can be assisted by these glycoglycerolipids.
37
  
1.4.4.2.1 Extraction and Analysis 
As glycolipids are not covalently attached to the cell wall, they are readily extracted 
using CHCl3/MeOH/H2O mixtures from fresh or lyophilised cells.
41,42
 In the past, 
glycoglycerolipids were extracted and analyzed using different staining methods, 
enzymatic reactions, paper chromatography with or without sodium periodate oxidation 
and sometimes silylation followed by GC.
43-45
 These analyzes led to the discovery that 
DGDGs are the major glycosyldiglyceride type found in bacteria and that MGDG do 
not usually accumulate in significant amounts even though they are biosynthetic 
precursors of diglycosyldiglycerides (Figure 1.8). Five major types of diglycosyl 
diglycerides were found in different bacteria as reviewed by Shaw.
46
 These consisted of 
α-Gal-α-Glc-diglyceride, α-Glc-α-Glc-diglyceride, β-Glc-β-Glc-diglyceride, α-Man-α-
Man-diglyceride and β-Gal-β-Gal-diglyceride. Also, triglycosyldiglycerides (TGDG) 
and tetraglycosyldiglycerides have been extracted in lower amounts in some bacteria. 
Figure 1.10 depicts examples of some of these different glycolipids found prior to 1970. 
As shown in this Figure, the major sugars detected were glucose, galactose and 
mannose. In a few cases, other glycolipids containing different sugars such as 
glucuronic and galacturonic acid were found in few cases. Also, an additional acylation 
at the 6-position of terminal sugars was believed to be due to an extraction artefact 
consisting of acyl migration, however shortly later, it was found that acyl transferases 
can also acylate glycolipids at this position.
47,48
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Figure 1.10 Examples of MGDG, DGDG and TGDGs found in bacteria, as reviewed 
by Shaw.
46
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Today, a few groups have started to revisit the field of bacterial glycoglycerolipids 
using constituent sugar analysis,
49
 glycosyl linkage analysis,
50
 NMR and MS.
51-53
 From 
these studies new structures were sometimes found. Examples of glyceroglycolipids 
found using modern techniques in Propionibacterium propionicum (Figure 1.11a),
51
 
Deinococcus radiodurans (Figure 1.11b), 
52
 c. Arthrobacter scleromae and 
Arthrobacter globiformis (Figure 1.11c)
53
 are given in Figure 1.11. Even though the 
glycolipids found in D. radiodurans and A. scleromae are typical glycoglycerolipids, a 
novel type of glycolipid containing an ether lipid was detected in P. propionicum. This 
finding shows that to revisit the field in glycolipid analysis might shed a new light on 
structures that were not detected before due to the limitations of previous analytic 
methods. 
 
Figure 1.11  Glycolipids found in; a. P. propionicum,
51
 b. D. radiodurans,
52
 c. A. 
scleromae and A. globiformis.
53
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1.4.4.3 Lipoteichoic Acids (LTA) and Lipoglycans 
LTAs are repeating units of alditol phosphates (e.g. glycerol phosphate) anchored to the 
cell membrane by a lipid anchor and they are believed to have roles such as being 
involed in autolysins regulation.
54
 LTAs are present mostly in firmicutes (low guanine 
and cytosine content) while lipoglycans are mostly found in Actinobacteria and 
Tenericutes (high in guanine and cytosine content) making these molecules phylum 
specific.
30
 Lipoglycans, in comparison to LTAs, contain a sugar repeating unit instead 
of an alditol.
54
 The immunological properties of LTAs have given conflicting results, in 
the past, due to contamination of the extracts with other cell wall components.
55
  
1.4.4.3.1 Extraction and Analysis 
LTAs and lipoglycans are usually extracted using hot phenol/water. However, these 
extractions were found to produce less active LTAs
56
 and a milder extraction method 
involving butanol is now usually used.
57
 The purification is difficult and involves 
multiple subsequent columns. By example, Morath et al. used at first a hydrophobic 
interaction chromatography system on an octyl-sepharose column with an increasing 
linear gradient of n-propanol in an ammonium acetate buffer (descending salt gradient). 
Then, an anion exchange chromatographic system with an increasing linear gradient of 
ammonium chloride was utilised with a DEAE-sephacel column. These types of 
chromatographic steps are often slow, even though sample collectors are available. In 
the specific case of the DEAE system, the elution speed is about 25 mL/h while 
collecting usually 6 mL fractions.
58
 Morath et al. collected 65 fractions over a total of 
15 h for one column. Also, detection of these LTAs is problematic as proteins are 
usually detected using a UV-Vis detector. As often LTAs contain also alanines visible 
in the UV-Vis spectrum, other types of detection are required as the ultimate goal is to 
purify LTAs from active lipoproteins. Thus Morath et al. used a phosphate 
determination assay where each individual fraction is determined for its phosphate 
content.
56
 The NMR spectrum measured from such LTAs show broad signals and for 
further analysis the LTAs must be degraded to obtain additional information via NMR 
(such as acetic acid treatment to obtain the glycolipid anchor). Then MS, constituent 
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sugar and linkage analysis as well as fatty acid analysis can be used to gain more 
information.
57
  
Bacterial LTAs are categorised into 4 types (I-IV). Type I is bound covalently to the 
membrane via a glycoglycerolipid (anchor). It consists of a 1,3-linked 
polyglycerophosphate chain. In type II, sugar residues are inserted between the 
glycerophosphate moieties. In contrast to type II, type III contains positively charged 
sugar residues (glucosamine) linked on sn-2 of the glycerol moieties present on the 
chain. Finally, type IV, does not contain a typical polyglycerophosphate chain, but it 
holds choline residues that compensate the negative charges on the phosphates.
59
 Figure 
1.12 shows two types of LTAs found in low G-C content bacteria (Streptococcus 
pneumonia in Figure 1.12a, and S. aureus in Figure 1.12b)
24,60,61
 and a lipoglycan found 
in high G-C content bacteria (Bifidobacteria bifidum var. pennsilvanicus, Figure 
1.12c).
62
 From those different types of LTAs, type I is the most widespread (Figure 
1.12b).
59
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Figure 1.12 a. S. pneumonia lipoteichoic acid,
24
 b. S. aureus lipoteichoic acid,
60
 c. B. 
bifidum var. pennsylvanicus lipoteichoic acid.
62
  
1.5 Chemical Synthesis and Biological Activity of 
Gram-Positive Cell Wall Components 
In this section, the synthesis and biological activity of different cell wall components 
will be discussed. Fatty acids, however, will be excluded from the discussion because 
pure fatty acids are usually bought directly from the supplier in synthesis and the 
literature on the immunological properties of fatty acids focuses mostly on 
polyunsaturated fatty acids and rarely discusses other free fatty acids.
63,64
 Even though 
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phosphoglycerolipids, WTAs, CPS and EPS can be interesting targets for further 
research concerning their biological properties, the glycolipids and lipoteichoic acids 
will be described in more detail as their synthesised structures were reported to be 
biologically active. 
1.5.1 Exopolysaccharides 
The immunological properties of EPS have been thoroughly reviewed by Ruas-Madiedo 
et al.
18
 In order to assess structure activity relationships in EPS, synthesis is necessary. 
Like PG, EPS are composed of long chains and the synthesis of EPS fragments is 
usually made.
65,66
 Scheme 1.1 shows the reported synthesis of a S. aureus EPS fragment 
65. First, glucosamine 23 was selectively protected at the 6-position with a trityl group. 
This step was followed by an improved benzoylation to form benzoylated compound 24 
as the β-anomer which is required for the oxazoline formation. The trityl group was then 
selectively removed and the 6-position was protected with an acetate to form acetylated 
compound 25. To obtain oxazoline 26, FeCl2 was utilised and subsequent coupling with 
thioglycoside 27 gave coupled product 28. After this, the selective deprotection of the 
acetate and the resulting deprotected compound coupling with bromide 29 afforded 
trisaccharide 30. Next, the coupling of trisaccharide 30 with glycosyl acceptor 31 and 
global deprotection gave EPS fragment 32.
65
  
1.5.2 Wall Teichoic Acids 
The study of WTAs immunological properties is of interest as they are believed to be a 
virulence factor.
67-69
 Like EPS, only fragments of WTAs are usually synthesised due to 
their high lengths, yet longer chains might show higher immunological properties. 
Scheme 1.2 shows the retrosynthesis of E. faecalis WTA fragment. Here, Hogendorf et 
al. predicted that target 33 could be assembled from benzylated glycerol 34 and 
phosphoramidites 35, 36 and 37. They successfully synthesised fragment 33 in 14 linear 
steps and 17% overall yield using a solution-phase synthetic strategy.
70
 This strategy 
aims to use, in the future, automated solid phase synthesis to achieve the synthesis of 
longer, hopefully active, polymers. 
21 
 
 
Scheme 1.1 Synthesis of S. aureus EPS fragment.
65
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Scheme 1.2 Retrosynthesis of a Enterococcus faecalis fragment.
70
 
1.5.3 Phospholipids 
Few articles and reviews discuss bacterial phospholipid immunoproperties and those 
that do focus mostly on cardiolipin.
71,72
 Indeed, phospholipids containing usual 
saturated and monounsaturated fatty acids might be used as drug carriers as they are 
biocompatible.
73
 In contrast, the synthesis of phospholipids has been widely covered.
74
 
Scheme 1.3 depicts an example of PA synthesis.
74
 Here 2,3-O-isopropylidene-sn-glycerol 
(-)-38 is esterified with R-COOH using DCC and DMAP, which is then deprotected with 
dimethylboronbromide to form ester 39. Tritylated DAG 40 is then obtained following 
tritylation of the primary alcohol and esterification of the secondary alcohol with a 
different fatty acid (R
1
-COOH). Deprotection of the trityl-group with BF3.OEt2 gave 
DAG 41, which was subsequently phosphorylated with phosphoryl chloride. The final 
PA 42 was obtained after hydrolysis of the chloride. 
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Scheme 1.3 Example of phosphatidic acid synthesis.
74
  
1.5.4 Glycoglycerolipids 
Many glycoglycerolipids have been found to be biologically active where the fatty acid 
chain has an influence on the nature of the activity.
63,75,76
 Glycoglycerolipids extracted 
from natural sources are mixtures of fatty acids with varying chain length and thus to 
gain a comprehensive understanding of structure/function it is necessary to synthesise 
analogues with clearly defined fatty acid chains.
63,77-79
 In this section the immunological 
properties of glycoglycerolipids will be summarised. In an early publication, Naito et al. 
evaluated the activation of mouse macrophage by synthetic glycerolipid liposomes. 
They reported that 3-O-(β-D-cellobiosyl)-1,2-di-O-palmitoyl-sn-glycerol, 3-O-(β-D-
maltosyl)-1,2-di-O-palmitoyl-sn-glycerol and 3-O-(β-D-lactosyl)-1,2-di-O-palmitoyl-sn-
glycerol strengthened the immune system against transplantable tumor cells in 
imprinting control region (ICR) mice and that macrophage seemed to be activated by 
glycoglycerolipids.
80
 Later, Deininger et al. observed the induction of cytokine release 
in whole blood cells by a specific LTA and the LTA anchor 3-O-(β-D-gentiobiosyl)-1,2-
di-O-myristoyl-sn-glycerol. In this case, the LTA derivatives showed a higher activity 
than the glycolipid anchor.
81
 Thereafter, Borrelia burgdorferi glycolipid analogues were 
synthesised and induced IL-2 production in mouse and human iNKT cells.
82
 The 
24 
 
glycolipid tested by Kinjo consisted of synthesised galactosyldiglycerides (Figure 1.13). 
Here they found that the position and length of the lipid mattered for iNKT cells 
activation and that BbGL-11c induced more IL-2 production than the other glycolipids 
tested. 
 
Figure 1.13 Galactosyldiglycerides synthesised and tested by Kinjo et al.
82
 
Furthermore, Kinjo et al. measured the secretion of IFN- by iNKT cells from two 
Streptococcus pneumonia purified glycolipids and five different synthesised analogues 
of α-glucosyldiacyldiglyceride. Here, the synthesised analogues had different fatty acid 
chain lengths and fatty acids positions on the glycerol moiety (sn-1 or sn-2). They found 
that the purified glycolipids were more active than the synthesised ones. In addition, 
only the glucosyldiglyceride analogue containing palmitic acid at the sn-1 position and 
cis-vaccenic acid at the sn-2 position of the glycerol showed significant activity.
78
 The 
same group later compared synthesised analogues of glucosyldiglycerides and 
galactosyldiglycerides. The glucose derivatives induced a higher IL-2 production in 
iNKT cells compared to the galactose derivatives. Also, they demonstrated that in 
addition to the sugar, the type and position of the fatty acid chain influenced IL-2 
production. Indeed, the galactose derivative with palmitic acid on sn-2 and cis-vaccenic 
acid on sn-1 of the glycerol moiety was more active than the galactose derivative with 
cis-vaccenic acid on sn-2 and palmitic acid on sn-1 of the glycerol moiety.
83
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Syntheses of glycosyldiglycerides have been widely reported.
74
 This usually involves 
coupling of a protected sugar moiety to isopropylidene glycerol, deprotection of the 
acetonide, esterification and final deprotection. An example of a forward synthesis is 
shown in Scheme 1.4.
84
 Here per-O-acetylated galactose imidate 43 was first coupled to 
chiral isopropylidene glycerol (+)-38 to form coupled product 44. Then the acetates 
were cleaved and the hydroxyls benzylated to afford benzylated compound 45. Then 
acetonide deprotection gave diol 46 and to obtain diglyceride 47 subsequent 
esterification using octanoyl chloride was undertaken. A final hydrogenation provided 
1,2-di-O-octanoyl-3-O-β-D-galactopyranosyl-sn-glycerol 48. 
In an attempt to simplify the synthesis of glycolipids, Schombs achieved a one pot 
synthesis of 1-O-palmitoyl-2-O-oleoyl-3-O-α-D-galactopyranosyl-sn-glycerol.85 Their 
method (Scheme 1.5) involves the iodination of per-O-trimethylsilylated glucoside 49, 
followed by the addition of diacylglycerol acceptor 50 in the presence of TBAI and 
DIPEA. After deprotection of the silyl groups they obtained glycosyldiglyceride 51 
using acidic resin in an overall yield of 72%. 
1.5.5 Lipoteichoic Acids 
In the past, it has been assumed that LTA is an immunostimulatory component of 
Gram-positive bacteria together with PG and lipopeptides. Indeed, pathogen-pattern 
recognizing receptors (PRRs) such as toll-like receptors (TLRs) recognize pathogen-
associated molecular patterns (PAMPS) on the surface of bacteria and activate innate 
immunity.
86
 In particular, TLR2 is activated by bacterial cell-wall glycopolymers and 
lately, it has been shown that the glycolipid anchor activity is amplified by the LTA 
poly(glycerophosphate) backbone.
81
 However, the study of the immunological 
properties of natural LTAs has been hampered because of the harsh extraction and 
purification conditions resulting in the isolation of artefactual compounds formed from 
LTA breakdown while using the hot phenol extraction method. The analysis can thus be 
misleading. Also, it is known that LTA derivatives extracted from bacteria contain 
active lipoproteins. In order to retain the structural integrity of natural LTAs, improved 
extraction methods using milder solvent (butanol) have been used rather than the hot-
26 
 
phenol extraction.
55
 Even though the problems surrounding the chemical 
characterisation of the LTAs seemed to be solved, the issues related to the purification 
of the LTAs are still remaining. In the past, many reports were published on lipoteichoic 
acid activity,
59,87,88
 yet today most of the LTA activity has actually been assigned to 
lipoprotein contamination.
12
 Hence, the need for clean samples, free of active 
contaminants for biological testing, has pushed forward the synthesis of LTA and LTA 
derivatives.
86
  
A first example of a retrosynthetic strategy is shown in Scheme 1.6. Here, to synthesise 
a fragment of S. aureus LTA, Stadelmaier et al. envisioned that target 52 could be made 
from the ligation of alcohol 53 and phosphoramidite 54. The synthesis of compound 53 
was then anticipated from the coupling of glycerol derivative 34 and phosphoramidites 
55 and 56. Then it was anticipated that regioselectively protected gentiobiosyl-DAG 57 
could form phosphoramidite 54 after protecting group manipulation, esterification and 
reaction with benzyloxybis(diisopropylamino)phosphine. From this strategy, they 
produced both D-alanine and L-alanine derivatives. These monoamphiphilic LTAs were 
then tested on human whole blood cells and found both to stimulate TNF-α production. 
However, differences were observed in the activity where the L-alanine derivative had a 
similar activity compared to the natural purified extract, while D-alanine derivative 
showed a 10 to 100 fold less activity.
89,90
 Later, Stadelmaier et al. also synthesised a 
bisamphiphilic moiety (Figure 1.14) and tested the compounds in the same assay. The 
bisamphiphilic moiety was twice as active as the monoamphiphilic moiety.
77
 As a 
significant effort is required for the synthesis of such derivatives, only few LTA 
fragments were synthesised and tested until now.
86
  
An additional, very interesting example of another synthesis of a specific LTA 
derivative is depicted in Schemes 1.7 and 1.8. The LTA derivative synthesised was 
based on a unique LTA, extracted primarily from Streptococcus sp. DSM 8747, which 
had a structure that differed from S. pneumonia LTA.
91
 This LTA also differed from 
other LTAs due to its single galactofuranose moiety. In most LTAs, the sugar residues 
are usually present in the pyranose form. Due to its peculiar characteristics, a fragment 
of this LTA was synthesised by Qiao et al.
92
 The first part of the chemical synthesis, the 
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synthesis of the galactofuranose building block, is shown in Scheme 1.7 while the 
reminder of the synthesis is depicted in Scheme 1.8.  
 
Scheme 1.4 Synthesis of 1,2-di-O-octanoyl-3-O-β-D-galactopyranosyl-sn-glycerol.84 
 
Scheme 1.5 Synthesis of 1-O-palmitoyl-2-O-oleoyl-3-O-α-D-galactopyranosyl-sn-
glycerol.
85
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Scheme 1.6 Retrosynthetic scheme of Staphylococcus aureus LTA adapted from 
Stadelmaier et al.
77  
 
Figure 1.14 Synthesised biamphiphilic LTA.
77
 
In Scheme 1.7, alkyl glycoside 59 is first formed from galactose 58. Then 
perbenzoylated compound 60 is obtained after treatment of galactofuranose 59 with 
benzoyl chloride in pyridine. Acetate formation of the anomeric position using acetic 
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anhydride and sulfuric acid gave acetylated compound 61 and the acetate was 
subsequently removed to form benzoylated compound 62. Treatment of the 
anomerically deprotected 62 with trichloroacetonitrille and DBU provided imidate 63 
which was next coupled with glycerol hexylidene derivative 64 to form coupled product 
65. The removal of the benzoyl groups and benzylation afforded galactofuranoside 
derivative 66. A final removal of the diol protecting group with p-toluenesulfonic acid 
gave precursor 67. In Scheme 1.8, diol 67 is esterified to yield to ester 68 then the 
benzyl-groups are removed to give deprotected 69. To obtain compound 70 the selective 
protection at O-6 using TBSCl was required. Then subsequent benzylation gave 
protected anchor 71. Phosphoramidite 73 was obtained after desilylation using TBAF to 
form alcohol 72 and phosphytilation. Finally, target compound 75 was formed after 
coupling with phosphate glycerol derivative 74, oxidation, MPM cleavage, partial 
esterification with alanine and final deprotection. Despite this successful synthetic 
route, the authors did not assess the biological activity of Galf LTA derivatives and no 
references to any biological evaluation of this molecule can be found in the literature. 
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Scheme 1.7 Synthesis of galactofuranose building block for Streptococcus DSM 
8747 LTA fragment.
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Scheme 1.8 Synthesis of Streptococcus pneumonia LTA fragment.
92
 
1.6 Bifidobacteria 
Bifidobacteria, first isolated from human faeces by Tissier as Bacillus bifidus
93
, then 
named L. bifidus,
94
 and later reclassified as the genus Bifidobacterium by Orla-Jensen,
95
 
belong to the phylum Actinobacteria. Nowadays, the Bifidobacterium genus includes 
over 30 species that can be isolated from various sources, including human faeces and 
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the female human urogenitary tract.
96
 Bifidobacteria are non-motile, Gram-positive, 
anaerobic and fermentative bacteria.
97
 Many reviews have been published on the 
properties and structure of bifidobacteria and their application and role as probiotics.
97,98
 
Also, the subject of whole bacterial immunological properties has been profusely 
covered.
99,100
 Depending on the species, bifidobacteria shape can vary greatly from a Y 
structure to branched rods measuring between 2 and 3 μm.101 A SEM photomicrograph 
of Bifidobacteria infantis ATCC 15702 is shown in Figure 1.15. 
 
Figure 1.15 Photomicrograph of Bifidobacterium longum subs. infantis ATCC 15702 
using a scanning electron microscope measured by David Flinn. 
Bifidobacteria are generally considered beneficial members of the human intestinal tract 
and their effects include tumour inhibition, immunity stimulation and alleviation of the 
symptoms of irritable bowel syndrome.
98
 Yet, the compounds responsible for these 
beneficial effects are actually unknown. Research on the structural components present 
in the cell-wall of Bifidobacterium has shown that components such as lipoteichoic 
acid,
102
 exopolysaccharides,
103
 and glycolipids are biologically active.
104
 However, the 
precise structure and purity of these biologically active components is often lacking due 
to a paucity of structural data. In this section, the bifidobacteria cell wall components 
1μm 
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will be explored, their chemical synthesis explained and the immunogenicity data 
described. 
1.6.1 Cell Wall Components (CPS and WTA) 
The cell wall components, such as CPS and WTA, are often obtained using digestion 
with RNAase, DNAase, trypsin, pepsin, and pronase.
105
 However, this extraction 
method often leads to mixtures of PG, CPS, and WTA. Furthermore, due to CPS and 
WTA high molecular weight, their structural characterisation is difficult. Typical 
analyzes of CPS and WTA consists of glycosyl linkage analysis, NMR, amino acid 
analysis, and comparative analysis using paper chromatography and post hydrolysis 
paper electrophoresis.
105,106
  
1.6.1.1 Cell Wall Polysaccharides 
CPS from a number of bifidobacterial species and strains have been extracted and 
analyzed. Fragments of proposed CPS structures show that these CPS from different 
species vary greatly (Figure 1.16).
105-110
 An early publication by Habu et al. described 
the CPS from 4 different strains of bifidobacteria. Not surprisingly, every strain showed 
different sugar composition and structure. An example of the structure proposed for B. 
breve YIT 4010 is shown in Figure 1.16a.
106
 Here, a repeating tetrasaccharide unit 
composed of [→3)β-Glc(1→3)β-Gal(1→4)α-Gal(1→2)α-Glc(1→] was branched on O-
6 of the α-Gal residue.  
In 1988, the same group detected an entirely different structure in the cell wall of B. 
adolescentis (Figure 1.16b).
107
 This structure consisted of a repeating unit of [→2)α-
6dTal(1→3)β-6dTal(1→3)β-6dTal(1→3)β-6dTal(1→2)α-6dTal(1→2)α-6dTal(1→] 
with glucose residues branches on O-3 of the α residues. Later, they also purified a 
structure containing L-rhamnose and galactose from B. longum YIT3028 (Figure 
1.16c).
108
 An additional paper from the same group described a polymer composed 
exclusively of galactose in B. catunelatum YIT4016 (Figure 1.16d).
109
 Here, the core 
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consisted of a galactofuranose repeating unit, branched with galactofuranose residues. 
As with the research done by Nagaoka et al., the analysis performed by Tone-
Shimokawa et al. revealed galactofuranose and galactopyranose in B. infantis CPS 
(Figure 1.16e).
105
 However, in this case, glucopyranose was detected as part of the 
branching units. A final example, where galactofuranose and galactopyranose were 
found, is depicted in Figure 1.16f. Here, in contrast to Tone-Shimokawa et al., 
Zdorovenko et al. described in B. bifidum BIM B-465 a repeating unit containing not 
only galactofuranose and galactopyranose, but also glucopyranose.
110
 Galactofuranose 
and galactopyranose were also found in Bifidobacteria adolescentis M101-4 and in B. 
pseudocatenulatum MBL8320 CPS. These CPS were shown to strongly stimulate 
murine splenocytes in vitro.
111,112
 
1.6.1.1.1 Synthesis of a CPS Fragment from B. catunelatum 
To test the immunological properties of compounds, it is important to know the level of 
purity of these compounds. As discussed earlier, different strains of bifidobacteria 
contain different CPS structures. To understand the immunologic properties of these 
compounds, knowledge of the structure analyzed is valuable. CPSs that have been 
isolated and analyzed are commonly contaminated with cell wall components. Thus, in 
order to test the immune function of these molecules, chemical synthesis is required to 
obtain pure compounds.
86
 However, as CPSs are often of high molecular weight (MW), 
only the synthesis of fragments is feasible. Scheme 1.9 shows the synthesis of a 
fragment from B. catunelatum.
113
 Here, diacetonide 76 is benzylated and a 
regioselective deprotection of the acetonide is achieved to form diol 77. Coupling of 
glycosyl acceptor 77 and glycosyl donor 78 with TMSOTf and NIS gave coupled 
product 79 in poor yield, as separation of the α and β anomers was only possible after 
acetylation. Deprotection of the acetate with a saturated solution of ammonia in 
DCM/MeOH followed by coupling of glycosyl acceptor 80 and imidate 81 gave 
coupled product 82. Then after subsequent protecting group manipulations and 
formation of the trichloroacetimidate, glycosyl donor 83 is treated with dodecanol to 
form trisaccharide 84. Selective acetate deprotection of the Galf moiety gave glycosyl 
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acceptor 85. The last steps were the coupling of glycosyl acceptor 85 with imidate 83 
and global deprotection to obtain final product 86. 
1.6.1.2 Wall Teichoic Acids 
Publications on the detection of WTA from bifidobacteria are scarce. Veerkamp et al. 
found a mannitol teichoic acid in B. bifidum var. pennsylvanicus.
114
 In Figure 1.17, the 
sugar portion is linked via a mannitol phosphate and contains L-rhamnose and glucose. 
Further research on the immunological properties of WTAs is sparse. 
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Figure 1.16 Proposed structures of CPS from a. B. breve YIT 4010,
106
 b. B. 
adolescentis
107
, c. B. longum YIT4028
108
, d. B. catunelatum,.
109
 e. B. infantis,
105
 f. B. 
bifidum BIM B-465.
110
 
37 
 
 
Scheme 1.9 Synthesis of B. catunelatum cell wall polysaccharide fragment.
113
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Figure 1.17 Proposed mannitol teichoic acid from B. bifidum var. pennsylvanicus.
114
 
1.6.2 Exopolysaccharides 
As the EPS is often strain or species specific, there is wide interest in the 
immunological properties of bifidobacteria EPS.
115,116
 EPS, released as a slime that 
surrounds the cell, is usually precipitated out of the growth medium using cold ethanol. 
The amount of EPS as well as the length and the level of branching obtained from this 
process vary between different species which is also observed for CPS.
117
 Impurities, 
such as proteins, are known to precipitate with the EPS when using the cold ethanol 
precipitation method. In order to test specifically EPS immunological properties, it is of 
importance to know the structure and purity of the mixture.
118
 Sugars contained in EPS 
are identified via different methods including enzymatic assays,
118
 GC-MS after 
hydrolysis and derivatisation,
119
 HPLC after hydrolysis,
115,120
 and NMR.
119
 Figure 1.18 
shows examples of proposed structures for B. longum (a.) and B. animalis (b.). In B. 
longum, the repeating unit reported was [→4)α-D-Gal(1→4)α-D-Gal(1→4)β-D-
Glc(1→3)α-D-Gal(1→3)β-L-Rha(1→] with branched glucose and galactose residues.121 
Rhamnose was also detected in the EPS from B. animalis subsp. lactis, but in contrast 
with Kohno et al. findings, galactofuranose was identified in the structure.
119
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Figure 1.18 EPS repeating unit of a. B. longum JBL05
121
 and b. B. animalis EPS.
119
 
1.6.3 Fatty Acids 
Usually, free fatty acids are found only in minor amounts in the bacteria and are 
commonly attached to phospholipids, glycolipids or waxes.
122
 For this reason, while 
analysing the whole cell fatty acids, a mixture from all the components in the cell is 
obtained. Initial studies used GC to determine what fatty acids were present. The fatty 
acids were derivatised by methanolysis using hexane and BF3-methanol at 100 °C for 15 
minutes and, after injection in the GC, their retention times (RTs) were compared to 
standards.
123-125
 The disadvantage of this method is that the RT of varying FAMEs are 
similar, leading to ambiguous results (Figure 1.19). 
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Figure 1.19 Example of a whole bacterial gas chromatogram of fatty acid methyl 
esters. 
The fatty acids from Bifidobacterium bifidum var. pennsylvanicus were studied 
thoroughly by Veerkamp and Fischer between 1970 and 1987.
123,124,126
 Here, the fatty 
acids obtained were saturated, unsaturated and branched (e.g. Iso-18:0 and Anteiso-
19:0) some of which contained a cyclopropane ring (e.g. Cyclo-19:0). In 1998, other 
groups started to identify FAMEs using the microbial identification system database 
(MIDI). This MIDI database uses actual GC FAME RTs for bacterial identification. 
However, as before, the comparison between the RTs can lead to ambiguous results due 
to overlapping signals. After methyl esterification, it was found using MIDI that FAME 
and dimethyl acetals (DMA) were present.
127-129
 Figure 1.20 shows examples of fatty 
acids extracted from bifidobacteria. The most accepted method used today to confirm 
the identity of compounds such as DMA is GC-MS. The DMA fragmentation pattern is 
very characteristic (strong fragment signal at m/z = 75 for C3H7O2
+
, Figure 1.21a) and 
differs greatly from saturated FAME fragmentation patterns (Figure 1.21b).
130,131
 DMAs 
(89), in contrast to FAMEs, are mainly formed from plasmalogen (87) under acidic 
conditions (Scheme 1.10). Indeed, the aldehyde 88 obtained from acid hydrolysis of 
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plasmalogen 87 reacts with methanol to form DMA 89. The presence of DMA in 
bifidobacteria was later confirmed by Oberg et al. who found these derivatives in B. 
animalis subs. lactis using GC-MS after methylation.
131
 
 
Figure 1.20 Example of fatty acids found in bifidobacteria. 
 
Scheme 1.10 Dimethyl acetal formation under acidic conditions.
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1.6.4 Phosphoglycerolipids 
As most of the phospholipids are considered biocompatible, a very limited amount of 
groups studied bifidobacterial phospholipids. In an early paper Exterkate and Veerkamp 
extracted the cytoplasmic lipids from bifidobacteria using the method of Blight and 
Dyer
42
 that uses CHCl3/MeOH/H2O extractions. The isolated lipids were purified on a 
silicic acid column using CHCl3/(CH3)2CO/(CHCl3/MeOH/H2O [10/10/1, v/v/v]). The 
resulting phospholipids were analyzed using 2D thin-layer chromatography (TLC) and 
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against standards. The major phospholipids identified were phosphatidyl- and 
diphosphatidylglycerol, phosphatidyl glycerol. Additionally, minor amounts of 
phosphatidic, alanyl phosphatidyl glycerol and mono-, di- and tri-acyl-bis-
(glycerophosphoryl)glycerol were also detected.
132
 Exterkate et al. also described the 
phospholipids composition of Bifidobacterium and more recently Lactobacillus strains. 
The most significant difference reported here was the presence of alanyl 
phosphatidylglycerol in bifidobacteria and its absence in lactobacilli.
133
 More recently, 
Novik et al. extracted the lipids from bifidobacteria using CHCl3/MeOH and purified 
them by silica gel column chromatography. After comparison of standards to the 
compounds using 2D TLC, they found the major phospholipid components to be 
diphosphatidylglycerol, phosphatidylglycerol, phosphatidylethanolamine and 
phosphatidylcholine with minor constituents such as phosphatidylinositol and lyso-
phosphatidylcholine.
134,135
 
1.6.5 Glycosyldiglycerides 
Veerkamp and co-workers first extracted glycolipids from bifidobacteria in 1969 using 
CHCl3/MeOH/acetate buffer mixtures. After silicic acid column chromatography, they 
obtained only galactolipids (diacyl-monogalactosyldiglyceride, monoacyl-
monogalactosyldiglyceride, monogalactosyldiglyceride, monoacyl-
digalactosyldiglyceride, monogalactosylmonoglyceride and digalactosyldiglyceride).
132
 
Following work in 1971 by Exterkate and Veerkamp studied the effect of cell-wall 
inhibition on the composition of lipids. After a bifidobacteria growth without human 
milk, they found a decrease in galactose glycolipid content and also observed an 
additional lipid (trigalactosyldiglyceride).
136
 Later, in 1972, Veerkamp published the 
structure of the galactosyldiglyceride in B. bifidum var. pennsylvanicus. The glycolipids 
were extracted and purified by preparative TLC and mono-, di- and tri-
galactosyldiglyceride-containing acyl derivatives were identified as the major 
glycolipids (Figure 1.22).
44
 These investigations, however, were limited by the 
analytical techniques available at the time and only partially described the structure of 
the galactolipids. For instance, fatty acid analysis (identification of the fatty acids using 
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GC-MS following methyl esterification of the fatty acids) of the glycosyldiglycerides 
was not reported, nor were full NMR and mass data.  
a.  
 
b. 
 
Figure 1.21 MS fragmentation spectrum of a. 18:1 DMA
131
 and b. Methyl 
palmitate.
130
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More recently, Novik and et al. 
104,134,137,138
 have isolated and analyzed by TLC the 
principal galactolipids from a number of bifidobacterial species and strains, although 
again no detail of their structure was given in their publication and the compounds were 
not purified. Novik also described that some glycolipids had different mobility on TLC 
than that described for other bacteria, suggesting unusual structures as the reason. These 
glycolipids have only been investigated via TLC or sugar analysis. As 
glycosyldiglycerides were found to be biologically active (Section 1.5.4) and as Novik 
et al. also found some activity in bifidobacterial extracts
104
 it is important that the 
identity of these compounds is established for further investigations concerning their 
synthesis and biological activity. Therefore, the data generated using NMR, ESI-MS, 
mass-spectrometry fatty acid analysis, and sugar analysis after purification would be a 
contribution to the literature on bifidobacterial glycoglycerolipids. 
 
Figure 1.22 Glycosyldiglycerides identified in B. bifidum var. pensylvanicus.
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1.6.6 Phosphated Galactolipids and Lipoteichoic Acid 
Bifidobacterial LTAs were shown to be biologically active and thus implicit knowledge 
of LTA structures is important.
102,139-143
 The structure of LTA extracted from B. bifidum 
was first proposed by Op Den Camp, then corrected by Fischer et al., and finally 
Fischer’s findings were confirmed by Iwasaki in 1990.62,124,144-146 The structure 
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confirmed by Iwasaki (Figure 1.23) which was extracted using hot phenol, contains a 
galactosyldiglyceride anchor, linked to a β-glucose polysaccharide. The last glucose is 
attached to a galactofuranose-glycerophosphate repeating unit. 
 
Figure 1.23 LTA fragment structure proposed for Bifidobacterium bifidum YIT 4007 
and YIT 4010, described by Iwasaki.
62
  
1.7 Lactobacillus 
Lactobacilli, as with bifidobacteria, are used as a probiotic and are also believed to be 
beneficial.
147
 Both bacteria are found in the human gut and are often discussed together 
as they are both part of the lactic acid bacteria group (LAB).
148,149
 Other similarities 
include the fact that they are also Gram-positive, fermentative bacteria and can be rod 
shaped. However, contrarily to bifidobacteria, lactobacilli belong to the Firmicutes 
genus while bifidobacteria belong to the Actinomycetes genus. In contrast to 
bifidobacteria, lactobacilli are ubiquitous, as they can be found in all environments 
containing carbohydrates such as milk products, food, beverages and the human 
intestinal tract.
150
 Due to lactobacilli omnipresence and the many different species (ca 
106),
150
 literature regarding lactobacilli is profuse (SciFinder
®
 ca. 64159 hits) and many 
reviews describe lactic acid bacteria and Lactobacillus cell wall.
151,152
 The study of the 
cell wall components from L. plantarum, previously named L. arabinosus,
153
 is one of 
the most investigated LABs because of its probiotic properties, is important.
154
 As this 
46 
 
research focuses on L. plantarum, only the publications discussing the compounds on 
the surface of L. plantarum will be discussed. In order to understand L. plantarum 
whole cells immunological properties, it is importand to determine structurally their 
surface components.
155-157
 
1.7.1 Wall Teichoic Acids 
The presence of ribitol phosphate and/or glycerol phosphate type polysaccharides was 
detected during initial studies of the immunologically active L. plantarum WTAs.
158,159
 
D-Ala or D-glucose was detected in a strain dependent manner on the ribitol phosphate 
and /or glycerol phosphate.
158,160-162
 After hydrolysis, the analysis revealed fragments of 
the structure that implied the presence of a polymer consisting of a long poly(ribitol-
phosphate) chain containing α-D-glucose residues on the 2 and 3 positions of the chain. 
Adams et al. found the same structural components, however the glucose residue was 
linked with phosphodiester bonds to form the backbone of the WTA.
163
 This finding 
was later confirmed by Archibald et al. and the repeating units of glucosylglycerol 
linked with phosphodiester bonds was also described (Figure 1.24).
164
 
 
Figure 1.24 WTA structure from L. plantarum N.I.R.D. C106.
164
 
Later, Tomita et al. isolated monomeric units of L. plantarum WTA and found 3,4-α-D-
diglucosyl-2-phosphoryl ribitol and 3,4-α-D-diglucosyl-1-phosphoryl ribitol.165 They 
also compared the WTA from different strains of L. plantarum and found two principal 
backbones depending on the strain (Figure 1.25). The first backbone consisted of 6-
linked units of 1-O-(α-D-glucosyl)-3-O-phosphoryl-sn-glycerol while the second 
backbone was formed with ribitol phosphate. Also, depending on the strain, the glucose 
residues were linked at different positions of the ribitol and contained either 
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monoglucosyl or diglucosyl moieties.
166
 Phosphorylated rhamnose-containing 
polysaccharides were also found in some strains of L. plantarum.
167-169
 
 
Figure 1.25 Ribitol and glycerol phosphate backbones.
166
 
1.7.1.1 Chemical Synthesis of Wall Teichoic Acids 
Sargent and Baddiley synthesised the 4-O-α-D-glucopyranosyl-D-ribitol 93 described by 
Archibald et al. (Section 1.7.1). As shown in Scheme 1.11 a selective protection step 
using benzoyl chloride and starting from partially protected ribitol 90 gave benzoylated 
precursor 91. Subsequent condensation of alcohol 91 with Brigl’s anhydride 92 and 
global deprotection afforded target compound 93.
170
 
1.7.2 Exopolysaccharides 
The structure of the immunologically active
171
 EPS from L. plantarum has been studied 
by Tallon et al. Here, two different types of EPS have been described. The first type had 
a lower molecular weight (4 x 10
4 
Da) and a ratio of 1/1/3, galactose/rhamnose/glucose, 
and contained smaller amounts of phosphate and glycerol. In the second type, a higher 
molecular weight component (8 x 10
4
 Da) and a ratio of 1/1/3, galactose/N-
acetylgalactosamine/glucose, was found.
154
 Later, Ismail and Nampoothiri purified and 
characterised the EPS from L. plantarum. In this case, α-D-mannose, α-D-glucose and β-
D-glucose were found using NMR, however, no additional information was given on the 
structure.
172
 In the same year, Wang et al. analyzed EPS produced by L. plantarum 
isolated from kefir. They found a ratio of 1/5/7 of mannose/glucose/galactose. Galactose 
and glucose were also exclusively detected in the EPS of L. plantarum in a medium 
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containing 13% whey and supplemented with yeast extract and glucose.
173
 In 2011, Liu 
et al. analyzed the EPS from different strains of lactobacilli. It was reported that 
arabinose, galactose, glucose, mannose, fructose and maltose were identified in EPS 
after hydrolysis. This EPS also induced macrophage activation.
174
 
 
Scheme 1.11 Synthesis of 4-O-α-D-glucopyranosyl-D-ribitol.170 
1.7.3 Fatty Acids 
The cell wall of L. plantarum contains saturated and monounsaturated fatty acids 
commonly found in most bacteria (C12 to C18).
175,176
 A fatty acid usually found in 
lactobacilli and is also present in L. plantarum is lactobacillic acid.
177-179
 In Scheme 
1.12, lactobacillic acid is depicted at the sn-2-position of the glycerol in 
phosphatidylethanolamine 95. As implied in Scheme 1.12 monounsaturated fatty acids 
are required for the synthesis of cyclopropane fatty acid (CFA). In this case, an extra 
step in the biosynthetic pathway is required, and is catalysed by a CFA synthase. Here, 
the double bond of the monounsaturated fatty acid, typically present on phospholipid 94 
or glycolipid, attacks the methyl group on the S-adenosine-methionine (AdoMet) and 
after elimination of a methyl proton, the cycle would be formed to give cyclic fatty acid 
95. Intermediates such as branched fatty acids can also be formed in this process.
180,181
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Further studies on the subject determined the absolute configuration to be 11R and 
12S.
182
 
 
Scheme 1.12 Biomechanism of cyclopropane fatty acid formation.
180
 
1.7.4 Phospholipids 
Only a few groups studied the phospholipids from L. plantarum using TLC and 
MALDI.
183,184
 The major phospholipids found by Exterkate et al. were 
diphosphatidylglycerol (DPG), phosphatidylglycerol, lysyl-phosophatidylglycerol and 
PA.
133
 Here, no mention of CL was made, and this phospholipid was later observed by 
Arbogast et al. in L. plantarum.
185
 The synthesis of CL from phosphatidylglycerol via a 
CL synthetase bound to the membrane in L. plantarum was subsequently studied by 
Buritt et al., who found that the amount of CL synthesised diminished with time.
186
 
Finally, the use of mass spectrometry to compare the phospholipids in different 
bacteria/strains allowed a putative assignment. This type of mass-spectrometric 
comparison was made by Drucker et al. who identified phosphatidylglycerol and PS
183
 
while Calvano et al., with similar analyzes, detected mainly phosphatidylglycerol and 
CL.
184
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1.7.5 Glycosyldiglycerides and Lipoteichoic Acids 
The literature regarding L. plantarum LTA and glycosyldiglycerides is very confusing. 
Though many groups have extracted and characterised LTA and glycosyldiglycerides, 
the reported configuration of the anomeric carbon on the glucose moiety at the non-
reducing end of the TGDG has been inconsistent. An early publication by Ikawa 
compared the lipids from different lactic acid bacteria including L. plantarum and 
determined that some lipids contained glycerol, glucose and galatose.
187
 Brundish et al. 
also analyzed the glycolipids from different lactobacilli species, identifying partially the 
structures of L. plantarum to be β-glucosylgalactosyl-β-glucosyl-(1→1)-glycerol.43,46 In 
contrast with the results published by Brundish et al., Shaw et al described 
glycoglycerolipids with α-glucose at the non-reducing end instead of β-glucose (Figure 
1.26).
46
 Nakano and Fischer also compared the glycolipids present in L. casei with the 
ones from L. plantarum using 2D TLC and suggested that the glycolipids from both 
species were similar.
188
 All reports of L. plantarum have not conclusively determined 
the glycoglycerolipids present in L. plantarum. 
 
Figure 1.26 L. plantarum glycolipids isolated by Shaw et al.
46
 
As LTAs are derived from glycosyldiglycerides (Section 1.4.4), the study of LTAs also 
shed light on the glycolipids present in L. plantarum. However, as with 
glycosyldiglycerides, the configuration of the residues was not conclusively determined. 
Early publications on L. plantarum LTAs described a glycolipid anchor containing a β-
glucose at the non-reducing end of TGDG (Figure 1.27a).
189,190
 Later, Jang et al. 
extracted the lipoteichoic acids from L. plantarum. Here, instead of a α-glucose at the 
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reducing end of TGDG, the structures proposed by Jang et al. suggested a β-glucose 
moiety (Figure 1.27b).
57
 Regarding the immunomodulatory properties of these 
glycolipids, many L. plantarum crude LTA extracts were found to be active. 
Additionally, it was anticipated that the immune response could be modulated by the D-
alanine content.
191-193
 Indeed, when cells of a Dlt
-
 mutant were tested for cytokine 
production in PBMCs, there was a significant reduction in proinflamatory cytokines 
(e.g. IL-12, TNFα), compared to cells of a L. plantarum wild type. These results 
suggested that the D-alanines are responsible for the biological activity observed in the 
wild type as the Dlt
-
 mutant cells do not contain D-alanines in their LTAs. This fact is 
interesting, however, none of these publications described the immunological properties 
of fully characterised purified compounds. 
 
Figure 1.27 L. plantarum LTA fragments isolated by a. Fischer
190
 and b. Jang et al.
57
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1.8 Aim and Outline of Thesis 
Due to the lack of characterisation data such as NMR and MS for the components 
present in lactobacilli and bifidobacteria and the absence of immunological testing on 
fully characterised pure compounds, from their cell wall it is important to fully 
characterise and assess their biological activity. Thus, this research aims to extract, 
characterise, synthesise and evaluate the immunological properties of bacterial 
commensal glycoglycerolipids. After purification, the glycolipids were analyzed using 
constituent sugar and glycosyl linkage analysis, fatty acid analysis, NMR and ESI/MS. 
In Chapter 2, the glycoglycerolipids from L. plantarum are described and tested in a 
macrophage activation assay. Chapter 3 reports a novel glycolipid isolated from B. 
longum subs. infantis and its immunological properties are also evaluated.  
Furthermore, due to contamination caused while extracting LTAs, the synthesis of such 
pure compounds for biological testing is of interest. The synthesis of eleven analogues 
of GL5 was achieved and the analogues were tested for their ability to induce 
macrophage activation as described in Chapter 4. Finally, Chapter 5 summarizes 
priliminary results and describes future prospects, and conclusions of the project. 
Additionally this chapter will discuss necessary steps to determine the stereochemistry 
of GL5. 
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Chapter 2  
 
Isolation and Structural Characterisation of 
the Major Glycoglycerolipids from 
Lactobacillus plantarum
194
 
To date, the structures of the glycoglycerolipids from Lactobacillus plantarum, a 
commonly used beneficial probiotic, have not been conclusively assigned. In this 
chapter, for the first time, the full characterisation of the four principal 
glycoglycerolipids of the L. plantarum cell wall is presented using sugar, linkage and 
FAME analysis, as well as ESI-MS/MS and 1D- and 2D-NMR spectroscopy. The major 
glycoglycerolipids are assigned as being: α-D-Glcp-diglyceride, α-D-Galp-(1→2)-α-D-
Glcp-diglyceride, β-D-Glcp-(1→6)-α-D-Galp-(1→2)-6-O-acyl-α-D-Glcp-diglyceride 
and β-D-Glcp-(1→6)-α-D-Galp-(1→2)-α-D-Glcp-diglyceride. 
2.1 Background 
Lactobacillus plantarum is a widespread member of the genus Lactobacillus and is 
commonly found in fermented food products and anaerobic plant matter.
195
 It is also a 
major coloniser of the human gastrointestinal tract and the mucosa of the mouth and 
nose.
196
 Due to the potential health benefits of lactobacilli, there has been wide interest 
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in the immunomodulatory properties of this commensal.
197
 It is well known that many 
bacterial glycoglycerolipids (e.g. LPS, TDMs and PIMs) have profound immunological 
effects,
63,76,198-202
 and for this reason, characterising the major glycoglycerolipids in L. 
plantarum is of interest. In the late 1960s, Shaw et al. reported on the isolation and 
structural characterisation of glycosyldiglycerides from L. plantarum
43
 and 
Lactobacillus casei,
203
 and found a glucosylgalactosylglucosyl-glycerol in L. plantarum, 
but were unable to deduce the glycosidic linkages and anomeric configurations.
46
 In 
1977, Nakano and Fischer elucidated the structures of mono-, di-, tri- and 
tetraglycosyldiglycerides from L. casei using enzymatic methods, TLC and gas–liquid 
chromatography. Through TLC analysis, Nakano and Fischer concluded that the 
membrane glycoglycerolipids from L. casei and L. plantarum were very similar.
188
 In 
addition, Fischer et al. studied the relationship of phosphoglycolipids and lipoteichoic 
acids of several Gram-positive bacteria and saw similar phosphoglycolipids present in 
both L. casei and L. plantarum.
189,190
 From the aforementioned studies, a number of 
glycoglycerolipids have been inferred to be present in L. plantarum,
43,46,57,188-190,203
 
however, no conclusive spectral information has been provided. This is an important 
omission that needs to be addressed if a better understanding of the taxonomy and 
immunomodulatory properties of L. plantarum is to be achieved.
204
 Herein, the 
structures of the four major glycoglycerolipids, isolated from L. plantarum IRL-560 
using modern analytical techniques, are unequivocally established.  
2.2 Experimental Procedures 
2.2.1 Bacteria and Cultivation 
[The bacterial growth was conducted by Jason Ryan, IRL] 
Cultures of L. plantarum IRL-560 cells were grown plated onto Refined Clostridium 
Media (RCM) agar and incubated anaerobically at 37 °C for 24 h. Glycolipid 
production was conducted anaerobically in a 18 L fermenter using a carbohydrate-free 
modified MRS (Man–Rogosa–Sharp) media in a 20 L Braun bioreactor (Sartorius-
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Stedim, Aubagne Cedex, France). The culture was then centrifuged at 3000 g for 10 min 
to yield a watery paste and the cell-mass was freeze dried. Next, the dried cell-mass was 
washed three times with PBS buffer (pH 7.3) and centrifuged (15 min, 31 186 g, 4 °C) 
or until the amount of carbohydrate detected in the washes by colorimetric assay was 
under 1% (w/v). To remove the PBS buffer, the cells were washed with deionised water 
and centrifuged, then freeze-dried and weighed. 
2.2.2 Isolation and Purification 
The dried cell-mass (8 g) was extracted twice (400 mL, 18 h, 37 °C) with 
CHCl3/MeOH/H2O (10/5/1, v/v/v). After filtration, the combined extracts were 
evaporated to dryness (ca. 0.9 g), suspended in CHCl3/MeOH/H2O (100 mL, 5/5/4.5, 
v/v/v) and rested overnight (16 h, 4 °C) to remove polar impurities. The organic fraction 
was evaporated to dryness and analyzed by TLC. The crude lipid extracts were 
preabsorbed onto silica gel and fractionated by silica gel column chromatography. 
Glycoglycerolipids were eluted successively with a step-wise gradient of MeOH in 
CHCl3 and further purified, if needed, using preparative TLC. GL2a and GL2b were 
separated from each other using size-exclusion chromatography on a Sephadex LH-20 
column eluting with DCM/MeOH (1/1, v/v). 
2.2.3 NMR Spectroscopy 
Purified glycoglycerolipids were dissolved in 0.7 mL CDCl3/CD3OD (2/1, v/v). 
Samples were analyzed at 22 °C and the chemical shift measured relative to chloroform 
and TMS. The fatty acid methyl esters were dissolved in CDCl3. NMR spectra were 
recorded on a Bruker Advance III 500 MHz spectrometer or a Varian DirectDrive 600 
(600 MHz for 
1
H, 150 MHz for 
13
C) spectrometer.  
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2.2.4 Electrospray Mass Spectrometry 
Electrospray mass spectrometry (or accurate mass measurement) was performed in the 
positive (or negative) ion mode on a Micromass Q-Tof Premier instrument. All MS/MS 
experiments were performed on a Q-Tof Premier mass spectrometer (Micromass, UK). 
2.2.5 General Analyzes 
Total carbohydrate was estimated colourimetrically by the phenol–sulfuric acid method 
using glucose (0–80 g) as the standard.205 For example, in Scheme 2.1, glucose is 
dehydrated to form 5-(hydroxymethyl)furfural using sulfuric acid. Following this, the 
furfural was condensed with two molecules of phenol to form a product that is 
measured at 490 nm on a spectrometer.  
 
Scheme 2.1 Phenol-sulfuric acid reaction with glucose. 
For TLC analysis, glycolipid samples were dissolved in CHCl3/MeOH (2/1, v/v) and 
applied to dried silica pre-coated TLC plates. The glycoglycerolipids were eluted with 
CHCl3/MeOH (6/1, v/v), sprayed and developed with a cerium molybdate (Hanessian’s) 
stain, with a molybdate stain for the detection of phosphorous and a sulfuric acid 
stain.
206,207
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2.2.6 Constituent Sugar Analysis 
The constituent neutral sugar composition was determined by GC–MS following acidic 
hydrolysis and derivatisation to alditol acetates.
49
 Briefly, samples were hydrolysed 
with 2 M TFA (400 L, 1 h, 120 °C), neutralised with 2 M NH4OH (0.4 mL), using 
50 g myo-inositol as an internal standard, reduced with 2% (w/v) NaBD4 in water, and 
then acetylated with acetic anhydride (200 L) in pyridine (Scheme 2.2). Alditol 
acetates were quantified by GC on a SGE BPX90 capillary column (30 m x 0.25 mm 
i.d., 0.25 m film thickness) with the GC oven programmed from 80 °C (held for 1 min) 
to 150 °C at a rate of 25 °C/min, and then to 250 °C at a rate of 4 °C/min and analyzed 
by MS using an Agilent 5973 Inert MSD. Identifications were based on peak retention 
times and by comparison of electron impact spectra with standard spectra (Figure 2.1 
and 2.2). Weight calibration constants were determined from standard sugar mixes 
(derivatised at the same time as the samples) following the TAPPI standard method 
T249 cm-85 (1995).
c
 
 
Scheme 2.2 Constituent sugar analysis forming glucitol hexaacetate from GL1. 
 
 
 
                                                 
c
 TAPPI, Technical Association of the Pulp and Paper Industry. In Carbohydrate Composition of 
Extractive-free Wood and Pulp by Gas-Liquid Chromatography; TAPPI Test Methods, T249 cm-85, 
TAPPI, Atlanta, GA, 1985. 
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Figure 2.1 GC-MS chromatogram of GL1 alditol acetates showing the glucitol 
hexaacetate signal. 
 
Figure 2.2 Glucitol hexaacetate electron impact spectrum taken from the signal at 
29.3 minutes in GL1 chromatogram (Figure 2.1). 
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2.2.7 Linkage Analysis 
Samples (ca. 0.5 mg) were methylated with methyl iodide and sodium hydroxide as 
described by Ciucanu and Kerek,
50
 with the exception that samples were dispersed in 
DMSO (0.5 mL) and heated (50 °C) overnight under argon. After extraction into 
chloroform, the methylated polysaccharides were hydrolysed with TFA, reduced and 
then acetylated to form partially methylated alditol acetates (PMAA) before analysis by 
GC–MS as described above (Scheme 2.3). Identifications were based on peak retention 
times and by comparison of electron impact spectra with the spectra obtained from 
reference standards (Figure 2.3 and 2.4). Here, the partially methylated alditol acetate 
standards were prepared following the method of Doares et al.
208
 
 
Scheme 2.3 Glucosyl linkage analysis method forming a PMAA from GL1. 
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Figure 2.3 GC-MS chromatogram of GL1 PMAA showing the glucitol PMAA 
signal. 
 
Figure 2.4 Glucitol PMMA electron impact spectrum taken from the signal at 18.7 
minutes in GL1 chromatogram (Figure 2.3). 
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2.2.8 Sugar Absolute Configuration 
Crude glycolipid extracts (1 mg) were hydrolysed with 2 M TFA (1 h, 120 °C), then 
dried. To this R-(-)-1-amino-2-propanol in methanol (20 L, 1.6 M), acetic acid (17 L, 
3.5 M) and sodium cyanoborohydride in methanol (13 L, 3% w/v) were added and 
heated to 65 °C for 1 h (Scheme 2.4). After drying the samples, the residues were 
acetylated as mentioned above, dissolved in acetone and then injected onto a GC–MS 
using a non-polar column (HP-5ms, 30 m, 0.32 mm i.d.). Here, the temperature 
programme started at 180 °C (held for 1 min) rose to 220 °C at a rate of 2 °C/min (held 
for 2 min), and then rose again to 250 °C at a rate of 1 °C/min (held 5 min). Crude 
samples were compared with derivatives of D- and L-glucose and galactose 
references.
209
 
 
Scheme 2.4 Derivatisation of D-galactose into a (2-hydroxypropylamino)alditol using 
sodium cyanoborohydride and R-(-)-1-amino-2-propanol. 
2.2.9 Fatty Acid Analysis 
Fatty acid methyl esters (FAME) were prepared by direct transesterification from 
samples of biomass (ca. 0.5 mg) without extraction, as described by Svetashev et al.
28
 
In brief, samples were dissolved in 1% sodium methoxide in dry methanol (30 min, 
80 °C), and then treated with 5% anhydrous HCl in methanol (30 min, 80 °C). The 
resulting FAMEs and DMA were taken up in hexane and analyzed by GC and GC-
MS.
210
 One of the possible methods, when using GC, is to compare equivalent chain 
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lengths (ECL). Here, as mentioned in Chapter 1 (Section 1.6.3) the fatty acid retention 
times (RT) are compared with standard RTs.
210
 Indeed, the relationship between the 
logarithm of the retention time and the chain length is linear if homologous standard 
straight-chain fatty acids are measured under identical isothermal conditions. The 
identity of the unknown fatty acids can then be read from the curve drawn of the 
standard fatty acids retention time logarithm against their chain length (semi-log 
plot).
211
 However, even if this method is useful for a fast determination of the fatty acids 
characterisation, it does not confirm without question, the exact identity of the fatty 
acids. Furthermore, as it has been shown that glycolipids can be active depending on 
their fatty acid content,
63,78
 it is of importance to know exactly what type of fatty acids 
are present in the glycolipid mixtures. Therefore, the identity of the fatty acids is 
confirmed using GC-MS and additional derivatisation methods.  
The ECL method was used in this study for preliminary results, and the fatty acids 
identity was confirmed using further analyzes. The hydroxyl fatty acids were converted 
into their TMS derivatives to locate the hydroxyl on the fatty acid.
212c
 The position of 
the cyclopropane group was elucidated after separation of the cyclopropanated fatty 
acids from the saturated fatty acids by means of silver ion SPE (Supelco).
c
 This 
separation step was followed by hydrogenation in acetic acid over Adam’s catalyst to 
open the cyclopropane ring.
213d
 The resulting fatty acids were converted into 
pyrrolidides using pyrrolidine/HOAc (10/1, v/v)
214
 and analyzed by GC–MS. The 
position of the double bond in the monounsaturated fatty acids and DMAs was located 
by GC–MS of the dimethyl disulfide adducts.214c The analysis was performed on an 
Agilent 5890N gas chromatograph, equipped with a flame ionisation detector (FID) and 
a polar column (SolgelWax, 30 m, 0.32 mm i.d.). Hydrogen was used as the carrier gas 
with a split ratio of 1:30 and a separation temperature of 195 °C. GC-MS analyzes were 
performed on an Agilent 5890N gas chromatograph, equipped with a 5973 Inert MSD 
and non-polar column (HP-5ms, 30 m, 0.32 mm i.d.).
215
 Helium was used as the carrier 
gas. The programme started at 100 °C, with a temperature gradient of 5 °C/min to 160 
°C, then 1 °C/min to 240 °C before being left at 240 °C for 25 min. 
                                                 
d
 Assay conducted by Kirill Lagutin, IRL 
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2.2.10 Macrophage Assay 
[Conducted by Ashna Khan and Stephanie Chee] 
2.2.10.1 Materials and Methods 
C57BL/6 male mice were bred and housed in a conventional animal facility at the 
Malaghan Institute of Medical Research, Wellington, New Zealand. All animals used 
for the experiments were aged between 8–10 weeks. All experimental procedures were 
approved by the Victoria University Animal Ethics Committee in accordance with their 
guidelines for the care of animals. Extracted glycolipids were tested to be endotoxin-
free (≤ 0.125 EU/mL) with an endotoxin kit (Pyrotell, LAL test, Associates of Cape 
Cod Inc., E. Falmouth, MA, USA).  
2.2.10.2 Generation of Bone Marrow Derived Macrophages (BMMs) 
Bone marrow cells were collected from the tibia and femur of C57BL/6 mice and were 
cultured (250000 cells per mL) in Iscove’s Modified Dulbecco’s Medium (IMDM, 
Gibco) supplemented with 5% FBS (Gibco), 1% Penicillin streptomycin (Gibco) and 2-
mercaptoethanol (55 mm, Invitrogen) containing 10 ng/mL GM-CSF (clone 
X63/GMCSF murine cells). Cells were incubated at 37 °C (5% CO2) and the medium 
was changed on days 2, 5 and 7. On day 10, the medium was removed, and the BMMs 
were primed with IFN- (10 ng/mL, Peprotech, Rocky Hill, NJ, USA) for 3 h prior to 
the addition of the compounds.  
2.2.10.3 BMM Assays 
Glycolipid stock solutions were prepared (2.5 mg/mL in PBS containing 2% DMSO), 
vortexed and warmed to 50 °C for 30 min (x 3) to ensure suspension of the compounds 
prior to administration to BMM cultures. BMM cultures were then treated with 20 or 40 
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g/mL of glycolipid anchors, with LPS (100 ng/mL) as a positive control and medium 
only for the times indicated. Supernatants were collected and tested immediately for NO 
levels using the Griess assay.
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2.3 Results and Discussion 
A large scale culture of L. plantarum yielded 8 g of washed, freeze-dried cells, from 
which 370 mg of crude lipid extract was isolated through extraction using 
CHCl3/MeOH/H2O.  
The configuration of the sugars present in the unpurified glycolipid extract was 
determined (Figure 2.5) after (2-hydroxypropylamino)alditol derivatives were formed 
from D-glucose and D-galactose. These residues were the sole constituent sugars present 
in the crude glycolipid mixture. Using the electron impact spectrum taken from the GC-
MS chromatogram (Figure 2.5), the (2-hydroxypropylamino)alditol signals were 
identified. The combined D- and L-galactose derivatives clearly show peak separation. 
Therefore, the differing retention times enabled the D- and L-galactose derivatives to be 
qualitatively determined. Finally, the sugar in the crude glycolipid mixture from L. 
plantarum was identified as D-galactose from its retention time. Glucose was similarly 
identified as D-glucose. This configuration is consistent with most other reports, which 
is not surprising as the D-configuration is predominant in nature. 
Thin-layer chromatography of the crude lipid extract (Figure 2.6) revealed the presence 
of two highly mobile lipids, designated L1 and L2, and three distinct glycoglycerolipids 
(GL1–3). Comparison with known standards suggested that GL1 is a 
monoglycosyldiglyceride, while the more polar GL2 appeared to be a 
diglycosyldiglyceride. GL3, which had a particularly low Rf, was deemed to be a 
glycolipid containing more than two sugar units. In order to fully identify the extracted 
components, the five individual compounds were then fractionated by silica gel column 
chromatography (L1, L2 and GL1-GL3, Figure 2.6) and analyzed using ESI-MS and 
NMR, in addition to lipid, sugar and linkage analysis.  
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Figure 2.5 GC-MS traces of (2-hydroxypropylamino)alditol derivatives of D- and L-
galactose, its mixture and the crude L. plantarum glycolipid extract showing the 
presence of D-galactose in the glycolipids. 
 
Figure 2.6 TLC of glycolipid and purified fractions from L. plantarum IRL-560. 
Silica gel TLC, eluted with CHCl3/MeOH (6/1, v/v) and developed with a cerium 
molybdate stain. 
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The NMR and ESI-MS analysis enabled L1 to be readily identified as oleic acid 
(HRMS calc. for [C18H33O2]
-
 = 281.2486, found: 281.2484). Lipid L2, slightly more 
polar than oleic acid, was identified as hydroxyoctadecanoic acid (HRMS calc. for 
[C18H35O3]
-
 = 299.2592, found: 299.2579). Both of these structures matched previously 
published data,
217-219
 although the position of the hydroxyl group of the 
hydroxyoctadecanoic acid still needed to be determined. This was easily determined 
using GC-MS by comparing the fragmentation pattern of FAME TMS derivatives with 
the unsilylated FAME. Figure 2.7 depicts the GC of the silylated FAME. In the 
chromatogram, one major signal (FAME-O-TMS) can be observed as well as plasticizer 
and the standard. The plasticizer is an inescapable artefact often observed due to the use 
of plastic in pipettes and caps. The electron impact spectrum of the peak at 56 min 
(Figure 2.8) shows two major fragments that were identified as the cleavage of the chain 
after (m/z = 273) or before (m/z = 215) the –OTMS group. The presence of 10-
hydroxyoctadecanoic acid was also confirmed by the electron impact spectrum of the 
non-derivatised FAME (Figure 2.9 and 2.10) that showed a weak fragment at m/z = 201 
corresponding to a FAME cleaved after the hydroxyl group. 
As anticipated, the structural elucidation of the purified glycoglycerolipids GL1–GL3 
was more involved, though full assignments were possible following consideration of 
fatty acid, sugar and linkage analysis, Rf values, yields and high-resolution mass 
spectrometry (HRMS) data (Table 2.1).  
2.3.1 GL1 
The fatty acid analysis for GL1 showed high amounts of palmitic (16:0), oleic (18:1n-9) 
and cis-vaccenic acid (18:1n-7) and the cyclopropane containing dihydrosterculic (9,10-
Mt 18:0) acid (Table 2.1). The presence of dihydrosterculic acid could also be 
confirmed via NMR, where a typically shielded signal was observed at -0.33 ppm 
(Figure 2.11) and was consistent with literature data and the fatty analysis data showed 
also the intermediate branched fatty acid (Section 1.7.3). Additionally, the cyclopropane 
ring was confirmed as being in the cis configuration as it showed a characteristic upfield 
signal at -0.33.
220
 The GC-MS spectrum of the FAME could not identify the position of 
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the cyclopropane ring as the electron impact spectrum of the cyclopropane FAME 
undergoes rearrangement to form double bonds with an additional carbon. This 
spectrum thus provided no information to determine the position of the cyclopropane 
ring and so other derivatisation methods were required.
221
  
At first, the cyclopropane ring was opened via hydrogenation in acetic acid using 
Adam’s catalyst (Scheme 2.5). Here, three products are usually obtained, a straight 
chain ester and the two possible branched chain isomers. The two branched chain 
isomers eluted at the same retention time in the GC-MS (Figure 2.12) and thus a 
mixture of fragmentation patterns was obtained for these derivatives. The signal at 42.8 
min (Figure 2.12 and 2.13), shows clearly the molecular ion for methyl 
hydroxyoctadecanoate (312 m/z) indicating that the ring opening worked (the molecular 
ion for methyl dihydrosterculic acid is at 310 m/z). Weak signals at 157 and 185 m/z 
represent the fragmentation of methyl 8-methyl-octadecanoate before and after the 
branching methyl, while the signals at 171 and 199 m/z represent the fragmentation of 
methyl 9-methyl-octadecanoate. In order to confirm the signals obtained from these 
data, the pyrrolidide derivatives were obtained using pyrrolidine/HOAc (10/1, v/v). The 
fragmentation patterns corresponding to the same type of branching was also observed. 
This is not surprising as the major fatty acid obtained was oleic acid. Indeed, as seen in 
Chapter 1 (Section 1.7.3) the cyclopropane rings require an additional step in the 
biosynthetic pathway and are formed with AdoMet of unsaturated fatty acids. 
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Figure 2.7 GC-MS chromatogram of silylated L2 FAME showing the silylated 
hydroxyoctadecanoic FAME signal. 
 
Figure 2.8 Silylated hydroxyoctadecanoic FAME electron impact spectrum taken at 
56 minutes in L2 chromatogram (Figure 2.7). 
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Figure 2.9 GC-MS chromatogram of L2 FAME showing the unsilylated 
hydroxyoctadecanoic FAME signal. 
 
Figure 2.10 Unsilylated hydroxyoctadecanoic FAME electron impact spectrum taken 
from the signal at 56 minutes in L2 chromatogram (Figure 2.9). 
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Table 2.1 Chemical characteristics of isolated compounds. 
 GL1 GL2 GL3 
Rf 0.56 0.26 0.06 
Yield
a
 1.0 0.5 0.1 
Neutral sugars
a
    
D-Gal 2.5 3.8 0.8 
D-Glc 25.7 6.9 1.0 
Total 28.1 10.6 1.8 
    
Linkage analysis
b
    
t-Galp 0.1 0.2 - 
1,6-Galp - 0.2 0.4 
t-Glcp 0.9 0.2 0.3 
1,2-Glcp - 0.4 0.3 
    
Fatty acid content
a
 25.5 23.0 2.6 
    
Fatty acids
a,c
    
14:0 2.5 2.1 - 
16:0 15.7 15.7 9.2 
16:1n-7 5.7 6.5 4.0 
DMA 18:1n-9 - 1.8 6.8 
18:0 3.3 4.3 14.9 
18:1n-9 28.8 20.9 48.4 
18:1n-7 14.4 18.0 4.4 
19:0br n-9 3.9 3.5 - 
9,10-Mt 18:0 23.8 29.8 7.8 
    
HRMS
d
 819.5950 981.6482 1143.7009 
  1393.9287  
a
 Weight % 
b
 Molar ratio 
c
 Fatty acids present under 1% are not shown 
d
 Major species. 
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Figure 2.11 Proton NMR spectrum of GL1 showing typical signals for 
dihydrosterculic acid, 
1
H spectrum CD3OD/CDCl3 (1/2, v/v), 500 MHz. 
Additional information was obtained using neutral sugar analysis and showed D-glucose 
and D-galactose in a 10/1 ratio, which was confirmed by linkage analysis. Only terminal 
glucopyranose (t-Glcp) was observed as the linkage analysis indicated that the glucose 
residue was unmodified at any of its hydroxyls. In accordance with the TLC analysis 
and HRMS (HRMS calc. for [C46H84NaO10]
+
 = 819.5957, found: 819.5950) and 
comparison with standards, this indicated that GL1 was a monoglucosyldiglyceride. 
NMR was then used to determine the anomeric configuration of the glucose residue (the 
galactose residue could not be observed using NMR) (Table 2.2), with resonances of the 
anomeric centre (H-1´ = 4.83 ppm, d, JH-1´,H-2´ = 3.8 Hz and C-1´ = 99.8 ppm) clearly 
revealing an α-linked terminal-glucopyranose (α-t-Glcp). The α-linkage was identified 
comparing the NMR chemical shift of the anomeric signal with the literature as well as 
considering a low vicinal coupling constant for JH-1´,H-2´ (3.8 Hz). Indeed, such as 
coupling constant is observed with a low dihedral angle between H-1´ and H-2´ 
indication of an α-linkage. In addition, the presence of a diglyceride was apparent from 
a distinct low field proton resonance at 5.29 ppm (H-2), which showed COSY signals 
with two ABX systems upfield (H-1 = 4.18 and 4.44 ppm, H-3 = 3.62 and 3.83 ppm) 
H-34a H-34b 
H-33 and H-35 
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(Figure 2.14). HMBC between the glycerol H-1 and the carbonyl carbon (C-7 = 174.6 
ppm) confirmed the presence of an acyl group at sn-1. An HMBC between the H-3 
glycerol protons and the anomeric carbon (C-1´), and between the anomeric proton (H-
1´) and glycerol carbon (C-3) confirmed the attachment of the sugar to the glycerol 
(Figure 2.15). All proton and carbon NMR signals were in accordance with literature 
data,
52,85
 which also allowed for the assignment of the glycerol (2S) configuration 
(Table 2.2). 
 
Scheme 2.5 Cyclopropane ring opening via hydrogenation in acetic acid using 
Adam’s catalyst. 
Using collision induced dissociation (CID), in positive ion mode, the connectivity 
between the structural components of GL1 was confirmed. ESI-MS/MS of the sodiated 
molecular ion (HRMS m/z = 819.5950 for [C46H84O10+Na]
+
) showed first the loss of 
oleic acid and dihydrosterculic acid (m/z = 537.3 and 525.3, respectively) (Figure 2.16). 
Here, the larger intensity of the m/z = 523.3 fragment indicates that the dihydrosterculic 
acid is esterified at the sn-1 position in the glyceride as the loss of the fatty acid at this 
position creates a more stable ion.
222
 This regioselectivity was also observed for GL2a, 
GL2b and GL3. Further fragmentation of the ion at m/z 523.0 to give a fragment ion of 
m/z 375.3 was consistent with the loss of hexose. The fragment obtained for the hexose 
itself (m/z = 185.0) was also readily observed. As such, GL1 was fully assigned as α-D-
glucopyranosyldiglyceride. This compound has not been previously identified in L. 
plantarum, although its presence in L. casei
203
 and other bacteria such as Deinococcus 
radiodurans
52
 has been noted.  
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Figure 2.12 GC-MS chromatogram of opened cyclopropane ring FAME showing the 
signal for the branched FAME. 
 
Figure 2.13 Electron impact spectrum of the signal at 42.8 min in the GC-MS 
spectrum in Figure 2.12. 
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Table 2.2 NMR spectroscopic data for GL1. 
Position 
δ1H 
(ppm) 
δ13C  
(ppm) 
COSY  
(H, H) 
HMBC 
(H, C) 
Literature 
δ1H(ppm)
85
 δ13C (ppm) 
52
 
1´ 
4.83  
(d, 3.8) 
99.8 2´ 3, 3´,5´ 
4.86 99.1 
2´ 
3.43  
(dd, 3.7, 9.4) 
72.4 1´,3´ - 
3.49 72.0 
3´ 3.65 74.3 2´,4´ 2’ 3.72 73.9 
4´ 3.40 70.6 5´,3´ 3´,5´,6´ 3.56-3.60 70.1 
5´ 3.56 72.3 6´ - 3.56-3.60 71.8 
6a´ 
3.75  
(ABX, 2.9, 11.9) 
62.0 5´ - 
3.82 
(bs) 
61.7 
6b´ 
3.72  
(ABX, 2.9, 11.9) 
3.82 
(bs) 
3a 
3.62  
(ABX, 6.2,10.7) 
66.6 
2,3b 1´,2,1 3.56-3.60 
66.2 
3b 
3.83  
(ABX, 5.4,10.8) 
2,3a 1´,2,1 
3.82 
(bs) 
2 5.29 (m) 69.7 1,3 - 5.25 69.8 
1a 
4.18  
(ABX, 6.1, 12.3) 
62.5 
2,1b 3,2,25 4.15 
62.3 
1b 
4.44  
(ABX, 3.4, 12.1) 
2,1a - 
4.38 
7 
- 
174.6 
- 
- - 
25 174.1 
8,26 2.34 (t, 7.5) 34.7 9 27 7.9,10 25,27,28 
9,27 1.61 (m) 25.3 8,10 26,28 8,11 26,29 
15,16 5.33 (m)  14 17 17 14 
14,17 2.03 (m) 27.6 15 16 12,16 15,17 
*10-13, 
1.25-1.35 (m) 28-32 - 
18-23, 
28-32, 
36-42 
34a -0.33 (q, 4.3) - - 
34b 0.58 (q, 4.2) - 33,35  - 
33,35 0.67 (q, 4.0) 16.2 
34b 
- 
 - 
24,43 0.89 (t, 7.0) 14.2 23 43 22 41 
* Overlapping signals 
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Figure 2.14 Proton to proton correlations showing the correlation (in blue) between 
GL1 H-2 and H-1/H-3 in the 
1
H,
1
H COSY spectrum CD3OD/CDCl3 (1/2, v/v), 500 
MHz. 
 
Figure 2.15 HMBC correlations proving the connections C-1´ to C-3 and C-1 to C(O) 
in GL1. 
H-2 
H-2   H-1b 
H-2   H-1a 
H-2   H-3b 
H-2   H-3a 
H-2   H-1b H-2   H-1a H-2   H-3b H-2   H-3a 
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Figure 2.16 ESI MS/MS of GL1 in positive ion mode. 
2.3.2 GL2 
Fatty acid analysis of GL2 showed almost the same lipid profile as for GL1, with 
palmitic, oleic and dihydrosterculic acid esters being the predominant lipids (Table 2.1). 
GL2 contained both D-glucose and D-galactose in a 1.8/1 ratio, with linkage analysis 
revealing the presence of both terminal and 1,6-linked galactose (t- and 1,6-Galp), and 
terminal and 1,2-linked glucose (t- and 1,2-Glcp). This suggested that GL2 might 
contain more than one compound, although the TLC analysis showed only one spot. 
Indeed, two signals were observed in the HRMS spectrum—a major peak at m/z = 
981.6482 for a diglycosyldiglyceride (GL2a), and a minor peak at m/z = 1407.9382 for 
[C76H136O21+Na]
+
 corresponding to an acylated triglycosyldiglyceride (GL2b). The 
NMR spectrum of this glycolipid mixture also clearly showed two different glycerides, 
with the major product (GL2a) containing two anomeric signals, and the minor 
component (GL2b) containing three. Altough GL2a and GL2b had similar mobilities on 
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silica, their appreciable differences in molecular weight indicated that they should 
separate on a size-exclusion column. Indeed, gel filtration using Sephadex LH-20, 
eluting with MeOH/DCM (1/1, v/v), resulted in a clean separation of the glycolipid 
mixture into homogenous GL2a and GL2b (Figure 2.17), with GL2b having a slightly 
higher mobility compared to GL2a. 
 
Figure 2.17 TLC of glycolipid and purified fractions from L. plantarum IRL-560. 
Silica gel, eluted with CHCl3/MeOH (6/1, v/v) and developed with sulfuric acid stain. 
For GL2a (Table 2.3), the chemical shifts for the anomeric signal (H-1´ = 5.00 ppm, C-
1´ = 96.8 ppm) were reminiscent of an α-glucopyranoside residue. This assignment was 
further supported by the coupling constants JH-1´, H-2´ = 2.5 Hz and 
1
JC-1´, H-1´ = 171 Hz 
with the large coupling constants JH-2´, H-3´ = 11.3 Hz and JH-3´, H-4´ = 8.6 Hz, and the H-
2´ proton chemical shift (H-2´ = 3.60 ppm) also confirming the glucose 
configuration.
223,224
 A second resonance in the anomeric region of the HSQC spectrum 
(H-1´´ 5.00 ppm, C-1´´ 97.4 ppm) had coupling constants JH-1´´, H-2´´ = 2.5 Hz and JC-1´´, H-
1´´ = 171 Hz, indicating an α-configuration. A large JH-2´´, H-3´´ = 11.9 Hz and very small 
JH-3´´, H-4´´ ≈ 1 Hz, resulting from a coupling between an axial and an equatorial proton, 
revealed that the second (terminal) sugar corresponded to α-D-Galp.225 Finally, HMBCs 
between the α-D-Glcp H-2´ and the α-D-Galp C-1´´, and between the α-D-Glcp H-1´ and 
the glycerol C-3 (C-3 66.1 ppm), showed the linkage between the two sugar residues to 
be Gal-(1→2)-Glc (Figure 2.18). This was in accordance with the linkage analysis and 
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confirmed the structure of GL2a to be α-D-galactopyranosyl-(1→2)-α-D-
glucopyranosyldiglyceride.  
The fragmentation pattern for GL2a was used to confirm the assignment. In the same 
way as GL1, ESI-MS/MS was performed on the sodiated molecular ion (HRMS m/z = 
981.6482 for [C52H94O15+Na]
+
) using CID, in positive ion mode. The observed 
fragmentation spectrum (Figure 2.19) revealed two major fragment ion peaks which 
were attributed to the loss of oleic acid and dihydrosterculic acid (m/z = 699.4 and 
685.4, respectively). Signals for the fragment ions (m/z = 819.6) and (m/z = 657.6) 
representing MGDG and DAG respectively were also readily identified, as was a 
disaccharide fragment ion (m/z = 347.1). Multiple subsequent fragmentations led to yet 
another series of ions, as identified by the loss of both fatty acids (m/z = 405.5), and the 
loss of a monosaccharide and either fatty acid (m/z = 523.3 and m/z = 537.3). These 
fragments confirm the connectivity of the structural components of GL2a and, in 
combination with the NMR analysis discussed above, unequivocally establish the 
structure of GL2a. 
Historically, there has been ambiguity about the reducing end anomeric configuration in 
Lactobacillus glycoglycerolipids. On the basis of enzymatic hydrolysis studies, 
Brundish et al.
43
 concluded that the monoglucosyldiglyceride was linked in a β-fashion 
with the glycerol, while Shaw
46
 later reported an α-linkage, though no experimental data 
was provided for this assignment. These studies confirm an α-D-glucopyranosyl linkage, 
which is also in accordance with Fischer’s studies on the glycerophospholipids from L. 
plantarum,
189,190
 and the structure found in L. casei by Shaw et al.
203
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Table 2.3 NMR spectroscopic data for GL2a. 
Position δ1H (ppm) δ13C (ppm) COSY (H-H) HMBC (H-C) 
1´ 5.00 (d, 2.5) 96.8 2´ 3, 2´, 5´ 
2´ 3.60 (d, 11.3) 77.0 1´, 3´ 1´´, 3´ 
3´ 3.77 (t, 11.4) 72.1 2´, 4´ 2´, 4´ 
4´ 3.44 (t, 8.6) 70.2 3´, 5´ 5´, 6´ 
5´ 3.57 (m) 72.3 4´ 4´ 
6a´ 3.75 (m) 
61.6 
- - 
6b´ 3.73 (m) - - 
1´´ 5.00 (d, 2.5) 97.4 2´´ 2´´, 3´´, 5´´ 
2´´ 3.80 (d, 11.9) 69.2 1´´ 1´ 
3´´ 3.80 (m) 70.4 4´´ 2´´, 5´´ 
4´´ 3.95 (m) 70.0 3´´, 5´´ 2´´, 3´´ 
5´´ 4.09 (m) 71.3 4´´, 6a´´, 6b´´ 4´´, 6´´ 
6a´´ 3.74 (m) 
62.2 
5´´, 6b´´ - 
6b´´ 3.79 (m) 5´´, 6a´´ - 
3a 3.64 (m) 
66.1 
3b, 2 1´, 2, 1 
3b 3.83 (m) 3a, 2 1´, 2, 1 
2 5.24 (m) 70.3 1, 3 25 
1a 4.20 (dd, 6.0) 
63.0 
2, 1b 3, 2, 7 
1b 4.43 (dd, 3.0) 2, 1a 3, 7 
7 
- 
174.6 
- 
25 174.1 
8,26 2.34 (t, 7.5) 34.4 9 27 7, 9, 10 25, 27, 28 
9,27 1.62 (m) 25.1 8, 10 26,28 7, 8, 11 25, 26, 29 
15,16 5.35 (m) 130.1 14 17 13, 17 14, 18 
14,17 2.03 (m) 27.4 13, 15 16, 18 12, 15 16, 19 
10-13* 
1.10-1.35 (m) 28-32 - 
18-23* 
28-32* 
36-42* 
34a -0.33 (q, 5.0) - 34b, 33, 35 33, 35, 36 
34b 0.57 (q, 4.2) - 34a, 33, 35 32, 33, 35 
33,35 0.65 (q, 4.0) 16.2 34a, 34b - 
24,43 0.89 (t, 6.2) 14.2 23 42 22, 23 42 
* Overlapping signals 
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Figure 2.18 HMBC correlations proving the connections C-1´ to C-3, C-2 to C(O), 
C-1 to C(O) and C-1´´ to C-2´. 
 
 
Figure 2.19 ESI-MS/MS of GL2a in positive ion mode. 
NMR analysis of GL2b (Table 2.4) also revealed the presence of the (1→2)-linked α-
Glcp and α-Galp residues observed for GL2a, however, the α-D-Glcp H-6a´ and H-6b´ 
were markedly shifted downfield (H-6a´ = 4.26, H-6b´ = 4.37 ppm) and showed an 
HMBC to a carbonyl carbon (C 174.5 ppm). This confirmed the presence of an 
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additional fatty acid ester at the α-D-Glcp 6´-position, as predicted by HRMS (m/z = 
1393.9287). An additional sugar unit was easily identified in the HSQC of GL2b, which 
showed a third residue with a distinct anomeric signal at H-1´´´ = 4.37 ppm and C-1´´´ = 
103.5 ppm and coupling constants JH-1´´´, H-2´´´ = 10.2 Hz, JH-2´´´, H-3´´´ = 9.7 Hz and JH-3´´´, 
H-4´´´ = 10.0 Hz. This data, in combination with the typical upfield chemical shift of H-
2´´´ (H-2´´´ = 3.30 ppm), confirmed the presence of a β-D-Glcp residue.
146
 This was 
confirmed in the COSY spectrum where H-1´´´ correlated with H-2´´´ in the β-glucose 
moiety (Figure 2.20). In addition to the HMBCs between α-D-Galp, α-D-Glcp and 
glycerol observed in GL2a, GL2b showed a correlation between the α-D-Galp CH2-6´´ 
(H-6a´´ = 3.82 and H-6b´´ = 4.00 ppm) and the β-D-Glcp C-1´´´ (C-1´´´ = 103.5 ppm), thus 
confirming the presence of the 1,6-Galp linkage detected in the linkage analysis (Figure 
2.21).  
 
Figure 2.20 Proton to proton correlations showing the correlation between shielded 
H-1´´´ and H-2´´´ in the 
1
H,
1
H COSY spectrum of GL2b CD3OD/CDCl3 (1/2, v/v), 600 
MHz. 
H-1´´´ 
H-1´´´   H-2´´´ 
H-1´´´   H-2´´´ H-2´´´ 
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Table 2.4 NMR spectroscopic data for GL2b. 
Position δ1H (ppm) δ13C (ppm) COSY (H-H) HMBC (H-C) 
1´ 4.94 (d, 3.0) 97.2 2´ 3, 3´, 5´ 
2´ 3.56 (d, 9.7) 79.6 1´, 3´ 1´´, 3´ 
3´ 3.80 (t, 9.7) 72.6 2´, 4´ 2´, 5´ 
4´ 3.36 (t, 9.7) 70.0 3´, 5´ 6´, 5´, 3´ 
5´ 3.79 (m) 69.6 4´, 6a´, 6b´ - 
6a´ 4.26 (m) 
63.8 
5´, 6b´ 42, 5´ 
6b´ 4.37 (m) 5´, 6a´ 42, 5´ 
1´´ 4.96 (d, 3.0) 99.1 2´´ 2´, 2´´ 
2´´ 3.79 (d, 9.7) 69.2 1´´ - 
3´´ 3.80 (d, 10.0) 70.4 4´´ - 
4´´ 3.93 (m) 69.7 3´´, 5´´ 3´´, 6´´ 
5´´ 4.32 (m) 71.0 4´´, 6a´´, 6b´´ 6´´ 
6a´´ 3.82 (m) 
69.5 
5´´, 6b´´ 1´´´, 5´´ 
6b´´ 4.00 (m) 5´´, 6a´´ 1´´´ 
1´´´ 4.37 (d, 10.2) 103.5 2´´´ 2´´´ 
2´´´ 3.29 (t, 7.5) 73.9 1´´´, 3´´´ 1´´´ 
3´´´ 3.42 (t, 7.5) 76.4 2´´´, 4´´´ 2´´´, 4´´´ 
4´´´ 3.37 (t, 8.4) 70.5 3´´´, 5´´´ 3´´´, 6´´´ 
5´´´ 3.31 (dd, 2.6) 76.0 4´´´, 6a´´´, 6b´´´ 3´´´, 1´´´ 
6a´´´ 3.72 (m) 
61.9 
5´´´, 6b´´´ 4´´´ 
6b´´´ 3.88 (d, 2.1) 5´´´, 6a´´´ - 
3a 3.64 (m) 
66.1 
3b, 2 1´, 2, 1 
3b 3.83 (m) 3a, 2 1´, 2, 1 
2 5.24 (m) 70.3 1, 3 26 
1a 4.20 (dd, 6.0) 
63.0 
2, 1b 3,2 
1b 4.43 (dd, 3.0) 2, 1a 3 
7, 26, 42* 
61, 79, 97* 
- 174.0-174.5 - 
8,27,43 
62, 80, 98 
2.34 (t, 7.5) 34.4 
-* 
9, 28, 44 
63, 81, 99 
1.62 (m) 25.1 
69,70 
87, 88 
105-106 
5.35 (m) 130.1 -* 
68,71 
86, 89 
104, 107 
2.03 (m) 27.4 -*    
10-13, 18-23* 
29-40* 
45-48, 54-59* 
82-85, 90-95* 
64-67, 72-77* 
100-103, 108-113* 
1.10-1.35(m) 28-32 - 
17 and 51a -0.33 (q, 5.0) - 
-* 
17 and 51b 0.57 (q, 4.2) - 
50, 52, 15, 16 0.65 (q, 4.0) 16.2 
25, 41, 60,  
78, 96, 114 
0.89 (t, 6.2) 14.2 
* overlapping signals 
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Species 1: 
 
Species 2: 
 
 
 
Figure 2.21 HMBC correlations proving the connections of C-1´ to C-3, C-2 to C(O), 
C-1 to C(O), C-1´´ to C-2´, C-1´´´ to C-6´´ and C-6´ to C(O) in GL2b. 
The fragmentation pattern of GL2b was more complex than that observed for GL2a. At 
first, the fragmentation of the major ion in positive ion mode (HRMS m/z = 1393.9287 
for [C76H136O21+Na]
+
) using collision induced dissociation (CID), gave three major ions 
(m/z = 1111, 1139 and 1097) (Figure 2.22). If it is assumed that the molecular ion 
contains three oleic acids, 1111 m/z corresponds to the loss of oleic acid and 1069 m/z to 
the loss of a disaccharide. However, the presence of the two other fragments can be 
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explained only if another species containing the same mass as 1393 m/z is also present 
in the mixture. Indeed, the same mass can be obtained if two dihydrosterculic acids and 
one palmitic acid are present on the residue. Then the loss of palmitic acid and 
dihydrosterculic acid leads to the formation of two other major fragments (m/z = 1139 
and m/z = 1097, respectively). The loss of a disaccharide on fragments 1139, 1111 and 
1097 could also be observed (m/z = 815, m/z = 787 and m/z = 773 respectively). Also, a 
fragment corresponding to the disaccharide (m/z = 347.1) itself was observed. Two 
additional ions were identified as a monoacylated-containing oleic acid-trisaccharide 
(m/z = 831) and monoacylated-containing dihydrosterculic acid-trisaccharide (m/z = 
845). These fragments confirm the connectivity of the structural components of GL2b. 
Using NMR, the ratio of these two species is of approximately 3:7 (Species 1/Species 
2). Indeed, this could be calculated using the integration of the cyclopropane protons (-
0.33 ppm) and the double bond protons (5.35 ppm). 
Taken as a whole, this enabled GL2b to be conclusively identified as β-D-
glucopyranosyl-(1→6)-α-D-galactopyranosyl-(1→2)-6-O-acyl-α-D-glucopyranosyl-
diglyceride, a glycolipid not previously observed in L. plantarum, although it has been 
observed in L. casei
188
 and the corresponding phosphoglycolipid has been isolated from 
L. plantarum.
189,190
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Figure 2.22 ESI-MS/MS of GL2b in positive ion mode. 
2.3.3 GL3 
In an analogous manner, the final glycolipid GL3 (Table 2.5) was found to contain t-
Glcp, 1,2-Glcp and 1,6-Galp. NMR data exhibited a remarkable resemblance to that of 
GL2b, except for the shielded α-D-Glcp CH2-6´ (H-6a´ = 3.75 ppm, H-6b´ = 3.73 ppm 
and C-6´ = 61.5 ppm), and the absence of an additional acyl group at this 6´-position. 
Using CID, in positive ion mode, the sodiated molecular ion (HRMS m/z = 1143.7009 
for [C58H104O20+Na]
+
) was fragmented to confirm the assignment of GL3. The observed 
fragmentation spectrum (Figure 2.23) revealed two major fragment ion peaks which 
were attributed to the loss of oleic acid and dihydrosterculic acid (m/z = 861.5 and 
847.5, respectively). Signals for DGDG (m/z = 981.7), MGDG (m/z = 819.6) and DAG 
(m/z = 657.5) were also readily identified, as were the disaccharide (m/z = 347.1) and 
trisaccharides (m/z = 509.2) fragments themselves. Multiple fragmentations led to yet 
Species 1: 
Species 2: 
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another series of ions, as identified by the loss of both fatty acids (m/z = 567.2), the loss 
of a saccharide and either fatty acid (m/z = 685.4 and m/z = 699.4) and the loss of a 
disaccharide and either fatty acid (m/z = 523.3 and m/z = 537.3). These fragments 
confirm the connectivity of the structural components of GL3 and, in combination with 
the NMR analysis discussed above, unequivocally establish the structure of GL3 to be 
β-D-glucopyranosyl- (1→6)-α-D-galactopyranosyl-(1→2)-α-D-
glucopyranosyldiglyceride. Here it should also be noted that Shaw identified a 
glucosylgalactosylglucosyldiglyceride from L. plantarum, although no information on 
the configuration of the anomeric centres was provided, nor was any experimental data 
given.
46
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Table 2.5 NMR spectroscopic data for GL3. 
Position δ1H (ppm) δ13C (ppm) COSY (H-H) HMBC (H-C) 
1´ 4.97 (d, 3.8) 97.4 2´ 3, 2´, 3´ 
2´ 3.58 (dd, 4.0, 5.7) 79.1 1´, 3´ 3´, 1´´ 
3´ 3.78 (t, 10.0) 72.5 2´, 4´ 2´, 4´ 
4´ 3.46 (t, 9.8) 69.8 3´, 5´ 3´, 6´ 
5´ 3.58 (m) 72.3 4´, 6´ 3´, 6´ 
6a´ 3.75 (m) 
61.5 
5´ - 
6b´ 3.73 (m) 5´ - 
1´´ 4.96 (d, 4.2) 98.7 2´´ 2´, 3´´, 5´´ 
2´´ 3.79 (dd, 4.7) 69.2 1´´, 3´´ - 
3´´ 3.78 (dd, 3.3) 70.4 2´´, 4´´ - 
4´´ 3.93 (d, 2.2) 70.0 3´´, 5´´ 2´´, 3´´ 
5´´ 4.34 (dd, 3.3) 71.2 4´´, 6a´´, 6b´´ - 
6a´´ 3.85 (dd, 2.5) 69.6 5´´, 6b´´ 1´´´ 
6b´´ 4.00 (dd, 2.5)  5´´, 6a´´ 1´´´ 
1´´´ 4.39 (d, 7.8) 103.6 2´´´ 6´´, 3´´´ 
2´´´ 3.28 (t, 9.0) 74.1 1´´´, 3´´´ 1´´´, 3´´´ or 5´´´ 
3´´´ 3.42 (t, 9.7) 76.6 2´´´ 1´´´, 2´´´, 4´´´ 
4´´´ 3.37 (t, 9.8) 70.5 - 3´´´ or 5´´´, 6´´´ 
5´´´ 3.30 (dd, 2.6) 76.5 6a´´´, 6b´´´ - 
6a´´´ 3.75 (dd, 5.6) 
61.9 
5´´´, 6b´´´ 5´´´ 
6b´´´ 3.90 (dd, 5.6) 5´´´, 6a´´´ - 
3a 3.67 (dd, 6.4) 
66.0 
3b, 2 1´, 2, 1  
3b 3.85 (dd, 6.4) 3a, 2 1´, 2, 1 
2 5.25 (m) 70.3 1a, 1b, 3a, 3b 25 
1a 4.20 (dd, 6.0) 
63.1 
2, 1b 2, 7 
1b 4.44 (dd, 3.0) 2, 1a 3, 7 
7 - 174.6 - - 
25 - 174.1 - - 
8,26 2.34 (t, 7.5) 34.5 9 27 7, 8, 10 25, 27, 28 
9,27 1.61 (m) 25.2 8 26 7, 8, 11 25, 27, 29 
15,16 5.35 (m) 130.1 14 17 13, 17 14, 18 
14,17 2.03 (m) 27.4 15 16 12, 16 15, 19 
*10-13, 
1.25-1.35 (m) 28-30 - 
18-23, 
28-32, 
36-42 
34a -0.33 (q, 5.0) - 34b, 33, 35 32, 33, 35, 36 
34b 0.58 (q, 4.2) - 34a, 33, 35 32, 33, 35, 36 
33,35 0.67 (q, 4.0) 16.1 34a, 34b - 
24,43 0.89 (t, 6.2) 14.2 23 42 22 41 
* overlapping signals 
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Figure 2.23 ESI MS/MS of GL3 in positive ion mode. 
2.3.4 Bioactivity of L. plantarum Glycoglycerolipids 
In order to provide an insight on the effects that L. plantarum glycolipids might have on 
the immune system, the purified compounds were tested in a macrophage activation 
assay. Macrophages are antigen presenting cells that play a crucial role in the first line 
of defence in an organism. When activated, macrophages produce nitric oxide (NO) 
which is known to be responsible for the cytotoxic effects of the cells.
226,227
 Although 
whole Lactobacillus cells were found to activate macrophages,
99
 biological data 
concerning the ability of L. plantarum glycolipids (incl. LTAs) to activate macrophages 
is scarce.
193
 Figure 2.24 shows that GL1 and GL2a activated bone marrow macrophages 
to a small extent, however as indicated by the error bars in the graph, this activation is 
not statistically significant. Additionally, GL2b and GL3 compared to LPS, did not 
show any activation. This data is not surprising as reports have shown that synthesised 
89 
 
glycolipid anchors from S. aureus only induced minor IL-8 production when tested in 
human whole blood cells.
81
 Previous reports have described this cytokine as being 
proinflammatory and indicates macrophage activation.
228
 As whole blood cells also 
contain macrophages, such an assay results that those anchors only weakly activate 
mouse macrophages and human macrophages. 
 
Figure 2.24 Glycoglycerolipids NO production by BMMs. BMMs were stimulated 
with glycoglycerolipid (GL1, GL2a, GL2b and GL3) (20 g/mL and 40 g/mL), or LPS 
(100 ng/mL) and the supernatants were analyzed for NO after 48 h using the Griess 
assay. Mean and SD of triplicate samples from a representative experiment of two are 
indicated. 
 
 
 
90 
 
2.4 Concluding Remarks 
In summary, four major glycoglycerolipids of L. plantarum IRL-560 were conclusively 
identified as α-D-Glcp-diglyceride (GL1), α-D-Galp-(1→2) α-D-Glcp-diglyceride 
(GL2a), β-D-Glcp-(1→6) -α-D-Galp-(1→2)-6-O-acyl-α-D-Glcp-diglyceride (GL2b) and 
β-D-Glcp-(1→6)-α-D-Galp-(1→2)-α-D-Glcp-diglyceride (GL3). Interestingly, these 
structures have also been found in L. casei, although there has been confusion about the 
anomeric configurations of similar glycoglycerolipids isolated from L. plantarum. By 
providing conclusive evidence for the structures of the isolated glycoglycerolipids, this 
will aid in correlating the biological activities of L. plantarum to its individual cell wall 
components. Moreover, the provision of detailed NMR and mass spectrometry data will 
be useful for the future identification of these types of compounds. Preliminary data on 
macrophage activation by L. plantarum glycolipids showed non-significant NO 
production. 
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2.5 Supplementary data-NMR, MS spectra and 
Compound Characterisation 
2.5.1 GL1 
ESI-MS, positive ion mode  
 
 
GL1: Colourless oil (12.3 mg) []D
23
 = 49.1 (c = 0.5, CHCl3/MeOH, 2/1, v/v); IR (film) 
3382, 2923, 2853, 1738, 1456, 1366, 1228, 1216, 1151, 1025, 632, 576 cm
-1
; 
1
H, 
13
C 
NMR, HRMS and Rf data, see Table 2.1 and 2.2. 
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1
H NMR, CD3OD/CDCl3 (1/2, v/v), 500 MHz  
 
13
C NMR, CD3OD /CDCl3 (1/2, v/v), 125 MHz 
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1
H,
1
H COSY, CD3OD/CDCl3 (1/2, v/v), 500 MHz 
 
1
H,
13
C, HSQC, CD3OD/CDCl3 (1/2, v/v), 500 MHz 
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1
H,
13
C, HMBC, CD3OD/CDCl3 (1/2, v/v), 500 MHz 
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2.5.2 GL2a 
ESI-MS, positive ion mode 
 
GL2a: Colourless oil (0.7 mg) []D
24
 = -45.6 (c = 0.03, CHCl3/MeOH, 2/1, v/v); IR 
(film) 3389, 2922, 2854, 1738, 1366, 1228, 1260, 1032, 632, 578 cm
-1
; 
1
H, 
13
C NMR, 
HRMS and Rf data, see Table 2.1and 2.3. 
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GL2a, 
1
H NMR, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL2a, 
13
C NMR, CD3OD/CDCl3 (1/2, v/v), 151 MHz 
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GL2a, 
1
H,
1
H COSY, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL2a, 
1
H,
13
C, HSQC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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GL2a, 
1
H,
13
C, HMBC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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2.5.3 GL2b 
GL2b, ESI-MS, positive ion mode 
  
GL2b: Colourless oil (0.9 mg) []D
20
 = -31.3 (c = 0.15, CHCl3/MeOH, 2/1, v/v); IR 
(film) 3382, 2922, 2851, 1738, 1366, 1216, 1054, 570, 569  cm
-1
; 
1
H, 
13
C NMR, HRMS 
and Rf data, see Table 2.1and 2.4. 
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GL2b, 
1
H NMR, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL2b, 
13
C NMR, CD3OD/CDCl3 (1/2, v/v), 151 MHz 
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GL2b, 
1
H,
1
H COSY, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
 
GL2b, 
1
H,
13
C, HSQC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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GL2b, 
1
H,
13
C, HMBC,CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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2.5.4 GL3 
GL3, ESI-MS, positive ion mode 
 
GL3: Colourless oil (0.6 mg) []D
25
 = -59.3 (c = 0.03, CHCl3/MeOH, 2/1, v/v); IR 
(film) 3409, 2923, 2853, 1738, 1456, 1366, 1245, 1216, 1154, 632, 569 cm
-1
; 
1
H, 
13
C 
NMR, HRMS and Rf data, see Table 2.1 and 2.5. 
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GL3
1
H NMR, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL3, 
13
C NMR, CD3OD/CDCl3 (1/2, v/v), 151 MHz 
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GL3, 
1
H,
1
H COSY, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL3, 
1
H,
13
C, HSQC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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GL3, 
1
H,
13
C, HMBC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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Chapter 3 
 
Discovery of a Novel Glycolipid from B. 
longum subs. infantis (ATCC 15702T) 
 
Bifidobacteria are dominant members of the microbial community in the intestinal tract. 
Studies have shown that glycolipids extracted from the cell surface of these bacteria 
elicit immune responses and as bifidobacteria are beneficial, the characterization of 
these compounds is of interest. Despite this, the chemical nature of such 
immunomodulatory compounds has not been well documented. Herein, is presented for 
the first time the isolation and full structural characterization of the glycolipids from 
Bifidobacterium longum, including a novel glycolipid structure comprising an 
unprecedented mixed acetal glycolipid and a rapid MALDI method is reported to 
analyze the whole-cell mass glycolipid spectra.  
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3.1 Background 
Bifidobacteria, dominant members of the microbial community in the intestinal tract of 
infants, are thought to be important in developing a healthy immune system. In adults, 
the presence of bifidobacteria is associated with reduced incidence of bowel cancer, is 
thought to alleviate the irritable bowel syndrome symptoms, and is believed to help 
reduce atopic disease.
98,229
 For this reason, Bifidobacterium longum has been used as 
probiotic in order to improve the consumers health.
230
  
The chemical basis of these health benefits is not fully understood, but evidence 
suggests that it is, in part, due to the modification of the immune responses. As 
discussed in Chapter 1, the bifidobacterial cell wall consists of glycolipids, a 
peptidoglycan layer, lipoteichoic acids, wall teichoic acids, cell wall polysaccharides 
and exopolysaccharides. Although the immunomodulatory effects of glycolipids present 
in other bacterial cell walls are well understood, there is little published literature on the 
composition and structure of bifidobacterial glycolipids.
231-233
 Veerkamp have identified 
the presence of mono-, di- and tri-galactosyldiglyceride derivatives as the major 
constituents of B. bifidum var. pennsylvanicus.
44
 More recently, Novik et al.,
104,134,137,138
 
analyzed the principal glycolipids from a number of bifidobacterial species and strains 
by thin layer chromatography (TLC) and found an increased anti-glycolipid antibody 
response against glycolipid fractions. However, in both studies, only limited detail 
pertaining to glycolipid structure was presented but as seen in Chapter 1, the 
immunological properties of glycolipids seem to be related to their chain lengths and 
thus structural characterization would give important insights for future structure 
activity relationship studies. A method, such as Matrix-assisted laser 
desorption/ionization (MALDI) can thus be used to rapidly screen the structures of 
these glycolipids.
234-237
  
The screening of bacterial samples using MALDI for lipid content is now a common 
occurrence in lipidomics.
238-240
 This technique consists of extracting the lipids or 
glycolipids and analyzing the crude mixture using MALDI.
238
 A faster and simpler 
method involves MALDI analysis of whole bacterial cells.
241-245
 Here, whole bacterial 
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cells are crystallized with a matrix and subjected to the MALDI laser beam. MALDI 
analysis on whole cells has been used mostly for taxonomy purposes, while the specific 
analysis of glycolipids using this technique has not been much utilized. Calvano et al. 
analyzed whole Lactobacillus plantarum cells by MALDI and observed masses 
corresponding to glycolipids including diglycosyldiglycerides (DGDGs) and 
triglycosyldiglycerides (TGDGs), and other polar lipids.
184
 Shu et al. also attributed 
specific masses as DGDG in Bacillus subtilis using whole cell MALDI analysis.
240
 
Glycolipids were attributed putatively and further structural analysis using NMR, ESI-
MS, sugar analysis and fatty acid analysis is required. 
There is growing interest in the beneficial effects of bifidobacteria as probiotics, 
however there is a lack of information on the chemical composition of the 
bifidobacterial cell wall. In this chapter, the glycolipids of bifidobacteria that have been 
shown to induce differential immune response in immune assays in vitro are 
analyzed.
104
 Accordingly, the objective of this work was to highlight the structures of 
the key glycolipids found in a human biotype of B. longum subs. infantis (ATCC 
15702T), and for the first time, provide full structural characterization of these 
glycolipids. This is a first step in gaining a better understanding of the structure/activity 
relationship providing the beneficial effects of bifidobacteria. 
3.2 Experimental Procedures 
For details on the experimental procedures see Chapter 2. 
3.2.1 Bacteria and Cultivation 
[The bacterial growth was conducted by Jason Ryan, IRL] 
B. longum subs. infantis (ATCC 15702L) was obtained from the American Type 
Culture Collection (ATCC, Manassas, USA) and B. longum subs. longum (DSM 20219) 
was obtained from the German Collection of Microorganism and Cell Cultures (DSM, 
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Braunschweig, Germany). The B. longum cultures were grown plated onto Refined 
Clostridium media (RCM) agar and incubated anaerobically at 37 °C for 24 h. 
Glycolipid production was conducted anaerobically at 37 °C for 24 h. Glycolipid 
production was conducted anaerobically in a 18 L fermenter using a Carbohydrate-free 
Man–Rogosa–Sharp (MRS) media in a 20 L Braun bioreactors (Sartorius-Stedim, 
Aubagne Cedex, France). The culture was then centrifuged at 3000 g for 10 min to yield 
a watery paste and the cell-mass was freeze-dried. Next, the dried cell-mass was washed 
three times with PBS buffer (pH 7.3) and centrifuged (15 min, 31 186 g, 4 °C) or until 
the amount of carbohydrate detected in the washes by colorimetric assay was under 1% 
(w/v). To remove the PBS buffer, the cells were washed with deionised water and 
centrifuged, then freeze-dried and weighed. 
3.2.2 MALDI 
Whole washed bacterial cells (10 mg) were suspended in a mixture of CHCl3/MeOH 
(1/1, v/v, 1 mL) or MiliQ water (1 mL). The cell suspension (1 μL) and MALDI matrix 
(1/1, v/v) was deposited using the dry droplet method onto a stainless steel plate in 
sextuplicate. Reproducible spectra were obtained using a solution of 2,5-
dihydroxybenzoic acid (DHB) (30 mg/mL) in CH3CN/H2O (7/3, v/v) as a matrix. The 
MS/MS experiments were conducted on a AB SCIEX TOF/TOF™ 5800 system 
operating in reflectron positive ion mode. Mass calibration was performed externally 
using a peptide mixture containing des-arg
1
-bradykinin, angiotensin 1, neurotensin and 
glu
1
-fibrinopeptide B. 
3.2.3 Thin layer chromatography (TLC) 
Bifidobacterial glycolipids samples were dissolved in CHCl3/MeOH (2/1, v/v) and 
applied to dried silica pre-coated TLC plates. The bifidobacterial glycolipids were 
eluted with CHCl3/MeOH (6/1, v/v), sprayed and developed with a cerium molybdate 
(Hanessian´s) stain and molybdate stain to detect phosphorous .
206,207
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3.2.4 Extraction and purification of glycolipids 
Bifidobacterial dried cell-mass (6 g) was extracted twice (400 mL, 18 h, 37 °C) with 
CHCl3/MeOH/H2O (10/5/1, v/v/v). After filtration, the combined extracts were then 
evaporated to dryness (ca. 0.8 g) and suspended (100 mL) in CHCl3/MeOH/H2O 
(5/5/4.5, v/v/v) and rested overnight (16 h, 4 °C) to remove the polar material. The 
organic fraction was evaporated to dryness and analyzed by TLC. The crude lipid 
extracts were preabsorbed onto silica gel and fractionated on silica columns. Glycolipids 
were eluted successively with a step-wise gradient of MeOH in CHCl3 and further 
purified, if needed, using preparative TLC.  
3.2.5 NMR spectroscopy 
Purified glycolipids were dissolved in 0.7 mL CDCl3/CD3OD (2/1, v/v). Samples were 
analyzed at 30 °C and the chemical shift measured relative to TMS. The fatty acid 
methyl esters were dissolved in CDCl3. NMR spectra were recorded on a Bruker 
Advance III 500MHz spectrometer or a Varian DirectDrive 600 (600 MHz for 
1
H, 150 
MHz for 
13
C) spectrometer. 
3.2.6 ESI-TOF MS 
Electrospray mass spectrometry (or accurate mass measurement) was performed in the 
positive (or negative) ion mode on a Micromass Q-Tof Premier instrument. All MS-MS 
experiments were performed on a Q-Tof Premier mass spectrometer (Micromass, UK). 
3.2.7 Alditol Acetates Method 
The constituent sugar neutral composition was determined by GC-MS following TFA 
mediated acid hydrolysis and derivatisation to alditol acetates.
49
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3.2.8 Glycosyl Linkage Analysis 
Bacterial glycolipids (ca. 0.5 mg) were methylated as described by Ciucanu and Kerek
50
 
with the exception that samples were dispersed in DMSO (0.5 mL) and heated (50 °C) 
overnight under argon. After extraction into chloroform, the methylated polysaccharides 
were hydrolysed with TFA, reduced, and then acetylated before analysis by GC-MS as 
described above. Identifications were based on peak retention times and by comparison 
of electron impact spectra with standard spectra. Here, the partially methylated alditol 
acetate standards were prepared following the method of Doares et al.
208
 
3.2.9 Sugar Absolute Configuration 
After hydrolysis, the sugar residues were subjected to a reductive amination with R-(-)-
1-amino-2-propanol and cyanoborohydride following the method of Cases et al.
209
  
3.2.10 Fatty Acid Analysis 
Fatty acid methyl esters (FAMEs) were prepared by direct transesterification from 
samples of biomass (ca. 0.5 mg) without extraction, as described by Svetashev et al.
28
 
The resulting FAMEs and DMA were taken up in hexane and analyzed by GC and GC-
MS.
210
 The hydroxy fatty acids were derived to their TMS derivatives.
212e
 The position 
of the cyclopropane group was elucidated after separation of saturated fatty acids 
fraction by means of silver ion SPE.
ee
 This separation step was followed by 
hydrogenation in acetic acid over Adam´s catalyst to open the cyclopropane ring.
213e
 
The resulting fatty acids were converted to pyrrolidides
214e
 and analyzed by GC-MS 
analyzes. The position of the double bond in the monounsaturated fatty acids and 
DMAs was located by GC-MS of dimethyldisulfide adducts.
214f
 
 
                                                 
e
 Supelco. 2006. Discovery® Ag-Ion SPE for FAME fractionation and cis/trans separation (technical 
report). 
http://www.sigmaaldrich.com/etc/medialib/docs/Supelco/Bulletin/t406062.Par.0001.File.tmp/t406062.pdf 
f
Assay conducted by Kirill Lagutin, IRL  
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3.3 Characterisation 
3.3.1 Whole Cell MALDI Analysis 
Heat-killed, whole cells of Bifidobacterium longum subsp. infantis (10 mg/mL) were 
suspended in either CHCl3/MeOH (1/1, v/v) or water using DHB (30 mg/mL) as a 
matrix and analyzed by MALDI mass spectrometry (Figure 3.1). The mass spectrum 
shows a number of molecular ions, with three (m/z 779, m/z 805 and m/z 819) 
corresponding to a monoglycosyldiglyceride (MGDG) containing different fatty acid 
chains (16:0/18:1, 18:1/18:1 and 18:1/19:1). The most abundant molecular ion in the 
mass spectrum (m/z 881) did not correspond to any known glycolipid even though a 
series of molecular ions at m/z 855, m/z 827 and m/z 881 differed from each other by 
masses consistent with varying fatty acid chain lengths (881-855= 26 m/z, CH=CH and 
855-827= 28 m/z, CH2CH2). Further, MALDI mass spectrometry of B. longum subsb. 
longum DSM 20219 also showed this mass pattern. In order to determine the nature of 
the compound with this intriguing mass (m/z 881), the glycolipids on the surface of B. 
longum subs. infantis were extracted and purified.  
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Figure 3.1 MALDI spectrum of heat-killed whole cells of B. longum subs. infantis 
ATCC15702T. 
3.3.2 Glycolipid Isolation and Structural Characterisation 
In order to isolate sufficient amounts of each compound observed by MALDI, cells 
were cultured in 18 L of medium, isolated by centrifugation and freeze-dried. Extraction 
of the resulting cell mass (6 g) using CHCl3/MeOH/H2O yielded 480 mg of crude lipid. 
Fractionation on silica gel of the extracts gave 5 individual fractions. These isolated 
compounds were analyzed using ESI-MS and NMR, in addition to fatty acid, sugar and 
linkage analysis. Two compounds with higher running spots on TLC (Rf = 0.21 and Rf = 
0.36, CHCl3/MeOH, 6/1, v/v, Figure 3.2) were identified as lipids. Analysis of lipid 1 
(L1) revealed the presence of oleic acid (HRMS calc. for [C18H33O2]
-
 = 281.2486, found 
: 281.2484), and the slightly more polar lipid L2 was attributed to 10-
hydroxyoctadecanoic acid (HRMS calc. for [C18H35O3]
-
 = 299.2592, found: 299.2579). 
Both structures matched previously published data.
29,218,219
 
115 
 
 
Figure 3.2 TLC of purified glycolipids from Bifidobacteria. B. l. crude lipid extract, 
L1–3, GL4 and GL5 extracted from B. longum subs. infantis. Silica gel, eluted with 
CHCl3/MeOH (6/1, v/v) and developed with Hannessian’s stain. 
Two compounds with an Rf on TLC of 0.56 and 0.41 (CHCl3/MeOH, 6/1, v/v, Figure 
3.2) were next identified as glycolipids (GL4 and GL5). Again, fatty acid, sugar and 
linkage analysis, in addition to Rf values, yields and HRMS, were used to provide an 
overview of the chemical characteristics of the individual glycolipids GL4 and GL5 
(Table 3.1). The glycolipids were then fully characterized using 
1
H- and 
13
C-NMR, and 
assignments were made using COSY, HSQC and HMBC experiments (Table 3.3 and 
3.4).  
 
 
 
 
B. l.  L1   L2 GL4 GL5 L3 
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Table 3.1 Chemical characteristics of isolated compounds. 
 B. l. subs. infantis 
 L3 GL4 GL5 
Rf 0.10 0.56 0.41 
Yield 0.3% 0.1% 1.8% 
Neutral sugar (w%)    
D-Gal - 10.6 15.6 
D-Glc - 0.8 - 
Total - 11.4 15.6 
Linkage analysis (mol ratio)    
t-Galf - - 1.0 
t-Galp - 0.8 - 
t-Glcp - 0.2 - 
Total fatty acid content 
(w%) 
48 32.0 54.7 
Fatty acids and DMA (w%)    
14:0 - - 1.7 
DMA 16:1n-7 1.9 - 1.0 
16:0 7.4 6.5 13.3 
16:1n-7 1.7 2.3 4.7 
DMA 18:1n-9 2.8 - 36.4 
18.00 7.4 4.3 3.1 
18:1n-9 35.4 41.6 23.4 
18:1n-7 2.8 38.9 9.7 
18:1n-6 1.2 - 3.1 
9,10-Mt-19:0 - 2.9 - 
HRMS    
Positive Ion Mode  805.5770 881.6349 
Negative Ion Mode 401.2466 - - 
 417.2421 - - 
* Fatty acids present under 1% are not shown. DMA = fatty aldehyde dimethyl acetal 
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3.3.3 GL4 
For GL4 (Table 3.2), sugar and linkage analysis revealed terminal galactopyranose (t-
Galp) as the major sugar present (0.8 mol ratio) as well as small amount (0.2 mol ratio) 
of terminal glucopyranose (t-Galp). In addition, fatty acid analysis showed that oleic 
acid accounted for most of the lipid content (41.6%) with cis-vaccenic acid in almost 
equal proportion (38.9%). Other fatty acids present included palmitic acid, palmitoleic 
acid, stearic acid and dihydrosterculic acid. HRMS of GL4 (m/z 805.5770 for 
[C45H82O10+Na]
+
) was consistent with the presence of a monoglycosyldiglyceride, and 
NMR analysis confirmed the presence of a β-linked galactopyranose (δH-1´ = 4.24 ppm, 
JH-1´, H-2´ = 7.8 Hz, and δC-1´ = 109.2 ppm, and the small JH-3´, H-4´ = 3.3 Hz).
246
 HMBC 
between 4.2 ppm (H-1
´
) with carbonyl carbon (C(O) = 174 ppm) confirmed the presence 
of an acyl group at this position. An HMBC between the 3.7/4.0 ppm glycerol protons 
and the anomeric carbon confirmed the attachment of the sugar to the glycerol.  
The connectivity between the structural components of GL4 was confirmed using ESI-
MS/MS. The sodiated molecular ion (HRMS m/z = 805.5770 for [C45H82O10+Na]
+
) was 
fragmented to give one major fragment corresponding to loss of a first oleic acid (m/z = 
525.3, Figure 3.3). Further fragmentation and loss of a second oleic acid gave another 
minor fragment (m/z = 243). β-D-galactopyranosyl-diglyceride common in nature in 
both plants and bacteria.
204,247
 GL4 was identified as a β-D-galactopyranosyl-diglyceride 
as all proton and carbon NMR signals were in accordance with literature data (Table 
3.2).
53
 Its presence has been observed previously in bifidobacteria,
44
 and has also been 
recorded in two opportunistic pathogens, found in soil: Arthrobacter globiformis and 
Artrobacter scleromae.
53,248
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Table 3.2 NMR spectroscopic data for GL4. 
Position 
δ1H 
(ppm) 
δ13C (ppm) 
COSY  
(H,H) 
HMBC 
(H,C) 
Literature 
δ1H 
(ppm)
53
 
δ13C 
(ppm)
52
 
1´ 
4.24  
(d,7.7) 
103.2 2´ - 
4.24 103.9 
2´ 
3.55 
(dd,7.7,9.9) 
70.3 1´, 3´ 1´, 3´ 
3.55 71.2 
3´ 
3.50  
(dd, 3.3, 9.9) 
72.5 2´, 4´ 2´, 4´ 
3.50 73.9 
4´ 
3.89  
(dd, 0.8, 3.3) 
67.9 3´, 5´ 5´ 
3.89 70.1 
5´ 
3.51  
(m) 
74.5 4´, 6a´, 6b´ 6´ 
3.51 74.8 
6a´ 
3.81  
(ABX, 6.9 11.6) 
60.6 5´, 6b´  
3.82 
61.7 
6b´ 
3.76  
(ABX, 5.5, 11.6) 
60.6 5´, 6a´ 5´ 
3.76 
3a 
3.97  
(ABX, 5.4, 10.7) 
66.9 
3b, 2 
1´, 2, 1  
3.96 
66.2 
3b 
3.73  
(ABX, 6.2, 10.7) 
3a, 2 
3.73 
2 
5.29  
(m) 
69.7 1, 3 - 
5.28 69.8 
1a 
4.40  
(ABX, 3.0, 12.1) 
62.0 
2,1b 
1, 2 
4.39 
62.3 
1b 
4.23  
(ABX, 6.1, 12.1) 
2,1a 
4.23 
7, 25 - 173.4 - - 
- - 
8, 26 2.33 (t,7.0) 33.3 9 27 7, 9, 10 25, 27, 28 
9, 27 1.60 (m) 24.0 8, 10 26, 28 10 28 
10, 28 
1.25-1.40 (m) 28.2-29.2 - - 
11, 29 
12, 30 
13, 31 
14, 32 
15, 33 
5.29 (m) 129.0 - - - - 
16, 34 
17, 35 
1.25-1.40 (m) 26.3 - - - - 
18, 36 
19, 37 
20, 38 
21, 39 
22, 40 
23, 41 
24, 42 0.87 (t, 6.5) 13.0 23 41 22 40 
*Overlapping signals 
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Figure 3.3 ESI MS/MS of GL4 in positive ion mode. 
3.3.4 GL5 
Glycolipid GL5 (Table 3.3) was of particular interest, as it showed unique mobility on 
TLC, intermediate to that of mono- and diglycosyldiglycerides (Figure 3.2). A 
compound with a similar mobility on TLC was also observed by Novik et al.,
104
 
however its structure was not elucidated. In contrast to GL4, constituent sugar and 
linkage analyzes of GL5 revealed the presence of terminal galactofuranose (t-Galf), 
which is a configuration previously observed in bifidobacterial glycolipids isolated by 
Veerkamp in the 1970s.
44
 Galactofuranoses are usually formed from UDP-Galp via a 
UDP-Galp mutase to lead to UDP-Galf. As seen in Chapter 1 (Section 1.4.4), a UDP-
sugar is usually bound to DAG via an YpfP enzyme to form the glycosyldiglyceride, 
and thus the presence of both sugars (Galp and Galf) can be explained.
249
 The presence 
of a t-Galf residue was readily confirmed by the 
1
H-NMR spectrum that showed an 
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apparent singlet at δ 4.94 ppm corresponding to H-1 of a β-Galf moiety. The presence of 
a singlet was due to a small vicinal coupling constant (< 2 Hz).
250
 This assignment was 
confirmed by the 
13
C chemical shift and the direct spin-spin coupling constant (
1
JC-1´,H-
1´) of the anomeric carbon (108.6 ppm, JC-1´,H-1´= 172 Hz)
251-253
 and the HMBC 
correlation between the anomeric proton and C-4´ (δ 85.1 ppm). In a galactofuranose 
moiety, the configuration of the anomeric position cannot be distinguished using the 
coupling constant. Indeed, the dihedral angle between H-1´ and H-2´ is very similar for 
an α- or a β- linkage resulting in similar coupling constants, thus indistinguishable. The 
use of the 
1
JCH coupling constant is commonly used to this effect. Due to 
stereoelectronic effects, an equatorial proton showed a 
1
JC-1´,H-1´coupling constant of 
~170 Hz, while a axial proton showed a 
1
JC-1´,H-1´ coupling constant of ~160 Hz. 
251-253
 
Other sugar resonances (
1
H and 
13
C), assigned on the basis of the COSY, HSQC and 
HMBC 2D NMR spectra, were all consistent with a β-t-Galf moiety.251,252 
Perhaps the most unique characteristic of GL5, however, was the positive-ion HRMS 
(m/z = 881.6349 for [C48H90O12+Na]
+
), which was previously observed by MALDI 
mass spectrometry of the whole cells. Such a molecular formula is unexpectedly high in 
oxygen for a monoglycosyldiglyceride, although it could correspond to the 
condensation product of a hexose, two glycerols, a fatty acid, and a lipid ether with an 
additional degree of unsaturation. Indeed, this realization proved key in solving the 
unique structure of GL4. Further information on the nature of the lipid ether was 
obtained via lipid analysis (Table 3.1), which in addition to the anticipated palmitic and 
oleic acids, revealed high amounts of dimethyl acetals (DMAs). DMAs typically arise 
from enol ether type lipids (e.g. plasmalogens) following methanol/acid treatment 
(Chapter 1, Section 1.6.3).
29,254
 Furthermore, NMR spectroscopy of GL5 showed an 
unusual triplet at δH-13 = 4.54 ppm (JH-13, H-14 = 5.9 Hz) with an associated δC-13 = 109 
ppm. COSY and HMBC experiments then showed this proton to be part of a long chain 
acetal, thus explaining the observed DMAs in the fatty acid analysis (Figure 3.4 and 
3.5). 
The connectivity of the acetal centre was readily established by way of HMBC analysis, 
which revealed correlations between the acetal centre and two CH2-groups of two 
different glycerols. One glycerol was acylated at the 2-position (δH-8 = 5.20 ppm), as 
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evidenced by an HMBC with a lipid carbonyl (δC-31 = 174.2), while the 7-position 
showed an HMBC with the H-1 of the galactofuranose. The second glycerol did not 
show any further HMBCs and appeared unsubstituted. All fragments predicted by 
HRMS were now connected and allowed the structure of GL5 to be formulated as a 1-β-
D-galactofuranosyl-3-glyceroplasmalo-monoglyceride. 
Table 3.3 NMR spectroscopic data for GL5. 
Position δ1H (ppm) δ13C (ppm) COSY (H-H) HMBC (H, C) 
1´ 4.94 (s) 108.6 2 2,4,7 
2´ 3.99 (dd, 1.0, 2.4) 80.9 1,3 - 
3´ 4.01 (dd, 2.4, 4.7) 78.2 2 - 
4´ 4.03 (dd, 3.0, 4.7) 85.1 5 - 
5´ 3.79 (m) 71.5 4,6 - 
6´ 3.67 (m) 63.7 5 4 
7a 3.65 (m) 66.0 7b,8 
1´,9 
7b 3.82 (m) 
66.0 
 
7a,8 
8 5.20 (m) 71.8 7, 9 31, 7, 9 
9a 3.62 (m) 
64.2 
8,9b 7, 8, 13 
9b 3.79 (m) 8,9a 7, 8, 13 
10a 3.48 (ABX, 10.0, 6.2) 
67.0 
10b 11, 12, 13 
10b 3.63 (m) 10a 11, 12, 13 
11 3.81 (m) 71.2 10, 12 - 
12a 3.58 (m) 
63.8 
11,12b 10, 11 
12b 3.68 (m) 11,12a - 
13 4.54 (t, 5.9) 109.2 14 9, 10, 14 
14 1.62 (m) 25.2 13 15 
20,38 2.00 (m) 27.2 19,21 37,39 19 37 
21,39 5.38 (m) 130.0 20 38,40 23 38 
22,40 5.38 (m) 130.0 23 39,41 20 41 
23,41 2.00 (m) 27.2 24 40,42 24 42 
16-19, 
24-29, 
34-37, 
42-47 
1.35-1.25 (m)* 29.5-28.5* - 
30,48 0.89 (t, 7.0) 14.2 29 47 29 47 
31 - 174.2 - - 
32 2.34 (t, 7.5) 34.6 - 31,33,34 
33 1.60 (m) 25.2 32,34 34 
* Overlapping signals 
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Figure 3.4 Proton to proton correlations showing that the acetal signal correlated to 
the fatty acid chains in the 
1
H,
1
H COSY spectrum of GL5, CD3OD/CDCl3 (1/2, v/v), 
600 MHz. 
 
Figure 3.5 Proton to carbon correlations showing the presence of a furanose moiety 
and the connections between the different parts of the molecule in the 
1
H,
13
C HMBC of 
GL5, CD3OD/CDCl3 (1/2, v/v), 600 MHz. 
H-13 
H-14 
H-13→C-14 
H-13→C-9 
H-13→C-10 
H-1´→C-7 
H-1´→C-3´ 
H-1´→C-4´ 
H-13    H-14 
H-13    H-14 
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To confirm GL5 assignment, ESI-MS/MS was used and all fragments were accounted 
for. The major molecular ion peak in positive ion mode (m/z = 881.6) was fragmented 
using CID and the most abundant fragment ion (m/z = 541.3) was attributed to the loss 
of glycerol and aldehyde (Figure 3.6a). Additional fragments at m/z = 789.6, 719.6, 
259.1 and 203.1 were also detected and could be explained by the loss of glycerol, 
galactose, fatty aldehyde and fatty acid, respectively (Figure 3.6a). In addition, MS/MS 
in negative ion mode (Figure 3.6b) showed the quasimolecular ion of m/z = 893.6 
[M+Cl]
-
 and loss of HCl (m/z = 857.6 [M-H]
-
). CID fragmentation of the m/z 893.6 
[M+Cl]
-
 ion provided a major fragment at m/z = 281.2 corresponding to the oleate 
anion. Higher mass fragments consisted of m/z = 431.3 (loss of galactose and oleate), 
m/z = 575.4 (loss of oleic acid) and m/z = 593.4 (loss of oleyl). The loss of these 
fragments confirms the connectivity of the structural components and unequivocally 
corroborated the unusual structure of GL5.  
Acetal containing glycolipids exist as plasmalogalactosylceramide and 
plasmalogalactosylalkylglycerol (Figure 3.7),
255,256
 glyceroplasmalopsychosine (Figure 
3.8),
257
 aldehydogenic ethanolamine phospholipid,
258
 and glycerol acetal of 
plasmalogen.
259,260
 These acetal type glycolipids have also been found in Sarcina 
ventriculi
261
, with the acetal moiety believed to be the result of a head-to-head coupling 
defense mechanism from the bacteria after a perturbating event (heat shock, pH, 
antibiotics). The mechanism would involve a nucleophilic attack of a hydroxyl group on 
the enol ether moiety of a plasmalogen under acidic conditions (Figure 3.9). This type 
of defense mechanism or even the occurrence of an acetal containing glycolipids 
remains unprecedented in bifidobacteria. 
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a. Positive ion mode 
 
b. Negative ion mode 
 
Figure 3.6 MS/MS of GL4 in a. positive ion mode and b. negative ion mode. 
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Figure 3.7 Plasmalogalactosylalkylglycerol glycolipid extracted from equine 
brain.
255,256
 
 
Figure 3.8 Glyceroplasmalopsycosine extracted from bovine brain.
257
 
 
Figure 3.9 Proposed mechanism showing coupling between plasmalogen lipids and 
DAG.
261
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3.3.5 L3 
The lowest spot on TLC (Rf = 0.10, CHCl3/MeOH, 6/1, v/v), L3, was found to be a 
mixture of phospholipids. As seen in Chapter 1 (Section 1.4.4), phospholipids are 
common bacterial cell wall constituents. The presence of phosphorous was confirmed 
by TLC using a molybdate stain
206,207
 and through 
31P NMR (δP = 0.2 ppm) although the 
signal was very weak and broad indicating a mixture of phospholipids. Two principal 
signals were detected using HRMS in negative ion mode (m/z = 401.2466 for 
[C21H38O6P]
-
 and m/z = 417.2421 [C21H38O5P]
-
) which were identified as C18:1-
plasmenyl-cPA and C18:1-cPA, respectively. The molecular ion of L3a (m/z = 401), 
dissociated into 4 fragments: m/z = 265 (C18:1 aldehyde), 135 (cyclophosphaglyceryl), 
97 (PO4
-
) and 79 (PO3
-
) (Figure 3.10). In contrast to L3a, collision induced dissociation 
(CID) of [L3b-H]
-
 (m/z = 417) produced two main fragments of m/z = 281 (oleate) and 
m/z = 153 (cyclophosphaglycerol) (Figure 3.11). The difference in dissociation pattern 
can be attributed to the presence of an enol-ether linkage, which provides different 
stabilities to the fragment ions. The presence of cPA’s in bifidobacteria is surprising, as 
this is the first time they have been isolated from bacteria. However, these cPAs have 
been found to be biologically active in the past,
262
 and evidences of plasmalogen 
presence has previously been identified in bifidobacteria (Chapter 1, Section 1.6.3). 
Plasmalogens are usually detected in animals and although they are not often found in 
facultative anaerobic bacteria,
263
 they have been detected in such by Oberg et al.
131
 
Plasmalogens in anaerobic bacteria have been known for ca. 50 years, and although the 
plasmalogen biosynthetic pathway is well understood in animals, the biosynthetic 
pathway regarding their formation in anaerobic bacteria is unknown. Scheme 3.1 shows 
the biosynthetic pathway to form plasmenylethanolamine 6. At first, dihydroxyacetone 
phosphate 1 is acylated via acyl-COA. The product (Acyl-DHAP) is then transformed 
through the action of alkyl-DHAP synthase to form Alkyl-DHAP. At this point, NADH 
reduces the ketone to alcohol 2. This compound is acylated and resulting phospholipid 3 
is dephosphorylated. After this, a phosphoethanolamine group is introduced via CDP-
Etn resulting in glycerolipid 4. The last step involves a 1´-alkyl desaturase that 
stereospecifically abstract a proton from C-1´ and C-2´ of the O-alkyl chain. Compound 
5 is thus transformed into a plasmalogen. As this last step involves oxygen, it is 
127 
 
believed that the biosynthetic pathway differs between anaerobic bacteria and 
animals.
263
 
 
Figure 3.10 MSMS of L3a in negative ion mode. 
 
Figure 3.11 MSMS of L3b in negative ion mode. 
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Scheme 3.1 Plasmalogen biosynthetic pathway in animals.
263
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3.4 Biological Screening of Extracted Compounds 
As seen in Chapter 1 (Section 1.6), bifidobacteria whole cells and components were 
found to be biologically active. Thus, the glycolipids were tested in three different in 
vivo and in vitro assays. Before screening the immunological properties of these 
compounds, they were first confirmed to be free of endotoxin, as determined by the 
Limulus amebocyte lysate (LAL) assay.
g
 It is important to note that the results obtained 
are only preliminary. Further assays would be required to establish the full biological 
assessment of those gycolipids. Firstly, the glycolipids were assessed for their 
allerginicity and sensitization potential.
h
 Secondly, the ability of the glycolipids to 
induce IL-10 and IL-12 production in human and mice DCs was tested.
i
 Finally, the 
glycolipids were tested in a macrophage activation assay.
j
 
The in vivo allerginicity and sensitization assay was deemed noteworthy due to a 
growing interest in the relationship between bifidobacteria and atopic disease.
264
 For 
example, research pursued by Young et al. showed that the bifidobacterial species 
present in the feces of infants from the United Kingdom and New Zealand, where there 
is a high incidence of atopic diseases, differ from those present in infants from Ghana, 
where incidence of atopic diseases is low.
264,265,266,267
 Thus, the allerginicity and 
sensitization assay was conducted on GL5. The results of this assay show that the 
glycolipids were not allergenic and additionally did not reduce the allergic response to 
dust mites in mice. However, in this case, the amount of glycolipid available for the 
assay was low and only two concentrations were tested (10 g/30 L and 100 g/30 
L). Hence, higher amounts of material would be required for a definitive answer on the 
allerginicity and sensitization of these glycolipids. 
A previous study, by Young et al., has indicated differential induction of IL-10 and IL-
12 in cord blood-derived dendritic cells (DCs) and in CD86 expression depending on 
                                                 
g
 Extracted bifidobacteria glycolipids were tested to be endotoxin-free at a sensitivity of 0.125 EU/mL 
with an endotoxin-kit (Pyrotell, Limulus amebocyte lysate) according to the manufacturer’s instructions. 
h
 Assay conducted by Mali Cambertis. 
i
 Assay conducted by Odette Shaw and Jacquie Harper. 
j
 Assay conducted by Ashna Khan and Stephanie Chee. 
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the bifidobacteria species.
264
 Thus GL5 capacity to induce IL-10 and IL-12 production 
in human and mice dendritic cells was tested. GL5 was found to be unable to induce 
pro- or anti-inflammatory cytokines in dendritic cells derived from human blood and 
this assay also showed negative results in mice DCs. However, to validate the results of 
the assays, a repeat of the assays would be required. Furthermore, additional 
experiments regarding cytokine induction in cells should be conducted. Here, the use of 
different cell type may be interesting for future assays (e.g. cord blood
264
 or human 
intestinal epithelial cells
139
). 
GL4 and GL5 were tested for their ability to activate mouse macrophages as 
bifidobacteria species have previously been shown to induce cytokine production in 
macrophages.
268
 In this assay, the glycolipids isolated from bifidobacteria showed no 
significant activity. This is not unexpected as research has reported marked differences 
in biological activity when surveying glycolipids with different fatty acid 
compositions.
63,77,78,269,270
 
Further work concerning the immunological properties of GL4 and GL5 would be 
required for a broader overview of the activity of these glycolipids. Indeed, iNKT cells 
assays could be conducted as Kinjo et al. reported that glycoglycerolipids from S. 
pneumonia induced IL-2 production in iNKT cells.
78
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3.5 Concluding Remarks 
In this chapter, MALDI was first used to screen whole bifidobacteria cells for their 
glycolipid components. Then, the glycolipids from Bifidobacterium longum subs. 
infantis were characterized. The analyzes showed the presence of previously identified 
β-D-Galp-diglyceride (GL4) and novel 1-β-D-Galf-3-glyceroplasmalo-monoglyceride 
(GL5). Additionally, a mixture of phospholipids containing cPAs was observed (L3). 
An attempt was made to screen the immunological properties of GL4 and GL5. 
Although the assays showed no significant activity, further research on the 
immunological properties of these glycolipids would be required for confirmation of the 
results obtained so far, and additional testing on different types of cells would be of 
interest to pursue. 
As LTAs have been found to show greater immunological properties compared to the 
glycolipid anchor in specific assays, the next step in the study of these glycolipid 
anchors is the synthesis of LTA derivatives for further testing (Chapter 4). Other 
interesting subjects are the extraction of bifidobacteria LTAs and the study of GL5 
stereochemistry (Chapter 5). Indeed, to date, only harsh conditions have been used for 
the extraction of bifidobacteria LTA and it is plausible that LTAs containing GL5 as an 
anchor could be extracted with milder conditions. 
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3.6 Supplementary Data-NMR and MS Spectra 
and Compound Characterisation 
3.6.1 GL4 
 
GL4: Colourless oil (0.5 mg) []D
20
 = -1.0 (c = 0.8, CHCl3/MeOH, 2/1, v/v); IR (film) 
3348, 2922, 2853, 1738, 1366, 1216, 1164, 1073, 567 cm
-1
; 
1
H, 
13
C NMR, HRMS and 
Rf data, see Table 3.1 and 3.2. 
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GL4, 
1
H NMR, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
 
GL4, 
1
H,
1
H COSY, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
 
 
135 
 
GL4, 
1
H,
13
C, coupled HSQC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
 
GL4, 
1
H,
13
C, HMBC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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3.6.2 GL5 
ESI-MS spectrum 
 
GL5: Colourless oil (8.6 mg) []D
20
 = -29.4 (c = 0.6, CHCl3/MeOH, 2/1, v/v); IR (film) 
3361, 2922, 2852, 1465, 1249, 1028, 720, 573 cm
-1
; 
1
H, 
13
C NMR, HRMS and Rf data, 
see Table 3.1 and 3.2. 
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GL5, 
1
H NMR, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
GL5, 
13
C NMR, CD3OD/CDCl3 (1/2, v/v), 151 MHz 
 
 
 
 
138 
 
GL5, 
1
H,
1
H, COSY, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
 
 
GL5, 
1
H,
13
C, coupled HSQC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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GL5, 
1
H,
13
C, HMBC, CD3OD/CDCl3 (1/2, v/v), 600 MHz 
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3.6.3 L3 
ESI-MS in negative ion mode 
 
L3, 
1
H-
31
P, HMBC, CD3OD/CDCl3 (1/2, v/v), 500 MHz 
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Chapter 4 
 
Synthesis and Biological Activity of the 
Lipoteichoic Acid Anchor from 
Streptococcus sp. DSM 8747
269
 
 
In this study, the role of lipoteichoic acid (LTA) anchors in the activation of the innate 
immune response was investigated through the chemical synthesis of a series of LTA 
derivatives and the determination of their ability to induce NO production in bone 
marrow-derived macrophages (BMM). To this end, an efficient synthesis of the sn-3-O-
(α-D-galactofuranosyl)-1,2-di-O-acylglycerol LTA core was developed, which was then 
used as a key structure to produce both phosphate and glycerylphosphate- 
functionalised LTA anchors, as well as galactofuranosyldiglycerides with varying fatty 
acid chain lengths. With a series of LTA anchors in hand, the effect of these glycolipids 
on the innate immune response was determined by exploring their capacity to activate 
macrophages. Here, it is reported that several of the LTA-derivatives were able to 
induce NO production by BMMs. In general, the unnatural (sn-1) core glycolipid 
anchors showed lower levels of activity than the corresponding natural (sn-3) 
analogues, and the activity of the glycolipids also appears to be dependent on the length 
of lipid present, with an optimum lipid length of C20 for the sn-3 derivatives. 
Interestingly, a triacylated anchor and the 6-O-phosphorylated anchor, showed only 
144 
 
modest activity, while the 6-O-glycerophosphorylated derivative was unable to induce 
NO production. Taken as a whole, the results of this study highlight the subtle effects 
that glycolipid length can have on the ability to activate BMMs. 
4.1 Background 
Poly(glycerophosphate) lipoteichoic acids (LTAs) are characteristic of Gram-positive 
bacteria,
68,86,202,271
 yet unlike their counterparts, lipopolysaccharides (LPS, endotoxin), 
which are found in Gram-negative bacteria,
86,202,272,273
 much debate still remains about 
the role of LTAs during bacterial infection.
86,202,274
 This is, in part, due to differences in 
the biological activities of extracted versus synthesised LTAs
86,275
 and highlights the 
need for structurally defined, non-contaminated LTAs when investigating the effect of 
these glycolipids on the innate immune response. 
LTAs have been classified into four types (types I-IV) based on chemical structure 
(Chapter 1, Section 1.4.4.3.1).
59
 Although they represent highly challenging synthetic 
targets, many elegant syntheses of LTAs have been achieved, most notably by Schmidt 
and colleagues who have made tremendous progress towards understanding the 
biological relevance of these highly abundant cell wall glycolipids (see Chapter 1, 
Section 1.5.5).
77,92,276
 Indeed, as one of their synthetic endeavours, Schmidt and co-
workers recently reported the first total synthesis of LTA 1 (n = 4, R
1
 = 30% D-alanine 
and 70% H, R
2
 = C13H27, Figure 4.1),
92
 which is a unique LTA isolated from the cell 
wall of the Streptococcus species DSM 8747.
91
 LTA 1 contains a D-alanyl substituted 
(1-3)-linked poly(glycerophosphate) chain linked to the 6-hydroxyl group of sn-3-O-(-
D-galactofuranosyl)-1,2-di-O-acyl-glycerol, and is the first example in which a 
monohexosylglycerol serves as a glycolipid anchor. Additionally, furanoses are scarcely 
seen in LTAs. Moreover, despite the genetic similarity of the Streptococcus sp. to 
Streptococcus pneumoniae, LTA 1 is quite different from the LTA found in 
Streptococcus pneumoniae, thus further arousing people’s interest in the biological 
function of 1. It is also interesting to note that this specific lipid anchor was thought to 
be present in Bifidobacterium bifidum var. pennsylvanicus,
277 
although subsequent 
studies by Fischer found an alternative lipoteichoic-acid-like amphiphile.
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Figure 4.1 Lipoteichoic acid from Streptococcus sp. DSM 8747. 
To understand the effects LTA 1 has on the immune response, the development of an 
efficient synthesis of the sn-3-O-(-D-galactofuranosyl)-1,2-di-O-acyl-glycerol core 
which could be used as a key structure to understand the effects of the different lipids on 
biological activity is described here. To date, no biological data have been presented for 
homogeneous synthetic LTA 1 or derivatives thereof, which is surprising given the 
marked and varied biological activities of differentially acylated bacterial 
glycolipids.
63,78,80,104,278
 To this end, here is reported a remarkably efficient synthesis of 
the core glycolipid anchor of LTA 1 and acylated analogues and, for the first time, 
insight is provided into the biological effects of these glycolipids on the innate immune 
response. 
4.2 Results and Discussion 
In devising the retrosynthetic analysis of the glycolipid anchor of LTA 1, the use of a 
regioselective deprotection strategy of a -D-Galf building block (Scheme 4.1) was 
envisioned. Here, it was proposed that the core glycolipid anchors 2a-d (R = H, R´ = 
C17H35, C19H39, C21H43 or C25H51, both glycerol diastereoisomers) could be readily 
prepared from the per-silylated precursor 6 via global deprotection, whereas the more 
complex triacylated anchor 3a (R = R´ = C17H35, sn-3-Galf), phosphorylated anchor 4a 
(R = PO3H, R´ = C17H35, sn-3) and the glycerophosphorylated anchor 5a (R = 
glycerophosphate, R´ = C17H35, sn-3) could be prepared from the selectively protected 
glycolipid anchor sn-3-7a containing the naturally occurring sn-3-Galf-glycerol 
stereochemistry. Esterification or phosphorylation of alcohol 7a followed by global 
146 
 
deprotection, would provide compounds 3a and 4a, respectively, whereas the more 
complex phosphorylated LTA anchor 5a would be available via phosphorylation of 
alcohol 7a with O-benzyl phosphoramidite 8.
279
 Preparation of the key differentially 
protected -D-Galf intermediate 7a was envisioned to be achieved via the selective 
removal of the TBS group at the 6-position of the furanoside following esterification of 
diol 9 with stearic (a), arachidic (b), behenic (c) or cerotic (d) acid. Finally, diol 9 could 
be prepared by way of a β-selective glycosylation between iodofuranoside 11, generated 
in situ,
280
 and chiral solketals 10, which are readily available in either enantiomeric 
form.
281,282
 
 
Scheme 4.1 Retrosynthesis of the LTA glycolipid anchor and lipidated derivatives. 
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With the retrosynthetic strategy in place, the synthesis of core glycolipid anchor 2 was 
first investigated. To this end, it was decided to synthesise building blocks (-)- and (+)-
10. The synthesis of chiral solketals has been previously documented by different 
groups 
281,282
 and chiral solketals (-)-10 and (+)-10 are commercially available (for 100 
mL, $2500, Fluka). In saying this, there are various advantages to synthesising the 
compounds. Firstly, they are expensive to purchase although the reagents used in their 
synthesis are relatively cheap. Secondly, large quantities are needed for the research and 
the shipping times to New Zealand were lengthy. To attempt the synthesis of glycerol 
derivative (-)-10, Hirth’s method was initially employed (Scheme 4.2).281 Here, the 
deamination was performed on L-serine 12 using sulfuric acid and sodium nitrite in 
water to obtain alcohol 13. After precipitation of sodium sulfate using methanol and 
acetone, the filtrate was concentrated in vacuo. Next, the appropriate amount of 
trimethoxymethane was added in excess with Dowex H
+ 
and methanol. However, only a 
small amount of the methyl ester 14 was recovered (3%). Consequently, the approach 
was altered and PTSA and dimethoxypropane were employed in an attempt to form 
methyl ester 14. Unfortunately, this method was also low yielding despite varying the 
amount of PTSA, dimethoxypropane, temperature and reaction time. Following these 
trials, the method of Dorp and co-workers was successfully implemented (Scheme 
4.3).
283
 Here instead of using sulfuric acid used in Hirth’s method, hydrochloric acid 
was used for the deamination and acid 13 was esterified and protected with an acetonide 
uneventfully. Crude methyl ester 14 was then pure enough for reduction using NaBH4 
to obtain chiral solketal (-)-10 in 40% overall yield after distillation (found: [α]D
19
 = -
9.8, c = 1.0, MeOH, literature: [α]D
20
 = -11.1, c = 5.0, MeOH).
281
 
 
Scheme 4.2 R-(-)-Solketal ((-)-10) synthesis from the method of Hirth et al.
281
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With chiral solketal (-)-10 in hand, chiral solketal (+)-10 was then synthesised. In 
contrast to the synthesis of chiral solketal (-)-10, D-mannitol was used as a starting 
material. The synthesis involved converting D-mannitol 15 into diacetonide 16 using 
acetone and zinc chloride. The diol was then cleaved using sodium periodate to form 
aldehyde 17, which was reduced with sodium borohydride (Scheme 4.4). Here, the 
compounds were not purified between steps, the only purification utilised was a 
distillation of final product (+)-10. The first time this methodology was attempted it 
produced a racemic mixture of products. As epimerisation is more likely to occur in the 
oxidation step, it was concluded that shorter reaction times were essential for this step. 
Indeed, after a shorter periodate oxidation step of 15 minutes, the reaction mixture was 
immediately reduced to give chiral solketal (+)-10 in 58% overall yield (found: [α]D
19
 = 
11.0, c = 1.0, MeOH, literature: [α]D
20
 = 11.6, c = 5.0, MeOH).  
 
Scheme 4.3 R-(-)-Solketal ((-)-10) synthesis from the method of Lok et al.
283
 
 
Scheme 4.4 S-(+)-Solketal ((+)-10) synthesis from the method of Eibl et al.
282
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With the R and S-solketals in hand, the recently developed procedure of Baldoni and 
Marino was then employed
280
 to synthesise the per-silylated furanoside 19 from D-
galactose 18 (72% yield) (Scheme 4.5). When compared to more traditional syntheses 
of similar galactofuranosyl donors, which involve a intricate series of protection and 
deprotection steps,
92,284-287
 the methodology of Baldoni and Marino was remarkably 
efficient, with the steric bulk of the TBS-groups being thought to favour formation of 
the furanose isomer.  
 
Scheme 4.5 Synthesis of core glycolipid anchor 2. 
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As seen in Chapter 1 (Section 1.5.5), a methodology that has been used to form 
galactofuranoses involves an anomeric O-alkylation step. This is followed by 
benzylation, deprotection of the anomeric position, and finally imidate formation for 
later coupling.
92,284
 The perbenzoylation of galactose with benzoyl chloride has also 
been reported to form the furanose.
285
 Here a α/β mixture of 56/44 was obtained in 77% 
yield. However, with this method a 2-step 1-pot glycosylation using TMSI is not 
recommended as the leaving benzoyl will preferrentially recouple to the anomeric 
position. Such a 2-step 1-pot glycosylation strategy using tin (IV) chloride with 
perbenzoylated and peracetylated galactofuranose moieties was successfully attempted 
but afforded only modest yields (60-67%) when compared to the silylation proposed by 
Baldoni.
286,287
 For these reasons, Baldoni’s 2-step 1-pot glycosylation strategy seemed 
appealing and was attempted.
280
 Here, protected galactofuranose building block 19 was 
treated with TMSI, to generate the intermediate glycosyl iodide, and to this (+)- or (-)-
solketal 10
281,282
 was added. While this methodology led to the formation of the target 
glycolipids 20, the yield for these glycosylations was highly variable (44-76%), this 
being attributed to the varying quality of the TMSI despite freshly distilling this reagent 
prior to use. Indeed, much improved and more consistent yields (90% for both sn-1-20 
and sn-3-20 derivatives) were observed if the TMSI was generated ex situ (via the 
addition of I2 to a small excess of neat TMSTMS)
288
 and then added to the per-silylated 
galactofuranose 19 to give derivative 20 (α/β, 1/9). It was also noted that the 
glycosylation reaction should be performed under dilute conditions (38 mL/mmol) to 
limit formation of bicyclic product 21 (HRMS calc. for [C24H52NaO5Si3]
+
 = 527.0315, 
found: 527.0310), which is obtained via cyclisation of the 6-position onto the iodinated 
anomeric centre. The β-configuration of the major product 20 was then confirmed by 
13
C NMR with C-1´ having a characteristic NMR shift of 108.8 ppm for the sn-3-Galf β-
anomer.
251,280 In contrast, the α-anomer had a shift of 102.3 ppm for C-1´.251,280 
Purification of the anomers (α-anomer, Rf = 0.44, EA/PE, 1/9, v/v; β-anomer, Rf = 0.41, 
EA/PE, 1/9, v/v) was possible via careful silica gel flash column chromatography, 
however separation became easier following deprotection of the acetonide (vide infra). 
Finally, to confirm that acceptor 10 had not racemised during the course of the reaction, 
the reaction was repeated using racemic (±)-10. Here, extra resonances were observed in 
the 
13
C NMR spectrum to account for the additional isomers that had been produced 
[e.g. two resonances (108.8 ppm and 108.6 ppm) were observed for C-1´ of the β-
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anomer when the glycosylation was performed using racemic 10]. In contrast, the use of 
enantiomerically pure 10 resulted in the formation of only one β-product (Figure 4.2).  
 
Figure 4.2 
13
C NMR spectrum of compounds 20 1., sn-3-20 2. and sn-1-20 3. 
showing the anomeric and acetal quaternary carbon region. 
Having selectively prepared glycosides 20 in good yields, attempts were then made to 
remove the acetonide without concomitant removal of the TBS groups. To this end, 
glycolipids 20 were treated with AcOH/H2O (4/1, v/v, 50 °C, overnight).
289
 
Unfortunately, this protocol resulted in O-desilylation as well as the desired acetonide 
deprotection and a complex mixture of products was observed. Other deprotection 
conditions were then investigated, including the use of CSA (2 equiv.)
290
 or SnCl2 (4 
equiv.),
291
 though in both instances only starting material was recovered. The use of 
TFA/H2O in DCM at room temperature
290
 appeared more promising, with diol 9 being 
obtained in a modest (20%) yield, along with a mixture of partially desilylated products. 
The use of THF instead of DCM led to a reduced yield of deprotected 9, so the 
TFA/H2O/DCM strategy was revisited. Indeed, close monitoring of the reaction by TLC 
1) 
 
 
2) 
 
 
3) 
C-1' C(CH3)2 
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indicated that a major product (Rf = 0.37, EA/PE, 3/7, v/v) was observed directly after 
the addition of TFA/H2O and that this product quickly disappeared over time leading to 
baseline material. In view of this, it was determined that very short reaction times were 
needed to prevent desilylation and thus the reaction (20 → 9) was quenched with a 
solution of NaHCO3 (sat. aq.) after only 10 minutes. Gratifyingly, this approach proved 
successful and both isomers of 9 were obtained in an excellent (93-96%) yield. 
Having established the selective deprotection conditions, an EDCI mediated 
esterification of diols 9 then followed. The esterification of diol 9 using stearic acid or 
arachidic acid proceeded uneventfully to yield the protected glycolipids 6a and 6b in 
excellent (87-97%) yields after heating at 40 °C for 14 h. The longer lipids, behenic or 
cerotic acid, however, were sluggish to react and required heating to 70 °C to give the 
target esters, 6c and 6d, in 65% and 77% yield, respectively. The formation of the first 
LTA glycolipid anchor, sn-3-2a, was then attempted via the treatment of a solution of 
protected anchor sn-3-6a in THF with TBAF (8 equiv.) for 12 h. These conditions 
resulted in the smooth transformation of the per-silylated 6a into anchor 2a as judged by 
TLC analysis (Rf = 0.61, MeOH/DCM, 1/6, v/v), although the purification of anchor 2a 
proved problematic due to contamination with TBAF. Repeated silica gel column 
chromatography and/or dialysis could yield pure glycolipid anchor 2a, but such 
purification measures severely compromised the yield. Consequently, the final 
deprotection of per-silylated 6a was attempted using Dowex-H
+
 resin. Although this 
gave a quantitative yield of desired 2a, long reaction times were required (7 days) due to 
the need to use only a small amount of resin to prevent cleavage of the stearic acid 
esters. Accordingly, deprotection of anchor 2a was further attempted using HF.pyridine. 
Indeed, this latter strategy proved the most successful with global deprotection being 
achieved after 24 h and in quantitative yield following aqueous work-up. The other 
glycolipid anchors 2b-d (sn-1 and sn-3) were similarly prepared via the treatment of 
their corresponding per-silylated counterparts with HF.pyridine. In summary, the 
synthesis of glycolipid anchor sn-3-2a was achieved in a remarkable six steps and in a 
51% overall yield, which is the most efficient synthesis to date.
92
 The other derivatives 
(with arachidic, behenic or cerotic acid) were also synthesised in excellent overall 
yields. The strategy, involving the use of TBS groups, is very versatile as fatty acids 
with unsaturation can also be coupled.  
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Having successfully prepared the core glycolipid anchors 2, the synthesis of the more 
complex LTA derivatives, sn-3-3a, sn-3-4a and sn-3-5a (Scheme 4.6 - 4.10) was then 
attempted. Here, the greater lability of the silyl group at the 6-position of protected 
anchor sn-3-6a was exploited with the reaction conditions optimised to achieve the 
selective deprotection of the primary silyl group without further desilylation. 
Interestingly, the use of TFA/H2O in DCM gave trace amounts of product 7a, with 
various O-desilylation products being formed. TFA/H2O in THF, however, resulted in a 
72% yield of alcohol 7a after stirring for 48 h. At this time, a small amount of starting 
material as well as some additional desilylation products, were observed by TLC 
analysis. Longer reaction times did not increase the yield and the 48 h time point was 
found to be optimum (Scheme 4.6). Confirmation of the synthesis of alcohol 7a was 
achieved via HRMS (HRMS calc. for [C63H128NaO10Si3]
+
: 1151.8708, found: 
1151.8713) and also by NMR analysis, with the 
1
H NMR spectrum clearly showing the 
disappearance of one TBS group and also a downfield shift of H-6´b (3.61 ppm) and H-
6´a (3.67 ppm) which showed COSY correlations to a hydroxyl proton at 2.41 ppm 
(Figure 4.3). This new methodology allowed for an improved synthesis of the key 
building block sn-3-7a (7 steps, 37% overall yield), which can be used for the synthesis 
of a number of derivatives of LTA 1.
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To illustrate the versatility of alcohol 7a and prepare a number of LTA anchor 
derivatives for biological assessment, LTA targets sn-3-3a and sn-3-4a were then 
synthesised (Scheme 4.6). First, alcohol 7a was esterified using stearic acid to obtain 
triacylated glycolipid sn-3-22a in quantitative yield. HMBC peakd between H-6´a (4.19 
ppm) and the carbonyl carbon (173.3 ppm) as well as H6´b (4.02 ppm) and the same 
carbonyl carbon were used to confirm the position of the new lipid (Figure 4.4). 
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Scheme 4.6 Synthesis of sn-3-3a and sn-3-4a. 
 
Figure 4.3 Magnification of the COSY NMR spectrum of sn-3-7a showing the 
correlation between H-6' and the hydroxyl proton.
 
H-6'   OH 
H-6'   OH 
H-6' 
OH 
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Figure 4.4 Magnification of sn-3-22a HMBC spectrum showing the correlations 
between H-6'a, H6'b, 1 and 2 to their respective carbonyl carbons.  
Deprotection using HF.pyridine then gave lipidated target sn-3-3a in 89% yield. The 
phosphorylated lipid anchor sn-3-4a was also readily prepared from alcohol 7a, first by 
treating compound 7a with freshly distilled POCl3 and then with H2O/TEA to install the 
corresponding phosphate to give phosphorylated sn-3-23a. Key in this step was the use 
of an acidic work-up (0.1 M HCl), rather than Dowex-Na
+
, to separate the desired 
product from the TEA salts. 
1
H-
31
P HMBC confirmed that the phosphorus was indeed 
coupled at the 6-position (Figure 4.5). The TBS groups were then deprotected, using 
Dowex-H
+
, to give the target phosphorylated lipid anchor sn-3-4a in excellent yield 
(80%) over two-steps. 
H-2   C(O) H-1a   C(O) 
H-1b and H-6'a   C(O) 
H-6'b   C(O) 
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Figure 4.5 
1
H, 
31
P HMBC of sn-3-23a showing the correlation between H6'a, H6'b 
and the phosphorous. 
The final LTA lipid anchor to be prepared was the phosphate ester sn-3-5a. At first, the 
synthesis of phosphoramidite 26 was attempted. As this phosphoramidite possesses a 
silyl group, it was hypothesised that the final LTA would be easier to deprotect than the 
usually used 1-O-(benzyloxybis(diisopropylamino)phosphine)-2,3-isopropylidene-sn-
glycerol.
279
 Although the conversion of phosphorous trichloride 24 (P = 219 ppm, 
coaxial tube, (CD3)2CO) to bis(diisopropylamino)chlorophosphine 25 (P = 128.8 ppm, 
CDCl3) was successful in reasonable yields (67%), attempts to synthesise 
phosphoramidite 26 were ultimately unsuccessful and gave only 27 (HRMS calc. for 
[C12H29NaOP]
+
 = 271.1910, found: 271.1918) (31P = 119.0 ppm, 121 MHz, CDCl3) 
without any desired product (Scheme 4.7). From these results, it was hypothesised that 
even though the amount of water was carefully calculated and added to compound 25, it 
interfered with the formation of phosphoramidite 26 and thus the use of building block 
29 was instead envisaged. To this end, 2-(trimethylsilyl)ethanol was treated with 
bis(diisopropylamino)chlorophosphine 25 and triethylamine to form phosphoramidite 
H-6'a and b    P 
H-6'a     P 
H-6'b      P 
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28 in 93% yield (P = 122.8 ppm, CDCl3) (Scheme 4.8).
292
 Coupling of 28 with R-
Solketal gave phosphoramidite 29 uneventfully (P = 145.62 and 145.60, CDCl3). Next, 
a solution of alcohol 7a in MeCN was treated with phosphoramidite 29,
279
 which, 
unfortunately resulted in the recovery of starting material, which was thought to be due 
to the poor solubility of glycolipid 7a in MeCN. A change to THF fared no better, and 
again, no reaction was observed. Fortunately, the use of a mixed solvent system (1/1, 
MeCN/THF, v/v) led to the formation of the protected phosphate ester sn-3-30a (27% 
yield) (31P = -1.39, CDCl3) and some starting material (sn-3-7a). Here attempts such as 
varying amounts of 1H-tetrazole, failed to improve the yield and starting material and 
small amounts of the target compound were found. With the product obtained from 
these investigations, the deprotection of protected LTA sn-3-30a using HF.Pyridine or 
TBAF failed to give desired compound sn-3-5a. Here small amounts of deprotected 
anchor and larger amounts of insoluble material were found in both the TBAF and 
HF.pyridine attempts. 
 
Scheme 4.7 Attempt to synthesise phosphoramidite 26. 
These results suggested that to improve the yield, a more conservative approach to the 
synthesis of desired target sn-3-5a would be required. In the literature, 1-O-
(benzyloxybis(diisopropylamino)phosphine)-2,3-isopropylidene-sn-glycerol has been 
commonly used in various syntheses.
293-295
 Thus, following the procedure of Hamamoto 
et al.
279
, compound 8 was synthesised in very good yields (Scheme 4.9). Compound 25 
was benzylated in excellent (97%) yields. Then chiral solketal (-)-10 was reacted with 
intermediate 32 and 1H-tetrazole to give phosphoramidite 8 in 93% yield. 
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Scheme 4.8 Synthesis of compound sn-3-30a.  
The synthesis of protected sn-3-33a required the use of a mixed solvent system (1/1, 
MeCN/THF, v/v) (Scheme 4.10). The formation of the protected phosphate ester sn-3-
33a was synthesised in good (71%) yield. NMR data for phosphotriester 33a included a 
diagnostic 
31
P signal (-1.03 ppm). Also, 
1
H, 
31
P-HMBCs between H-6´b (3.96 ppm), H-
6´a (4.12 ppm), sn-1´´ (4.00 ppm), CH2Bn (5.09 ppm) and 
31
P (-1.03 ppm) were 
observed (Figure 4.5). Additionally, in the 
13
C NMR, some carbon resonances [e.g. 
73.95 and 73.88 (C-sn-2´´)] showed separate signals for the two diastereomeric 
phosphotriesters (e.g. Two signals for C-2'') as well as 
31
P-
13
C couplings resulting in a 
broad signal for C-6' (Figure 4.6).  
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Scheme 4.9 Synthesis of phosphoramidite 8. 
 
Scheme 4.10 Synthesis of target compound sn-3-5a. 
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Figure 4.5 
1
H, 
31
P-HMBC NMR spectrum of sn-3-33a showing HMBC correlations 
between H-6', H-3'' and CH2Bn with the phosphorous atom. 
 
C-2'' 
C-5' 
C-2 
CH2Bn 
C-6' 
C-3''
 
 C-6' 
C-1''
 
 C-6' 
C-1
 
 C-6' 
C-3
 
 C-6' 
CH2(Bn)   
31
P H-6' and H-3''   
31
P 
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Figure 4.6 Magnification of 
13
C NMR spectrum from sn-3-33a showing separate 
signals for the two phosphotriesters and coupling with phosphorous (e.g. Two signals 
for C-2'', one broad signal for C-6'). 
Phosphoester 33a was hydrogenated and attempts were then made to deprotect the TBS 
groups using HF.pyridine at various concentrations, and using different proportions of 
pyridine and THF as the solvent. Unfortunately, under all conditions attempted, the 
hydrolysis product (glycolipid anchor 2a) was always observed. To overcome this 
problem, Dowex-H
+
 resin was used to remove the TBS groups and sn-3-5a was 
obtained in an excellent (92%) yield over the two steps. 
With the series of the different LTA anchors in hand, the effect that these glycolipids 
had on the innate immune response was investigated by exploring their capacity to 
activate macrophages. Accordingly, all synthetic compounds were first confirmed to be 
free of endotoxin, as determined by the Limulus amebocyte lysate (LAL) assay,
k
 and 
the compounds were then assessed for their ability to induce NO production in IFN- 
primed bone marrow macrophages (BMMs) using the Griess assay.
63
 Using anchor sn-
1-2a, a time course was established which determined that NO production reached a 
plateau after 48 h (data not shown). This time point was then taken for all subsequent 
measurements, with two different concentrations of compound being tested, 20 g/mL 
and 40 g/mL. LPS served as a positive control and unlipidated sn-3-galactofuranosyl-
glycerol (GalfGro) as a negative control. 
As illustrated in Figure 4.7, several of the LTA-derivatives were able to induce NO 
production by BMMs. On the whole, the unnatural (sn-1) core glycolipid anchors (2a-d) 
showed lower levels of activity than the corresponding natural (sn-3) analogues with the 
exception of anchor sn-1-2a. The activity of the glycolipids (2a-d) also appears to be 
dependent on the type of lipid present, with there appearing to be an optimum lipid 
length (C20, sn-3-2b) for the sn-3-2a-d derivatives. Whether this is due to specific 
receptor-ligand interactions or the result of solubility and the formation of micelles or 
                                                 
k
 Synthesised LTA-derivatives were tested to be endotoxin-free at a sensitivity of 0.125 EU/ml with an 
endotoxin kit (Pyrotell, Limulus amebocyte lysate) according to the manufacturer’s instructions. 
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other molecular assemblies warrants further investigation.
296
 Interestingly, the tri-
acylated anchor 3a and the phosphorylated anchor 4a showed only modest activity, 
while the glycerophosphorylated anchor 5a was unable to induce NO production. For all 
substrates tested, a concentration dependence was observed with greater levels of NO 
being produced in response to higher concentrations of substrate being tested.  
 
Figure 4.7 BMM were stimulated with LTA-derivatives (2a-d, 3a, 4a, 5a) (20 
g/mL and 40 g/mL), or LPS (100 ng/mL), or sn-3-galactofuranosyl-glycerol 
(GalfGro, 20 g/mL and 40 g/mL) and the supernatants analyzed for NO after 48 h 
using the Griess assay. Mean and SD of triplicate samples from a representative 
experiment of two are indicated. 
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4.3 Concluding Remarks 
Taken as a whole, the results point to the subtle effects that glycolipid length might 
have on the ability to activate BMMs. This phenomenon is not unexpected given that 
others have observed quite marked differences in biological activities when surveying 
glycolipids with different lipid compositions.
63,77,78,270
 However, in the studies 
presented, absolute levels of NO production are small and further studies will be 
required to determine the physiological relevance of these differences. Indeed, in related 
work by Schmidt and co-workers, structure-activity studies concerning synthetic 
Staphylococcus aureus LTA anchors (which contain a gentiobiosyl diacylglyceride) 
revealed similar biological activities for sn-1/3 analogues and mixtures thereof.
89
 In 
addition, changing the gentiobiosyl moiety for lactose did not alter activity. From these 
results, it was concluded that the pattern recognition of the lipid anchor was relatively 
loose, allowing for variability of the lipid anchor.
81,89,90
 Schmidt and co-workers also 
observed that LTA structures including the anchor, glycerophosphate backbone and D-
alanyl residues were required for optimal biological activity. Future work would include 
the synthesis and immunological evaluation of more complex derivatives of LTA 1 such 
as D-alanine derivatives and further investigation of the biological effect of LTA 
derivatives in a wider range of assays. 
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4.4 Experimental Section 
4.4.1 General Methods 
Unless otherwise stated all reactions were performed under Ar. Prior to use, pyridine 
was dried and stored over 4 Å molecular sieves (4 Å MS), DCM was distilled from 
P2O5 and toluene was dried and stored under Na wire. Anhydrous DMF (Acros), HCl 
(Panreac), L-Serine (Sigma), Sodium nitrite (Chem Supply), dimethoxypropane (Sigma-
Aldrich), Acetone (Pure science), PTSA (Sigma-Aldrich), NaBH4 (Aldrich), Mannitol 
(M  B), Zinc Chloride (Sigma-Aldrich), Ammonia (Fischer Scientific), Sodium 
periodate (M  B), NaH (Riedel de Haën), KOH (Pure Science), TBSCl (Appolo 
Scientific), Imidazole (Appolo Scientific), D-Galactose (J. T. Baker chemical), 
TMSTMS (Acros), I2 (M  B), DIPEA (Sigma-Aldrich), Na2S2O3 (Perkin’s Reagent), 
THF (Panreac), HF.Pyridine (Acros), Pyridine (Fischer Scientific), POCl3 (Aldrich), 
TEA (Aldrich), t-BuOOH (6 M in Octane, Aldrich), MeCN (Panreac), Benzyl alcohol 
(Ajax Chemicals), PCl3 (Aldrich), Diisopropylamine (Sigma-Aldrich), TFA (Aldrich), 
EDCI (Aldrich), DMAP (Merck), arachidic acid (Sigma), Pd (OH)2/C (Aldrich, 20 
wt%), Dowex H+ (Supelco), anhydrous Et2O (Biolab), EtOAc (Pancreac), petroleum 
ether (Pure Science), anhydrous MeOH (Pancreac), CHCl3 (Pancreac), NaHCO3 (Pure 
Science), MgSO4 (Pure Science) and NaCl (Pancreac) were used as received. Stearic 
acid was recrystallised from MeCN (x6) and acetone (x3) until no trace of the other 
fatty acids was observed by 
1
H NMR and MS. All solvents were removed under 
reduced pressure. Reactions were monitored by TLC analysis on Macherey-Nagel silica 
gel coated plastic sheets (0.20 mm with fluorescent indicator UV254) via detection by 
UVabsorption (short wave–254 nm; long wave–366 nm) and by dipping in 10% H2SO4 
in EtOH followed by charring at 150 °C. Silica gel flash column chromatography was 
performed using Pure Science silica gel (40-63 μm). High resolution mass spectra were 
recorded on a Waters Q-TOF Premier
TM
 Tandem Mass Spectrometer using positive 
electro-spray ionisation. Optical rotations were recorded on a Perkin-Elmer 241 
polarimeter or Autopol II (Rudolph Research Analytical) at 589 nm (sodium D-line). 
Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR 
spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory 
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and are reported in wave numbers (cm
-1
). Nuclear magnetic resonance spectra were 
recorded at 20 °C in CDCl3, CDCl3/CD3OD (2/1, v/v) or CDCl3/CD3OD/D2O (70/40/6, 
v/v/v) using a Varian INOVA operating at 500 MHz. Chemical shifts are given in ppm 
(δ) relative to CDCl3. NMR peak assignments were made using COSY, HSQC and 
HMBC, 
1
H-
31
P-HMBC 2D experiments. Melting points were obtained using a 
Gallenkamp Melting Point Apparatus. 
4.4.2 Macrophage Assay 
[Conducted by Ashna Khan and Stephanie Chee] 
4.4.2.1 Materials and Methods 
C57BL/6 male mice were bred and housed in a conventional animal facility at the 
Malaghan Institute of Medical Research, Wellington, New Zealand. All animals used 
for the experiments were aged between 8–10 weeks. All experimental procedures were 
approved by the Victoria University Animal Ethics Committee in accordance with their 
guidelines for the care of animals. Extracted glycolipids were tested to be endotoxin-
free (≤ 0.125 EU/mL) with an endotoxin kit (Pyrotell, LAL test, Associates of Cape 
Cod Inc., E. Falmouth, MA, USA).  
4.4.2.2 Generation of bone marrow derived macrophage (BMMs) 
Bone marrow cells were collected from the tibia and femur of C57BL/6 mice and were 
cultured (250000 cells per mL) in Iscove’s Modified Dulbecco’s Medium (IMDM, 
Gibco) supplemented with 5% FBS (Gibco), 1% Penicillin streptomycin (Gibco) and 2-
mercaptoethanol (55 mmol, Invitrogen) containing 10 ng/mL GM-CSF (clone 
X63/GMCSF murine cells). Cells were incubated at 37 °C (5% CO2) and the medium 
was changed on days 2, 5 and 7. On day 10, the medium was removed, and the BMMs 
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were primed with IFN- (10 ng/mL, Peprotech, Rocky Hill, NJ, USA) for 3 h prior to 
the addition of the compounds.  
4.4.2.3 BMM assays 
Glycolipids stock solutions were prepared (2.5 mg/mL in PBS containing 2% DMSO), 
vortexed and warmed to 50 °C for 30 min (x 3) to ensure suspension of the compounds 
prior to administration to BMM cultures. BMM cultures were then treated with 20 or 40 
g/mL of glycolipid and with LPS (100 ng/mL) as a positive control and medium only 
for the times indicated. Supernatants were collected and tested immediately for NO 
levels using the Griess assay.
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4.4.3 Compound Characterisation 
2,3-O-Isopropylidene-sn-glycerol, R-solketal ((-)-10). (-)-10 was prepared 
following the procedure of Lok et al. and Hirth et al. with some variations.
281,283
 To a 
solution of L-serine (26 g, 250 mmol) in water (1.5 L) and conc. HCl (37.5 mL), was 
added NaNO2 (20 g, 290 mmol) in small portions at 0 °C for 24 h. The solution was 
then stirred at RT for 24 h and concentrated in vacuo. Then, MeOH (75 mL), conc. HCl 
(7.5 mL) and dimethoxypropane (200 mL) were added and the reaction mixture was 
stirred for 2 h. After filtration, concentration in vacuo and the addition of acetone (200 
mL), 2,2-dimethoxypropane (50 mL) and PTSA (0.25 g, 1.5 mmol) the mixture was 
stirred for 12 h at RT. The reaction mixture was then filtered, concentrated in vacuo and 
distilled under vacuum to give the methyl ester (24.8 g, 142 mmol, 57%). Then to a 
solution of the methyl ester (12.7 g, 79.2 mmol) in MeOH (130 mL) at 0 °C, NaBH4 
(2.4 g, 62.6 mmol) was added and the solution slowly warmed up to RT and then stirred 
for 1 h. Acetone (5 mL) and water (4 mL) were added to the reaction mixture and after 
5 min, the reaction mixture was concentrated in vacuo. The residue was diluted with 
DCM, NaCl (4g) added then washed with brine (16 mL). The organic phase was then 
dried (MgSO4), filtered, concentrated in vacuo and the residue distilled under high 
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vacuum to give pure (-)-10 as a colourless oil (7.3 g, 55.4 mmol, 70%); (Rf = 0.40, 
EtOAc/PE, 8/2, v/v); bp20mbar = 82 °C; (found: [α]D
19
 = -9.8 (c = 1.0, MeOH), literature: 
[α]D
20
 = -11.1, (c = 5.0, MeOH);
281
 ρ = 1.02 g/mL; IR (film) 3374, 2987, 2904, 2832, 
1455, 1372, 1256, 1213, 1156, 1027, 844, 791 cm
-1
; 
1
H NMR (500 MHz, CDCl3) found: 
 4.20 (m, 1H, H-2), 4.08 (t, JH-3a, H-3b = JH-1a, H-2 = 7.8 Hz, 1H, H-3a), 3.76 (ABX, JH-3b, 
H-3a=JH-3b, H-2 = 7.5 Hz , 1H, H-3b), 3.68 (ABX, 1H, H-1a), 3.57 (ABX, 1H, H-1b), 2.42 
(bs, 1H, OH), 1.41 and 1.35 (s, 3H, CH3(iPr)); 
1
H NMR (solvent and frequency 
unknown) literature:  4.21 (m, 1H, H-2), 4.06 (t, JH-3a, H-3b = JH-1a, H-2 = 8.0 Hz, 1H, H-
3a), 3.80 (ABX, JH-3b, H-3a=JH-3b, H-2 = 5.2 Hz , 1H, H-3b), 3.75 (m, 1H, H-1a), 3.52 (m, 
1H, H-1b), 2.34 (bs, 1H, OH), 1.39 and 1.45 (s, 3H, CH3(iPr));
13
C NMR (125 MHz, 
CDCl3)  109.4 (C(CH3)2), 76.2 (C-2), 65.7 (C-3), 62.9 (C-1), 26.7 and 25.2 (CH3(iPr)); 
HRMS(ESI) m/z calcd. for [C6H12NaO3]
+
: 155.0679, found: 155.0677. 
1,2-O-Isopropylidene-sn-glycerol ((+)-10). (+)-10 was prepared following 
the procedure of Eibl et al.
282
 Mannitol (20 g, 110 mmol) was added to a solution of 
zinc chloride (20 g, 110 mmol) in acetone (170 mL). The reaction was stirred until full 
consumption of the starting material into the diacetonide product gauged (Rf = 0.70, 
MeOH/DCM, 1/9, v/v). A minor amount of the monoacetonide was also observed (Rf = 
0.20, MeOH/DCM, 1/9, v/v). Brine was added and the aqueous layer extracted three 
times with DCM. The combined organic layers were washed with ammonia (5%, v/v) 
and concentrated in vacuo. The residue was dissolved in methanol (20 mL) and slowly 
added to a chilled (0 °C) solution of sodium periodate (17.7 g, 82.5 mmol) in water (170 
mL), adjusted to pH 6 using LiOH. After 10 minutes and complete conversion of the 
diol into the aldehyde (Rf = 0.21, EtOAc/PE, 2/8, v/v), the pH was adjusted to 8, by the 
addition of KOH, methanol (144 mL) added and the solution filtered. The filtrate was 
subjected to sodium borohydride (2.75 g, 72.6 mmol) until complete reduction of the 
aldehyde was observed (ca. 2 h), (Rf = 0.37, EtOAc/PE, 8/2, v/v); NaCl (20 g) and 
petroleum ether were added and the organic layer was discarded. The reaction mixture 
was extracted three times with DCM. The organic layer was washed with water, dried 
(MgSO4), filtered, evaporated to dryness and distilled to give pure (+)-10 as a colourless 
liquid (8.4 g, 63.8 mmol, 58%). B.p.20mbar = 82 °C ; found: [α]D
19
 = 11.0 (c = 1.0, 
MeOH), literature: [α]D
20
 = 11.6 (c = 5.0, MeOH)
281
; ρ = 1.01 g/mL; 1H NMR (500 
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MHz, CDCl3) found:  4.20 (m, 1H, H-2), 4.08 (t, JH-3a, H-3b = JH-1a, H-2 = 7.8 Hz, 1H, H-
3a), 3.76 (ABX, JH-3b, H-3a=JH-3b, H-2 = 7.5 Hz , 1H, H-3b), 3.68 (ABX, 1H, H-1a), 3.57 
(ABX, 1H, H-1b), 2.42 (bs, 1H, OH), 1.41 and 1.35 (s, 3H, CH3(iPr)); 
1
H NMR (solvent 
and frequency unknown) literature:  4.21 (m, 1H, H-2), 4.06 (t, JH-3a, H-3b = JH-1a, H-2 = 
8.0 Hz, 1H, H-3a), 3.80 (ABX, JH-3b, H-3a=JH-3b, H-2 = 5.2 Hz , 1H, H-3b), 3.75 (m, 1H, 
H-1a), 3.52 (m, 1H, H-1b), 2.34 (bs, 1H, OH), 1.39 and 1.45 (s, 3H, CH3(iPr)); 
13
C 
NMR (125 MHz, CDCl3)  109.4 (C(CH3)2), 76.2 (C-2), 65.7 (C-1), 62.9 (C-3), 26.6 
and 25.2 (iPr); IR (neat): 2982, 2903, 1439, 1372, 1246, 1214, 1185, 1159, 1126, 1087, 
1047, 1022, 968, 919, 880, 849, 800, 737 cm
-1
; HRMS(ESI) m/z calcd. for 
[C6H12NaO3]
+
: 155.0679, found: 155.0685. 
1,2,3,5,6-Penta-O-tert-butyldimethylsilyl-β-D-galactofuranose (19). 
19 was prepared following the synthesis of Baldoni et al.
280
 Imidazole (27.4 g, 402 
mmol) and TBSCl (31.4 g, 209 mmol) were added to D-galactose (5.0 g, 27.8 mmol) in 
dry DMF (140 mL), and the reaction was stirred for 72 h, during which time the product 
gradually precipitated. The reaction mixture was then diluted with EtOAc and washed 
with water, HCl (5%), NaHCO3 (sat. aq.) and brine. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. The residue was then crystallised from 
MeOH to obtain white needles (15.0 g, 20.0 mmol, 72%). (Rf = 0.76, EtOAc/PE, 1/9, 
v/v); mp found = 109.4-109.6 °C, mp literature = 109.0-111.0 °C, []D
20
 = -25.0 (c = 
1.0, CHCl3); IR (film) 2955, 2858, 1472, 1251, 1109, 1005, 834, 777, 743 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3)  5.13 (d, JH-1´, H-2´ = 2.3 Hz, 1H, H-1´), 4.10 (m, 1H, H-3´), 
4.01 (t, JH-4´, H-3´ = JH-4´, H-5´ = 4.0 Hz, 1H, H-4´), 3.92 (m, 1H, H-2´), 3.74 (m, 1H, H-
5´), 3.68 (ABX, JH-6´a, H-6´b = 10.1 Hz, JH-6´a, H-5´= 6.5 Hz ,1H, H-6´a), 3.56 (ABX, JH-6´a, 
H-6´b = 10.1 Hz, JH-6´a, H-5´= 6.0 Hz, 1H, H-6´b), 0.95-0.85 (m, 45H, C(CH3)3), 0.15-0.03 
(m, 30H, Si(CH3)2). 
13
C NMR (125 MHz, CDCl3)  102.8 (C-1´), 85.8 (C-2´), 84.5 (C-
4´), 79.5 (C-3´), 74.0 (C-5´), 64.6 (C-6´), 26.0 and 25.9 and 25.8 and 25.7 and 25.7 
(C(CH3)3), 18.3 (C(CH3)3), 18.2 (C(CH3)3), 17.9 (C(CH3)3), 17.87 (C(CH3)3), 17.78 
(C(CH3)3), -3.87 (Si(CH3)2), -4.18 (Si(CH3)2), -4.23 (x2) (Si(CH3)2), -4.33 (Si(CH3)2), -
4.6 (Si(CH3)2), -4.7 (Si(CH3)2), -5.1 (Si(CH3)2), -5.43 (Si(CH3)2), -5.37 (Si(CH3)2); 
HRMS(ESI) m/z calcd. for [C36H82NaO6Si5]
+
: 773.4850, found: 773.4852. 
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1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D-
galactofuranosyl)-2,3-O-isopropylidene-sn-glycerol (sn-1-20). A solution of 19 (0.49 
g, 0.66 mmol) in anhydrous DCM (70 mL) was stirred with 4Å mol. sieves for 30 min. 
and then cooled to 0 °C. To this was added neat TMSI (160 mg, 0.80 mmol), which was 
freshly prepared under Ar by the addition of TMSTMS (0.66 g, 4.5 mmol) to iodine 
(0.76 g, 3.0 mmol) and the reaction heated at 60 °C until the mixture turned colourless. 
After 15 min., TLC showed full consumption of 19 into two glycosyl iodides [Rf = 0.67 
(EtOAc/PE, 1/9, v/v) and Rf = 0.53 (EtOAc/PE, 1/9, v/v)], at which point DIPEA (190 
mg, 1.47 mmol) and isopropylidene glycerol (-)-10 (0.19 g, 1.47 mmol) were added and 
the reaction stirred at RT for 3 h until full consumption of the iodide into a slightly 
higher running product (Rf = 0.68, EtOAc/PE, 1/9, v/v). The reaction mixture was then 
diluted with EtOAc, washed with NaHCO3 (sat. aq.), Na2S2O3 (sat. aq.) and brine, dried 
(MgSO4), filtered and concentrated. The residue was then purified by silica gel flash 
column chromatography (EA/PE, 2/98, v/v), to give a 1/9 mixture of the α- and β- 
isomers as a colourless oil (0.45 g, 0.61 mmol, 90%). Here, it should be noted that 
separation of the anomers could be achieved via careful silica gel column 
chromatograpy (DCM/PE, 1/1, v/v), however, separation of the anomers became easier 
following acetonide deprotection (vide infra). (Rf = 0.68, EtOAc/PE, 1/9, v/v); β isomer; 
[]D
26
 = -34.0 (c = 1.0, CHCl3); IR (film) 2930, 2858, 1473, 1254, 1109, 837, 773 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.84 (d, JH-1´, H-2´ = 2.1 Hz, 1H, H-1´), 4.26 (m, 1H, H-2), 
4.12 (dd, JH-3´, H-2´ = 3.2 Hz, JH-3´, H-4´ = 5.7 Hz, 1H, H-3´), 4.06 (ABX, JH-3a, H-3b = 8.4 
Hz, JH-3a, H-2=6.3 Hz, 1H, H-3a), 4.00 (dd, JH-2´, H-1´ = 2.2 Hz, JH-2´, H-3´= 3.3 Hz, 1H, H-
2´), 3.94 ( dd, JH-4´, H-3´= 5.7 Hz, JH-4´, H-5´=3.1, H-4´), 3.76 (m, 1H, H-5´), 3.74 (ABX, 
JH-3b, H-3a=8.4 Hz, JH-3b, H-2=6.0 Hz, 1H, H-3b), 3.66 (m, 1H, H-6´a), 3.64 (ABX, JH-1a, H-
1b = 9.8 Hz, JH-1a, H-2=6.8, 1H, H-1a), 3.58 (ABX, JH-6´b, H-6´a=10.1 Hz, JH-6´b, H-5´ = 6.2 
Hz, 1H, H-6´b), 3.52 (ABX, JH-1b, H-1a = 9.6 Hz, JH-1b, H-2 = 5.5 Hz, 1H, H-1b), 1.40 and 
1.35 (s, 3H, iPr), 1.0-0.8 (m, 36H, C(CH3)3), 0.2-0.0 (m, 24H, Si(CH3)2); 
13
C NMR (125 
MHz, CDCl3)  109.3 (C), 108.6 (C-1´), 84.4 (C-2´), 84.0 (C-4´), 79.5 (C-3´), 74.5 (C-
2), 73.2 (C-5´), 68.7 (C-1); 67.5 (C-3), 64.5 (C-6´), 26.8 (iPr), 26.02 (C(CH3)3), 25.96 
(C(CH3)3), 25.8 (C(CH3)3), 25.7 (C(CH3)3), 25.5 (iPr), 18.33 ((C(CH3)3), 18.32 
((C(CH3)3), 17.9 ((C(CH3)3), 17.8 ((C(CH3)3), -3.6 (Si(CH3)2), -4.0 (Si(CH3)2), -4.40 
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(Si(CH3)2), -4.41 (Si(CH3)2), -4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 
(Si(CH3)2); HRMS(ESI) m/z calcd. for [C36H78NaO8Si4+]
+
: 773.4666, found: 773.4673. 
   3-O-(2,3,5,6-Tetra-O-tert-butyldimethylsilyl-β-
D-galactofuranosyl)-1,2-O-isopropylidene-sn-glycerol (sn-3-20). A solution of 19 
(1.31 g, 1.75 mmol) in anhydrous DCM (70 mL) was stirred with 4Å mol. sieves for 30 
min. and then cooled to 0 °C. To this was added neat TMSI (0.408 mL), which was 
freshly prepared under Ar by the addition of TMSTMS (0.66 g, 4.5 mmol) to iodine 
(0.76 g, 3.0 mmol) and the reaction heated at 60 °C until the mixture turned colourless. 
After 15 min., TLC showed full consumption of 19 into two glycosyl iodides [Rf = 0.67 
(EtOAc/PE, 1/9, v/v) and Rf = 0.53 (EtOAc/PE, 1/9, v/v)], at which point DIPEA (0.51 
g, 3.96 mmol) and isopropylidene glycerol (+)-10 (0.52 g, 3.96 mmol) were added and 
the reaction stirred at RT for 3 h until full consumption of the iodide into a slightly 
higher running product (Rf = 0.68, EtOAc/PE, 1/9, v/v). The reaction mixture was then 
diluted with EtOAc, washed with NaHCO3 (sat. aq.), Na2S2O3 (sat. aq.) and brine, dried 
(MgSO4), filtered and concentrated. The residue was then purified by silica gel flash 
column chromatography (EA/PE, 2/98, v/v), to give a 1/9 mixture of the α- and β- 
isomers as a colourless oil (1.22 g, 1.62 mmol, 90% overall yield). Here, it should be 
noted that separation of the anomers could be achieved via careful silica gel column 
chromatograpy (DCM/PE, 1/1, v/v), however, separation of the anomers became easier 
following acetonide deprotection (vide infra). β isomer; []D
25
 = -7.3 (c = 1.0, CHCl3); 
IR (film) 2930, 2858, 1473, 1251, 1106, 836, 777 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  
4.83 (d, JH-1´, H-2´ = 2.2 Hz, 1H, H-1´), 4.29 (m, 1H, H-2), 4.13 (dd, JH-3´, H-2´ = 3.3 Hz, 
JH-3´, H-4´ = 5.8 Hz, 1H, H-3´), 4.05 (ABX, JH-3a, H-2 =6.3 Hz, JH-3a, H-3b =8.4, H-3a), 4.02 
(dd, JH-2´, H-1´ = 2.2 Hz, JH-2´, H-3´= 3.4 Hz, 1H, H-2´), 3.94 ( dd, JH-4´, H-3´= 5.8 , JH-4´, H-
5´=3.0, H-4´), 3.83 (ABX, JH-1b, H-2 =6.3 Hz, JH-1b, H-3a =8.4, 1H, H-1b), 3.77 (ABX, JH-3a, 
H-2 = 4.7 Hz, JH-3a, H-3b = 10.0 Hz, 1H, H-3a), 3.75 (m, 1H, H-5´), 3.66 (ABX, JH-6´a, H-5´ 
= 6.9 Hz, JH-6´a, H-6´b = 10.0 Hz, 1H, H-6´a), 3.58 (ABX, JH-6´b, H-5´ = 5.9 Hz, JH-6´b, H-6´a = 
10.0 Hz, 1H, H-6´b), 3.42 (ABX, JH-3b, H-2 = 6.7 Hz, JH-3b, H-3a = 10.0 Hz, 1H, H-3b), 
1.42 and 1.36 (s, 3H, CH3(iPr)), 0.92-0.85 (m, 36H, C(CH3)3), 0.13-0.03 (m, 24H, 
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CH3Si); 
13
C NMR (75 MHz, CDCl3)  109.1 (C(CH3)2), 108.8 (C-1´), 84.4 (C-2´), 83.9 
(C-4´), 79.5 (C-3´), 74.5 (C-2), 73.1 (C-5´), 68.3 (C-3), 67.2 (C-1), 64.6 (C-6´), 26.7 
and 25.5 (iPr), 26.01 (C(CH3)3), 25.95 (C(CH3)3), 25.77 (C(CH3)3), 25.7 (C(CH3)3), 
18.32 (SiC(CH3)3), 18.31 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), -3.6 
(Si(CH3)2), -4.0 (Si(CH3)2), -4.36 (Si(CH3)2), -4.41 (Si(CH3)2), -4.6 (Si(CH3)2), -4.8 
(Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. for 
[C36H78NaO8Si4+]
+
: 773.4666, found: 773.4667. 
1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D-
galactofuranosyl)-sn-glycerol (sn-1-9). A solution of sn-1-20 (48.5 mg, 0.064 mmol) 
in TFA/H2O/DCM (2.5/2.5/95, v/v/v, 3 mL) was stirred for 10 min. at RT, after which 
the reaction was quenched by the addition of NaHCO3 (sat. aq.). The mixture was then 
extracted with EtOAc and the combined organic layers washed with NaHCO3 (sat. aq.) 
and brine, dried (MgSO4), filtered and concentrated. Purification of the residue by silica 
gel flash column chromatography (EtOAc/PE, 1/9, v/v), gave the pure β-isomer as a 
colourless oil (43.0 mg, 0.061 mmol, 96%). (Rf = 0.35, EtOAc/PE, 3/7, v/v); []D
20
 = -
20.0 (c = 0.1, CHCl3); IR (film) 3463, 2954, 2928, 2857, 1463, 1255, 1103, 837, 780, 
759 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.83 (s, 1H, H-1´), 4.11 (t, JH-3´, H-2´ = JH-3´, H-
4´= 3.8 Hz, 1H, H-3´), 3.99 (m, 1H, H-4´), 3.98 (m, 1H, H-2´), 3.77 (m, 1H, H-2), 3.72 
(m, 1H, H-5´), 3.69 (m, 1H, H-1a), 3.67 (m, 1H, H-1b), 3.64 (m, 1H, H-3a), 3.62 (m, 
1H, H-3b), 3.59 (m, 1H, H-6´a), 3.57 (m, JH-6´b, H-6´a= 10.0 Hz, JH-6´b, H-5´ = 5.83 Hz, 1H, 
H-6´b), 3.21 (s, 1H, OH(2)), 2.22 (s, 1H, OH (3)), 1.0-0.8 (m, 36H, C(CH3)3), 0.2-0.0 
(m, 24H, Si(CH3)2); 
13
C NMR (125 MHz, CDCl3)  108.9 (C-1´), 85.5 (C-4´), 83.3 (C-
2´), 78.7 (C-3´), 73.4 (C-5´), 70.4 (C-2), 70.3 (C-1), 64.5 (C-6´), 64.0 (C-3), 25.96 
(C(CH3)3), 25.93 (C(CH3)3), 25.73 (C(CH3)3), 25.70 (C(CH3)3), 18.3 (SiC(CH3)3), 18.2 
(SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), -3.9 (Si(CH3)2), -4.2 (Si(CH3)2), -4.44 
(Si(CH3)2), -4.46 (Si(CH3)2), -4.5 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 
(Si(CH3)2); HRMS(ESI) m/z calcd. for [C33H74NaO8Si4]
+
: 733.4353, found: 733.4365. 
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3-O-(β-D-galactofuranosyl)-sn-glycerol (GalfGro). To a solution 
of sn-3-9 (68 mg, 0.26 mmol) in MeOH (1 mL) was added Dowex-H
+
 and the reaction 
mixture stirred at RT for 12 h. The solution was filtered and concentrated in vacuo. 
Purification of the residue by silica gel flash column chromatography (MeOH/EtOAC, 
15/85, v/v) gave GalfGro as a white solid (41.6 mg, 0.16 mmol, 63%). (Rf = 0.14, 
MeOH/EtOAc, 1/4, v/v); []D
26
 = -40.0 (c = 0.1, H2O); IR (film) 3465, 2928, 1462, 
1309, 1250, 1162, 1031, 834 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.84 (s, 1H, H-1´), 
3.93 (dd, JH-2´, H-1´ = 1.92, JH-2´, H-3´ = 3.55, 1H, H-2´), 3.79 (m, JH-4´, H-3´ = 5.8 Hz , JH-4´, 
H-5´= 4.3 Hz, 1H, H-4´), 3.90 (dd, JH-3´, H-2´ = 3.55, JH-3´, H-4´ = 6.15, 1H, H-3´), 3.74 (m, 
1H, H-2), 3.67 (m, 1H, H-5´), 3.56 (m, 1H, H-3a), 3.46 (m, 1H, H-3b), 3.54 (m, 1H, H-
6´a), 3.47 (m, 1H, H-6´b), 3.44 (m, 1H, H-1a), 3.40 (m, 1H, H-1b); 
13
C NMR (125 
MHz, CDCl3)  106.9 (C-1´), 82.6 (C-4´), 80.9 (C-2´), 76.6 (C-3´), 70.7 (C-5´), 70.0 (C-
2), 68.4 (C-3), 62.5 (C-6´), 62.3 (C-1); HRMS(ESI) m/z calcd. for [C9H18NaO8]
+
: 
277.0894, found: 277.0895. 
   3-O-(2,3,5,6-Tetra-O-tert-butyldimethylsilyl-β-
D-galactofuranosyl)-sn-glycerol (sn-3-9). A solution of sn-3-20 (149 mg, 0.20 mmol) 
in TFA/H2O/DCM (2.5/2.5/95, v/v/v, 10 mL) was stirred for 10 min. at RT, after which 
the reaction was quenched by the addition of NaHCO3 (sat. aq.). The mixture was then 
extracted with EtOAc and the combined organic layers washed with NaHCO3 (sat. aq.) 
and brine, dried (MgSO4), filtered and concentrated. Purification of the residue by silica 
gel flash column chromatography (EtOAc/PE, 1/9, v/v), gave the pure β-isomer as a 
colourless oil (131 mg, 0.18 mmol, 93%). (Rf= 0.37, EtOAc/PE, 3/7, v/v); []D
24
 = -
20.0 (c = 0.1, CHCl3); IR (film) 3498, 2955, 2929, 2858, 1472, 1361, 1253, 1107, 836, 
776, 670 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  4.85 (d, JH-1´, H-2´ = 2.2 Hz, 1H, H-1´), 
4.14 (dd, JH-3´, H-2´ = 3.1 Hz, JH-3´, H-4´ = 4.5 Hz, 1H, H-3´), 4.0 (m, 2H, H-2´ and H-4´), 
3.83 (m, 2H, H-2), 3.75 (m, 1H, H-5´), 3.69 (m, 2H, H-3a and b), 3.68 (ABX, 1H, H-
1a), 3.63 (ABX, JH-6´a, H-2 = 3.4 Hz, JH-6´a, H-6´b = 10.3 Hz, 1H, H-6´a), 3.60 (ABX, JH-3b, 
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H-2 = 5.6 Hz, JH-3a, H-3b = 11.2 Hz 1H, H-1b), 3.59 (ABX, JH-6´b, H-5´ = 5.74 Hz, JH-6´b, H-6´a 
= 10.0 Hz 1H, H-6´b), 3.31 (d, JH-2, OH = 4.3 Hz, 1H, OH), 2.3 (t, JH-1, OH = 5.8 Hz, 1H, 
OH) ), 1.0-0.8 (m, 36H, C(CH3)3), 0.2-0.0 (m, 24H, Si(CH3)2); 
13
C NMR (75 MHz, 
CDCl3)  108.4 (C-1´), 85.3 (C-4´), 83.7 (C-2´), 79.0 (C-3´), 73.5 (C-5´), 70.9 (C-3), 
70.6 (C-2), 64.6 (C-6´), 63.7 (C-1), 25.96 (C(CH3)3), 25.95 (C(CH3)3), 25.8 (C(CH3)3), 
25.7 (C(CH3)3), 18.3 (SiC(CH3)3), 18.26 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 
(SiC(CH3)3), -3.8 (Si(CH3)2), -4.2 (Si(CH3)2), -4.40 (Si(CH3)2), -4.43 (Si(CH3)2), -4.49 
(Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. for 
[C33H74NaO8Si4]
+
: 733.4353, found: 733.4366. 
General esterification procedure. 
To a solution of alcohol (0.2 M) and the appropriate fatty acid (4.4 equiv.) in dry 
toluene was added EDCI (4.4 equiv.) and DMAP (0.15 equiv.). The reaction was then 
heated as required (see specific procedures) until TLC showed complete conversion of 
starting material. The reaction mixture was then diluted with EtOAc, washed with 
NaHCO3 (sat. aq.) and brine, dried (MgSO4), filtered and concentrated in vacuo. 
Purification of the residue by silica gel flash column chromatography afforded the title 
compound. 
1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-2,3-di-O-stearoyl-sn-glycerol (sn-1-6a). Subjection of sn-1-9 (71 
mg, 0.1 mmol), stearic acid (124 mg, 0.44 mmol), DMAP (1.8 mg, 0.015 mmol) and 
EDCI (68.3 mg, 0.44 mmol) to the general esterification procedure at 40 °C for 12 h 
gave the title compound sn-1-6a (108.5 mg, 0.087 mmol, 87%) as a colourless oil after 
column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.60, EtOAc/PE, 1/9, v/v); []D
25
 
= -20.0 (c = 1, CHCl3); IR (film) 2924, 2854, 1745, 1463, 1252, 1111, 836, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.19 (m, 1H, H-2), 4.79 (d, JH-1´, H-2´ = 2.0 Hz, 1H, H-1´), 
4.36 (ABX, JH-3a , H-2 = 3.7 Hz, JH-3a, H-3b = 12.0 Hz, 1H, H-3a), 4.13 (ABX, JH-3b, H-2 = 
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6.3 Hz, JH-3b, H-3a = 8.3 Hz, 1H, H-3b), 4.11 (m, 1H, H-3´), 4.00 (dd, JH-2´, H-3´ = 3.0 Hz, 
JH-2´, H-1´ = 2.1 Hz, 1H, H-2´), 3.92 (dd, JH-4´, H-3´ = 5.3 Hz, JH-4’, H-5’ = 3.4 Hz, 1H, H-4´), 
3.79 (ABX, JH-1a, H-2 = 5.3 Hz, JH-1a, H-3b = 10.4 Hz, 1H, H-1a), 3.76 (m, 1H, H-5´), 3.67 
(ABX, JH-6´a, H-5´ = 6.2 Hz, JH-6´a, H-6´b = 10.1 Hz, 1H, H-6´a), 3.57 (ABX, JH-6´b, H-5´ = 5.9 
Hz, JH-6´b, H-6´a = 10.0 Hz, 1H, H-6´b), 3.55 (ABX, JH-1b, H-2 = 5.9 Hz, JH-1b, H-1a = 10.3 
Hz, 1H,H-1b), 2.30 (t, JHα, Hβ = 7.6 Hz, 4H, CH2α), 1.60 (m, 4H, CH2β), 1.37-1.14 (m, 
56H, CH2), 0.9-0.8 (m, 42H, CH3 and C(CH3)3), 0.16-0.00 (m, 24H, Si(CH3)2); 
13
C 
NMR (125 MHz, CDCl3)  173.3 and 173.0 (C(O)), 108.3 (C-1´), 84.5 (C-4´), 84.1 (C-
2´), 79.5 (C-3´), 73.4 (C-5´), 70.1 (C-2), 65.6 (C-1), 64.7 (C-6´), 62.8 (C-3); 34.3 and 
34.1 (CH2α), 31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 26.0 (C(CH3)3), 26.97 (C(CH3)3), 
25.8 (C(CH3)3), 25.7 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 (SiC(CH3)3), 
17.8, 14.1 (CH3) (SiC(CH3)3), -3.7 (Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (Si(CH3)2), -4.43 
(Si(CH3)2), -4.5 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.35 (Si(CH3)2); 
HRMS(ESI) m/z calcd. for [C69H142NaO10Si4]
+
: 1265.9572, found: 1265.9584. 
1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-2,3-di-O-arachidoyl-sn-glycerol (sn-1-6b). Subjection of sn-1-9 
(19.0 mg, 0.026 mmol), arachidic acid (35.8 mg, 0.114 mmol), DMAP (0.47 mg, 0.0039 
mmol) and EDCI (17.7 mg, 0.114 mmol) to the general esterification procedure at 40 °C 
for 12 h gave the title compound sn-1-6b (33.1 mg, 0.025 mmol, 98%), as a colourless 
oil after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.56, EtOAc/PE, 1/9, 
v/v); []D
21
 = -21.0 (c = 0.1, CHCl2); IR (film) 2925, 2854, 1743, 1769, 1555, 1512, 
1463, 1401, 1275, 1258, 1108, 1005, 922, 836, 764, 750, 711, 668 cm
-1
; 
1
H NMR (500 
MHz, CDCl3)  5.18 (m, 1H, H-2), 4.78 (d, JH-1´, H-2´= 1.8 Hz, 1H, H-1´), 4.34 (ABX, 
JH-3a, H-2 = 3.6 Hz, JH-3a, H-3b = 11.8 Hz, 1H, H-3a), 4.13 (ABX, JH-3b, H-2 = 6.3 Hz, JH-3b, H-
3a = 8.3 Hz, 1H, H-3b), 4.10 (m, 1H, H-3´), 3.98 (dd, JH-2´, H-3´= 3.3 Hz, JH-2´, H-1´= 2.3 
Hz, 1H, H-2´), 3.88 (dd, JH-4´, H-3´ = 5.7 Hz, JH-4’, H-5’ = 3.4 Hz, 1H, H-4´), 3.75 (ABX, 
JH-1a, H-2 = 5.3 Hz, JH-1a, H-3b = 10.4 Hz, 1H, H-1a), 3.72 (m, 1H, H-5´), 3.67 (ABX, JH-6´a, 
H-5´ = 6.3 Hz, JH-6´a, H-6´b = 9.8 Hz, 1H, H-6´a), 3.57 (ABX, JH-6´b, H-5´= 5.9 Hz, JH-6´b, H-6´a 
= 10.2 Hz, 1H, H-6´b), 3.55 (ABX, JH-1b, H-2 = 5.5 Hz, JH-1b, H-1a = 10.2 Hz, 1H, H-1b), 
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2.30 (t, JCH2α, CH2β = 7.6 Hz, 4H, CH2α), 1.58 (m, 4H, CH2β), 1.36-1.17 (m, 64H, CH2), 
0.9-0.8 (m, 42H, CH3 and C(CH3)3), 0.12-0.02 (m, 24H, Si(CH3)2); 
13
C NMR (125 
MHz, CDCl3)  173.3 and 173.0 (C(O)), 108.2 (C-1´), 84.4 (C-4´), 84.2 (C-2´), 79.4 (C-
3´), 73.4 (C-5´), 70.1 (C-2), 65.6 (C-1), 64.7 (C-6´), 62.8 (C-3); 34.3 and 34.1 (CH2α), 
31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 26.0 (C(CH3)3), 26.96 (C(CH3)3), 25.75 
(C(CH3)3), 25.70 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 (SiC(CH3)3), 
17.8 (SiC(CH3)3), 14.1 (CH3), -3.7 (Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (Si(CH3)2), -4.44 
(Si(CH3)2), -4.6 (Si(CH3)2), -4.9 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); 
HRMS(ESI) m/z calcd. for [C73H150NaO10Si4]
+
: 1322.0198, found: 1322.0210. 
1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-2,3-di-O-behenoyl-sn-glycerol (sn-1-6c). Subjection of sn-1-9 (16.7 
mg, 0.023 mmol), behenic acid (39.0 mg, 0.10 mmol), DMAP (0.42 mg, 0.003 mmol) 
and EDCI (15.7 mg, 0.10 mmol) to the general esterification procedure at 70 °C for 6 
days gave the title compound sn-1-6c (20.9 mg, 0.015 mmol, 77%), as a colourless oil 
after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.50, EtOAc/PE, 1/9, v/v); 
[]D
21
 = -24.5 (c = 1.0, CHCl3); IR (film) 2921, 2852, 1744, 1464, 1252, 1108, 835, 776 
cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.20 (m, 1H, H-2), 4.79 (d, JH-1´, H-2´ = 1.8 Hz, 1H, 
H-1´), 4.36 (ABX, JH-3a, H-2 = 3.4 Hz, JH-3a, H-3b = 11.8 Hz, 1H, H-3a), 4.13 (m, 1H, H-
3b), 4.11 (m, 1H, H-3´), 3.99 (m, 1H, H-2´), 3.92 (dd, JH-4´, H-3´ = 5.9 Hz, JH-4’, H-5’ = 3.5 
Hz, 1H, H-4´), 3.79 (ABX, JH-1a, H-2 = 5.6 Hz, JH-1a, H-3b = 10.4 Hz, 1H, H-1a), 3.76 (m, 
1H, H-5´), 3.66 (ABX, JH-6´a, H-5´ = 6.2 Hz, JH-6´a, H-6´b = 9.8 Hz, 1H, H-6´a), 3.58 (ABX, 
JH-6´b, H-5´ = 6.0 Hz, JH-6´b, H-6´a = 9.8 Hz, 1H, H-6´b), 3.50 (ABX, JH-1b, H-2 = 5.8 Hz, JH-1b, 
H-1a = 10.3 Hz, 1H, H-1b), 2.30 (t, JCH2α, CH2β = 7.4 Hz, 4H, CH2α), 1.60 (m, 4H, CH2β), 
1.35-1.21 (m, 72H, CH2), 1.0-0.8 (m, 42H, CH3 and C(CH3)3), 0.15-0.03 (m, 24H, 
Si(CH3)2); 
13
C NMR (125 MHz, CDCl3)  173.3 and 173.0 (C(O)), 108.3 (C-1´), 84.4 
(C-4´), 84.2 (C-2´), 79.4 (C-3´), 73.4 (C-5´), 70.1 (C-2), 65.6 (C-1), 64.7 (C-6´), 62.7 
(C-3); 34.3 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 26.0 (C(CH3)3), 
26.96 (C(CH3)3), 25.75 (C(CH3)3), 25.70 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) 
(SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 14.1 (CH3), -3.7 (Si(CH3)2), -4.0 
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(Si(CH3)2), -4.4 (Si(CH3)2), -4.44 (Si(CH3)2), -4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 
(Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. for [C77H158NaO10Si4]
+
: 1378.0824, 
found: 1378.0820. 
1-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-2,3-di-O-cerotoyl-sn-glycerol (sn-1-6d). Subjection of sn-1-9 (24.7 
mg, 0.035 mmol) cerotic acid (61.1 mg, 0.15 mmol), DMAP (0.60 mg, 0.0050 mmol) 
and EDCI (23.9 mg, 0.15 mmol) to the general esterification procedure at 70 °C for 6 
days gave the title compound sn-1-6d (33.4 mg, 0.022 mmol, 65%), as a colourless oil 
after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.55, EtOAc/PE, 1/9, v/v); 
[]D
18
 = -0.19 (c = 1.0, CHCl3); IR (film) 2917, 2849, 1744, 1470, 1253, 1110, 836, 774 
cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.20 (m, 1H, H-2), 4.79 (d, JH-1´, H-2´ = 1.5 Hz, 1H, 
H-1´), 4.36 (ABX, JH-3a, H-2 = 3.5 Hz, JH-3a, H-3b = 11.9 Hz, 1H, H-3a), 4.13 (m, 1H, H-
3b), 4.11 (m, 1H, H-3´), 3.99 (m, 1H, H-2´), 3.92 (dd, JH-4´, H-3´ = 5.4 Hz, JH-4’, H-5’ = 3.5 
Hz, 1H, H-4´), 3.79 (ABX, JH-1a, H-2 = 5.4 Hz, JH-1a, H-3b = 10.3 Hz, 1H, H-1a), 3.76 (m, 
1H, H-5´), 3.66 (ABX, JH-6´a, H-5´ = 6.2 Hz, JH-6´a, H-6´b = 10.2 Hz, 1H, H-6´a), 3.58 
(ABX, JH-6´b, H-5´ = 6.0 Hz, JH-6´b, H-6´a = 10.0 Hz, 1H, H-6´b), 3.50 (ABX, JH-1b, H-2 = 5.8 
Hz, JH-1b, H-1a = 10.4 Hz, 1H, H-1b), 2.30 (t, JCH2α, CH2β = 7.3 Hz, 4H, CH2α), 1.60 (m, 
4H, CH2β), 1.35-1.18 (m, 88H, CH2), 1.0-0.8 (m, 42H, CH3 and C(CH3)3), 0.14-0.03 
(m, 24H, Si(CH3)2); 
13
C NMR (125 MHz, CDCl3)  173.3 and 173.0 (C(O)), 108.3 (C-
1´), 84.4 (C-4´), 84.2 (C-2´), 79.4 (C-3´), 73.4 (C-5´), 70.1 (C-2), 65.6 (C-1), 64.7 (C-
6´), 62.7 (C-3); 34.3 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 30.0-29.0 (CH2), 26.0 
(C(CH3)3), 26.96 (C(CH3)3), 25.75 (C(CH3)3), 25.70 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) 
(SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 14.1 (CH3), -3.7 (Si(CH3)2), -4.0 
(Si(CH3)2), -4.4 (Si(CH3)2), -4.44 (Si(CH3)2), -4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 
(Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. for [C85H174NaO10Si4]
+
: 1490.2076, 
found: 1490.2079. 
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  3-O-(2,3,5,6-Tetra-O-tert-butyldimethylsilyl-β-
D-galactofuranosyl)-1,2-di-O-stearoyl-sn-glycerol (sn-3-6a). Subjection of sn-3-9 
(98.1 mg, 0.14 mmol), stearic acid (172 mg, 0.607 mmol), DMAP (2.5 mg, 0.02 mmol) 
and EDCI (116 mg, 0.607 mmol) to the general esterification procedure at 40 °C for 12 
h, gave the title compound sn-3-6a as a colourless oil (163.6 mg, 0.13 mmol, 94%) after 
column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.76, EtOAc/PE, 1/9, v/v); []D
26
 
= -5.75 (c = 0.1, CHCl3); IR (film) 2924, 2853, 1740, 1463, 1113, 837, 759 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3)  5.20 (m, 1H, H-2), 4.79 (d, JH-1´, H-2´ = 1.8 Hz, 1H, H-1´), 
4.35 (ABX, JH-1a, H-2 = 3.5 Hz, JH-1a, H-1b = 12.0 Hz, 1H, H-1a), 4.20 (ABX, JH-1b, H-2 = 
7.0 Hz, JH-1b, H-1a = 11.9 Hz, 1H, H-1b), 4.13 (m, JH-3´, H-2´ = 3.1 Hz, JH-3´, H-4´ = 5.5 Hz 
1H, H-3´), 4.00 (t, JH-2´, H-3´ = JH-2’, H-1’ = 2.5 Hz, 1H, H-2´), 3.91 (dd, JH-4´, H-3´ = 6.0 Hz, 
JH-4’, H-5’ = 3.2 Hz, 1H, H-4´), 3.79 (ABX, JH-3a, H-2 = 4.8 Hz, JH-3a, H-3b = 10.9 Hz, 1H, 
H-3a), 3.76 (m, 1H, H-5´), 3.65 (ABX, JH-6´a, H-5´ = 6.6 Hz, JH-6´a, H-6´b = 9.9 Hz, 1H, H-
6´a), 3.57 (ABX, JH-6´b, H-5´ = 6.0 Hz, JH-6´b, H-6´a = 10.0 Hz, 1H, H-6´b), 3.55 (ABX, JH-
3b, H-2 = 5.2 Hz, JH-3b, H-3a = 10.9 Hz, 1H, H-3b), 2.28 (t, JHα, Hβ = 7.7 Hz, 4H, Hα), 1.59 
(m, 4H, Hβ), 1.37-1.17 (m, 56H, CH2), 0.9-0.8 (t, 42H, CH3 and C(CH3)3), 0.16-0.00 
(m, 24H, Si(CH3)2); 
13
C NMR (126 MHz, CDCl3)  173.3 (C(O)1), 172.9 (C(O)2), 
108.3 (C-1´), 84.4 (C-2´), 84.2 (C-4´), 79.3 (C-3´), 73.2 (C-5´), 70.0 (C-2), 65.6 (C-3), 
64.6 (C-6´), 62.7 (C-1); 34.3 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 
26.0 (C(CH3)3), 26.9 (C(CH3)3), 25.8 (C(CH3)3), 25.7 (C(CH3)3), 24.94 and 24.90 
(CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.2 (SiC(CH3)3), 14.1 (CH3), -3.6 
(Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (x2) (Si(CH3)2), -4.5 (Si(CH3)2), -4.9 (Si(CH3)2), -5.3 
(Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. for [C69H142NaO10Si4]
+
: 1265.9572, 
found: 1265.9578. 
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3-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-1,2-di-O-arachidoyl-sn-glycerol (sn-3-6b). Subjection of sn-3-9 
(70 mg, 0.098 mmol), arachidic acid (134 mg, 0.43 mmol), DMAP (1.8 mg, 0.014 
mmol) and EDCI (66.9 mg, 0.43 mmol) to the general esterification procedure at 40 °C 
for 12 h gave the title compound sn-3-6b as a colourless oil (111.7 mg, 0.086 mmol, 
88%) after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.44, EtOAc/PE, 1/9, 
v/v); []D
26
 = -13.0 (c = 1.0, CHCl3); IR (film) 2924, 2854, 1744, 1463, 1252, 1112, 
836, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.21 (m, 1H, H-2), 4.80 (s, 1H, H-1´), 
4.35 (m, 1H, H-1a), 4.20 (ABX, JH-1b, H-2 = 6.6 Hz, JH-1b, H-1a = 11.6 Hz, 1H, H-1b), 4.13 
(m, 1H, H-3´), 4.00 (bs, 1H, H-2´), 3.93 (bs, 1H, H-4´), 3.79 (m, JH-3a, H-2 = 4.5 Hz, JH-3a, 
H-3b = 10.9 Hz, 1H, H-3a), 3.76 (m, 1H, H-5´), 3.66 (ABX, JH-6´a, H-5´ = 6.0 Hz, JH-6´a, H-
6´b = 9.3 Hz, 1H, H-6´a), 3.59 (m, 1H, H-6´b), 3.55 (ABX, JH-3b, H-2 = 5.9 Hz, JH-3b, H-3a = 
11.9 Hz, 1H, H-3b), 2.29 (bs, 4H, Hα), 1.61 (bs, 4H, Hβ), 1.44-1.18 (m, 56H, CH2), 1.0-
0.8 (t, 42H, CH3 and C(CH3)3), 0.24-0.00 (m, 24H, Si(CH3)2); 
13
C NMR (125 MHz, 
CDCl3)  173.3 (C(O)-1), 172.9 (C(O)-2), 108.2 (C-1´), 84.3 (C-2´), 84.2 (C-4´), 79.4 
(C-3´), 73.2 (C-5´), 70.0 (C-2), 65.6 (C-3), 64.6 (C-6´), 62.7 (C-1); 34.3 and 34.1 
(CH2α), 31.9 (CH2CH2CH3), 30.1-28.0 (CH2), 26.0 (C(CH3)3), 25.96 (C(CH3)3), 25.76 
(C(CH3)3), 25.70 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 (SiC(CH3)3), 
17.8 (SiC(CH3)3), 14.1 (CH3), -3.6 (Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (x2) (Si(CH3)2), -
4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. 
for [C73H150NaO10Si4]
+
: 1322.0198, found: 1322.0201. 
3-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-1,2-di-O-behenoyl-sn-glycerol (sn-3-6c). Subjection of sn-3-9 (10.9 
mg, 0.015 mmol) to the general esterification procedure at 70 °C for 6 days, behenic 
acid (22.4 mg, 0.066 mmol), DMAP (0.27 mg, 0.0022 mmol) and EDCI (10.2 mg, 
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0.066 mmol) gave the title compound sn-3-6c (15.1 mg, 0.011 mmol, 73%), as a 
colourless oil after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.48, 
EtOAc/PE, 1/9, v/v); []D
18
 = -20.0 (c = 0.5, CHCl3); IR (film) 2923, 2853, 1745, 1252, 
1112, 836, 776 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.21 (m, 1H, H-2), 4.80 (s, 1H, H-
1´), 4.35 (ABX, JH-1a, H-2a = 3.30 Hz, JH-1a, H-2a = 12.11 Hz, 1H, H-1a), 4.19 (ABX, JH-1b, 
H-2 = 6.4 Hz, JH-1b, H-1a = 11.4 Hz, 1H, H-1b), 4.13 (m, 1H, H-3´), 4.00 (bs, 1H, H-2´), 
3.93 (m, 1H, H-4´), 3.80 (m, JH-3a, H-2 = 5.0 Hz, JH-3a, H-3b = 11.0 Hz, 1H, H-3a), 3.76 (m, 
1H, H-5´), 3.66 (ABX, JH-6´a, H-5´ = 6.6 Hz, JH-6´a, H6´b = 9.4 Hz, 1H, H-6´a), 3.58 (ABX, 
JH-6´b, H-5´ = 6.0 Hz, JH-6´b, H-6´a = 9.4 Hz, 1H, H-6´b), 3.55 (ABX, JH-3b, H-2 = 4.9 Hz, JH-3b, 
H-3a = 10.6 Hz, 1H, H-3b), 2.29 (m, 4H, CH2α), 1.60 (bs, 4H, Hβ), 1.35-1.18 (m, 72H, 
CH2), 1.0-0.8 (t, 42H, CH3 and C(CH3)3), 0.17-0.01 (m, 24H, Si(CH3)2); 
13
C NMR (125 
MHz, CDCl3)  173.4 (C(O)-1), 173.0 (C(O)-2), 108.2 (C-1´), 84.4 (C-2´), 84.2 (C-4´), 
79.4 (C-3´), 73.2 (C-5´), 70.0 (C-2), 65.6 (C-3), 64.6 (C-6´), 62.7 (C-1); 34.3 and 34.1 
(CH2α), 31.9 (CH2CH2CH3), 30.2-28.0 (CH2), 26.0 (C(CH3)3), 25.96 (C(CH3)3), 25.76 
(C(CH3)3), 25.70 (C(CH3)3), 24.9 (CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 (SiC(CH3)3), 
17.8 (SiC(CH3)3), 14.1 (CH3), -3.6 (Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (x2) (Si(CH3)2), -
4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); HRMS(ESI) m/z calcd. 
for [C73H150NaO10Si4]
+
: 1378.0824, found: 1378.0820. 
3-O-(2, 3, 5, 6-Tetra-O-tert-butyldimethylsilyl-β-D 
galactofuranosyl)-1,2-di-O-cerotoyl-sn-glycerol (sn-3-6d). Subjection of sn-3-9 (15 
mg, 0.021 mmol), cerotic acid (36.6 mg, 0.092 mmol), DMAP (0.38 mg, 0.0031 mmol) 
and EDCI (14.3 mg, 0.092 mmol) to the general esterification procedure at 70 °C for 6 
days gave the title compound sn-3-6d (23.4 mg, 0.016 mmol, 76%), as a colourless oil 
after column chromatrography (EtOAc/PE, 1/99, v/v). (Rf = 0.55, EtOAc/PE, 1/9, v/v); 
[]D
18
 = -9.0 (c = 0.1, CHCl3); IR (film) 2917, 2850, 1744, 1470, 1253, 1110, 837, 776, 
668 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.21 (m, 1H, H-2), 4.80 (s, 1H, H-1´), 4.35 
(ABX, JH-1a, H-2 = 3.3 Hz, JH-1a, H-1b = 11.8 Hz, 1H, H-1a), 4.19 (ABX, JH-1b, H-2 = 6.6 Hz, 
JH-1b, H-1a = 11.8 Hz, 1H, H-1b), 4.13 (dd, JH-3´, H-2´ = 2.9 Hz, JH-3´, H-4´ = 5.4 Hz, 1H, H-
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3´), 4.00 (bs, 1H, H-2´), 3.93 (dd, JH-4´, H-5´ = 3.3 Hz, JH-4´, H-3´ = 5.2 Hz 1H, H-4´), 3.80 
(ABX, JH-3a, H-2 = 4.8 Hz, JH-3a, H-3b = 11.1 Hz, 1H, H-3a), 3.76 (m, 1H, H-5´), 3.66 
(ABX, JH-6´a, H-5´ = 6.7 Hz, JH-6´a, H-6´b = 9.6 Hz, 1H, H-6´a), 3.59 (ABX, JH-6´b, H-5´ = 6.0 
Hz, JH-5´b, H-5´a = 9.9 Hz, 1H, H-6´b), 3.55 (ABX, JH-3b, H-2 = 5.5 Hz, JH-3b, H-3a = 10.4 Hz, 
1H, H-3b), 2.29 (t, JHα, Hβ = 7.9, 4H, Hα), 1.61 (bs, 4H, Hβ), 1.44-1.18 (m, 88H, CH2), 
1.0-0.8 (m, 42H, CH3 and C(CH3)3), 0.16-0.01 (m, 24H, Si(CH3)2); 
13
C NMR (125 
MHz, CDCl3)  173.4 (C(O)-1), 173.0 (C(O)-2), 108.2 (C-1´), 84.3 (C-2´), 84.2 (C-4´), 
79.4 (C-3´), 73.2 (C-5´), 70.0 (C-2), 65.6 (C-3), 64.6 (C-6´), 62.7 (C-1); 34.3 and 34.1 
(CH2α), 31.9 (CH2CH2CH3), 30.1-28.0 (CH2), 26.0 (C(CH3)3), 25.96 (C(CH3)3), 25.76 
(C(CH3)3), 25.70 (C(CH3)3), 24.94 and 24.91 (CH2β), 18.3 (x2) (SiC(CH3)3), 17.9 
(SiC(CH3)3), 17.8 (SiC(CH3)3), 14.1 (CH3), -3.6 (Si(CH3)2), -4.0 (Si(CH3)2), -4.4 (x2) 
(Si(CH3)2), -4.6 (Si(CH3)2), -4.8 (Si(CH3)2), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2); 
HRMS(ESI) m/z calcd. for [C85H174NaO10Si4]
+
: 1490.2076, found: 1490.2073. 
Global desilylation procedure for glycolipids sn-1-6a-d and sn-3-6a-d 
To a solution of compounds 6 in THF (0.9 mL) was added HF.pyridine (0.1 mL). After 
12 h, the reaction mixture was neutralised with NaHCO3 (sat. aq.), diluted with EtOAc, 
washed with HCl (0.1 M) and brine, dried (MgSO4), filtered and concentrated in vacuo. 
1-O-(β-D-Galactofuranosyl)-2,3-di-O-stearoyl-sn-glycerol 
(sn-1-2a). Subjection of sn-1-6a (23.2 mg, 0.019 mmol) to the global desilylation 
procedure gave the title compound sn-1-2a, as a colourless oil (14.9 mg, 0.019 mmol, 
quant.), (Rf = 0.57, MeOH/DCM, 1/6, v/v); []D
25
 = -21.4 (c = 1.0, Pyridine); IR (film) 
3560, 2955, 2917, 2849, 1740, 1462, 1377, 1164 cm
-1
; 
1
H NMR (500 MHz, 
CD3OD/CDCl3, 1/2, v/v)  5.18 (m, 1H, H-2), 4.90 (s, 1H, H-1´), 4.24 (ABX, JH-3a, H-2 = 
3.7 Hz, JH-3a, H-3b = 12.1 Hz, 1H, H-3a), 4.10 (ABX, JH-3b, H-2 = 6.3 Hz, JH-3b, H-3a = 12.0 
Hz, 1H, H-3b), 4.00 (t, JH-4´, H-3´=JH-4´, H-5´= 3.0Hz, 1H, H-4´), 3.96 (m, 1H, H-3´), 3.91 
(m, 1H, H-2´), 3.76 (m, 1H, H-5´), 3.75 (m, 1H, H-1a), 3.63 (ABX, JH-6´a, H-6´b = 11.7, 
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JH-6´a, H-5´ = 6.7, 1H, H-6´a), 3.61 (ABX, JH-6´b, H-6´a = 11.7, JH-6´b, H-5´ = 5.1, 1H, H-6´b), 
3.53 (ABX, JH-1b, H-2 = 6.6 Hz, JH-1b, H-1a = 10.5 Hz, 1H, H-1b), 2.27 (m, 4H, Hα), 1.55 
(m, 4H, Hβ), 1.38-1.10 (m, 56H, CH2), 0.75 (t, JCH3, CH3CH2 = 6.8, 6H, CH3); 
13
C NMR 
(151 MHz, CD3OD/CDCl3, 1/2, v/v)  173.8 (C(O)-3), 173.6 (C(O)-2), 108.4 (C-1´), 
86.3 (C-4´), 79.5 (C-2´), 78.2 (C-3´), 71.0 (C-5´), 70.0 (C-2), 65.8 (C-1), 63.6 (C-6´), 
62.4 (C-3), 34.2 and 34.0 (CH2α), 31.8 (CH2CH2CH3), 29.8-28.8 (CH2), 24.85 and 
24.79 (CH2β), 22.5 (CH2CH3), 13.9 (CH3); HRMS(ESI) m/z calcd. for [C45H86NaO10]
+
: 
809.6113, found: 809.6116. 
 1-O-(β-D-Galactofuranosyl)-2,3-di-O-arachidoyl-sn-
glycerol (sn-1-2b). Subjection of sn-1-6b (23.2 mg, 0.018 mmol) to the global 
desilylation procedure gave the title compound sn-1-2b as a colourless oil (15.1 mg, 
0.018 mmol, quant.), (Rf = 0.41, MeOH/DCM, 1/6, v/v); []D
27
 = -21.0 (c = 1.0, 
Pyridine); IR (film) 3463, 2916, 2849, 1738, 1466, 1246, 1175, 1104, 1022, 794, 720, 
668, 634 cm
-1
; 
1
H NMR (500 MHz, CD3OD/CDCl3, 1/2, v/v)  5.18 (m, 1H, H-2), 4.9 
(s, 1H, H-1´), 4.25 (m, 1H, H-3a), 4.09 (ABX, JH-3b, H-2 = 6.2 Hz, JH-3b, H-3a = 12.7 Hz, 
1H, H-3b), 3.96 (m, 1H, H-4´), 3.94 (m, 1H, H-3´), 3.91 (m, 1H, H-2´), 3.76 (m, 1H, H-
5´), 3.75 (m, 1H, H-1a), 3.60 (m, 1H, H-6´a), 3.61 (m, 1H, H6´b), 3.53 (ABX, JH-1b, H-2 
= 6.0 Hz, JH-1b, H-1a = 11.0 Hz, 1H, H-1b), 2.26 (m, 4H, Hα), 1.55 (m, 4H, Hβ), 1.36-
1.08 (m, 64H, CH2), 0.89 (t, JCH3, CH3CH2 = 5.0, 6H, CH3); 
13
C NMR (125 MHz, 
CD3OD/CDCl3, 1/2, v/v)  173.9 (C(O)-3), 173.7 (C(O)-2), 108.3 (C-1´), 85.5 (C-4´), 
80.0 (C-2´), 77.9 (C-3´), 71.1 (C-5´), 70.0 (C-2), 65.6 (C-1), 63.4 (C-6´), 62.5 (C-3), 
34.2 and 34.0 (CH2α), 31.8 (CH2CH2CH3), 30.1-28.6 (CH2), 24.8 and 24.7 (CH2β), 22.6 
(CH2CH3), 13.9 (CH3); HRMS(ESI) m/z calcd. for [C49H94NaO10]
+
: 865.6739, found: 
865.6750. 
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  1-O-(β-D-Galactofuranosyl)-2,3-di-O-behenoyl-
sn-glycerol (sn-1-2c). Subjection of sn-1-6c (4 mg, 0.0029 mmol) to the global 
desilylation procedure gave the title compound sn-1-2c, as a colourless oil after aqueous 
workup (2.6 mg, 0.0029 mmol, quant.), (Rf = 0.56, MeOH/DCM, 1/6, v/v); []D
25
 = -
20.0 (c = 0.1, Pyridine); IR (film) 3463, 2955, 2917, 2850, 1735, 1465, 1377, 1106, 783, 
735, 632 cm
-1
; 
1
H NMR (500 MHz, CD3OD/CDCl3, 1/2, v/v)  5.17 (m, 1H, H-2), 4.90 
(s, 1H, H-1´), 4.29 (ABX, JH-3a, H-2 = 3.2 Hz, JH-3a, H-3b = 12.5 Hz, 1H, H-3a), 4.09 
(ABX, JH-3b, H-2 = 5.8 Hz, JH-3b, H-3a = 12.3 Hz, 1H, H-3b), 3.94 (m, 1H, H-4´), 3.93 (m, 
1H, H-3´), 3.91 (m, 1H, H-2´), 3.76 (m, 1H, H-5´), 3.71 (m, 1H, H-1a), 3.60 (m, 2H, H-
6´a and H-6´b), 3.53 (m, 1H, H-1b), 2.26 (m, 4H, Hα), 1.54 (m, 4H, Hβ), 1.32-1.10 (m, 
72H, CH2), 0.81 (t, JCH3, CH3CH2 = 7.0, 6H, CH3); 
13
C NMR (125 MHz, CD3OD/CDCl3, 
1/2, v/v)  173.8 (C(O)-3), 173.6 (C(O)-2), 108.2 (C1´), 84.7 (C4´), 79.8 (C2´), 78.2 
(C3´), 71.0 (C5´), 70.0 (C-2), 65.5 (C-1), 63.6 (C6´), 62.4 (C-3), 34.0 and 33.8 (CH2α), 
31.7 (CH2CH2CH3), 29.8-28.8 (CH2), 24.7 and 24.6 (CH2β), 22.4 (CH2CH3), 13.6 
(CH3); HRMS(ESI) m/z calcd. for [C53H102NaO10]
+
: 921.7365, found: 921.7364 
1-O-(β-D-Galactofuranosyl)-2,3-di-O-cerotoyl-sn-glycerol 
(sn-1-2d). Subjection of sn-1-6d (24.7 mg, 0.016 mmol) to the global desilylation 
procedure gave the title compound sn-1-2d as a colourless oil (16.5 mg, 0.016 mmol, 
quant.), (Rf = 0.59, MeOH/DCM, 1/6, v/v); []D
25
 = -10.4 (c = 1.0, Pyridine); IR (film) 
3464, 2955, 2920, 2849, 1731, 1460, 1378, 1024 cm
-1
; 
1
H NMR (500 MHz, 
CD3OD/CDCl3, 1/2, v/v)  5.18 (m, 1H, H-2), 4.90 (s, 1H, H-1´), 4.28 (ABX, JH-3a, H-2 = 
3.8 Hz, JH-3a, H-3b = 12.1 Hz, 1H, H-3a), 4.09 (ABX, JH-3b, H-2 = 6.4 Hz, JH-3b, H-3a = 11.9 
Hz, 1H, H-3b), 3.95 (m, 1H, H-4´), 3.95 (m, 1H, H-3´), 3.91 (m, 1H, H-2´), 3.76 (m, 
1H, H-5´), 3.71 (m, 1H, H-1a), 3.61 (m, 1H, H-6´a), 3.59 (m, 1H, H-6´b), 3.53 (ABX, 
JH-1b, H-2 = 6.7 Hz, JH-1b, H-1a = 10.6 Hz, 1H, H-1b), 2.26 (m, 4H, Hα), 1.54 (m, 4H, Hβ), 
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1.32-1.14 (m, 56H, CH2), 0.81 (t, JCH3, CH3CH2 = 6.8, 6H, CH3); 
13
C NMR (151 MHz, 
CD3OD/CDCl3, 1/2, v/v)  174.0 (C(O)-3), 173.8 (C(O)-2), 108.4 (C-1´), 85.0 (C-4´), 
80.5 (C-2´), 77.9 (C-3´), 71.2 (C-5´), 70.2 (C-2), 65.7 (C-1), 63.5 (C-6´), 62.7 (C-3), 
34.2 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 29.9-28.8 (CH2), 24.84 and 24.83 (CH2β), 
22.6 (CH2CH3), 13.8 (CH3); HRMS(ESI) m/z calcd. for [C61H118NaO10]
+
: 1033.8617, 
found: 1033.8629. 
3-O-(β-D-Galactofuranosyl)-1,2-di-O-stearoyl-sn-glycerol 
(sn-3-2a). Subjection of sn-3-6a (24.4 mg, 0.02 mmol) to the global desilylation 
procedure gave sn-3-2a as a colourless oil (15.7 mg, 0.02 mmol, quant.), (Rf = 0.61, 
MeOH/DCM, 1/6, v/v); []D
25
 = -35.7 (c = 0.1, Pyridine); IR (film) 3446, 2917, 2849, 
2361, 2341, 1734, 1451, 1119, 1023, 977, 668 cm
-1
; 
1
H NMR (600 MHz, 
CD3OD/CDCl3, 1/2, v/v)  5.18 (m, 1H, H-2), 4.90 (s, 1H, H-1´), 4.32 (ABX, JH-1a, H-2 = 
3.5 Hz, JH-1a, H-1b = 12.0 Hz, 1H, H-1a), 4.11 (ABX, JH-1b, H-2 = 6.5 Hz, JH-1a, H-1b = 12.0 
Hz, 1H, H-1b), 3.99 (m, 3H, H-4´, H-3´, H-2´), 3.75 (m, 2H, H-3a, H-5´), 3.68 (m, 2H, 
H-6´a and b), 3.58 (ABX, JH-3b, H-2 = 5.5 Hz, JH-3b, H-3a = 11.0 Hz, 1H, H-3b), 2.28 (t, 
JHα, Hβ = 7.3 Hz, 4H, Hα), 1.57 (m, 4H, Hβ), 1.35-1.14 (m, 56H, CH2), 0.84 (t, JCH3, CH2 
= 6.9 Hz 6H, CH3); 
13
C NMR (151 MHz, CD3OD/CDCl3, 1/2, v/v)  173.9 and 173.6 
(C(O)), 108.4 (C-1´), 85.3 (C-4´), 80.3 (C-2´), 77.9 (C-3´), 71.1 (C-5´), 69.9 (C-2), 65.7 
(C-3), 63.5 (C-6´), 62.6 (C-1); 34.2 and 34.0 (CH2α), 31.8 (CH2CH2CH3), 29.9-28.8 
(CH2), 24.81 and 24.78 (CH2β), 22.6 (CH2CH3), 13.9 (CH3); HRMS(ESI) m/z calcd. for 
[C45H86NaO10]
+
: 809.6113, found: 809.6111. 
 3-O-(β-D-Galactofuranosyl)-1,2-di-O-arachidoyl-sn-
glycerol (sn-3-2b). Subjection of sn-3-6b (43.3 mg, 0.033 mmol) to the global 
desilylation procedure gave the title compound sn-3-2b as a colourless oil (28.0 mg, 
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0.033 mmol, quant.), (Rf = 0.59, MeOH/DCM, 1/6, v/v); []D
26
 = -26.0 (c = 0.1, 
Pyridine); IR (film) 3454, 2917, 2849, 1734, 1265, 895, 758, 733, 704 cm
-1
; 
1
H NMR 
(600 MHz, CD3OD/CDCl3, 1/2, v/v)  5.15 (m, 1H, H-2), 4.85 (s, 1H, H-1´), 4.30 (m, 
1H, H-1a), 4.09 (m, 1H, H-1b), 3.96-3.87 (m, 3H, H-4´, H-3´, H-2´), 3.76-3.65 (m, 2H, 
H-5´ and H-3a), 3.62-3.49 (m, 3H, H-6´a, H-6´b and H-3b), 2.25 (m, 4H, Hα), 1.53 (m, 
4H, Hβ), 1.30-1.09 (m, 64H, CH2), 0.80 (m, 6H, CH3); 
13
C NMR (151 MHz, 
CD3OD/CDCl3, 1/2, v/v)  174.0 (C-1), 173.6 (C-2), 108.4 (C-1´), 84.8 (C-4´), 80.7 (C-
2´), 77.7 (C-3´), 71.1 (C-5´), 70.0 (C-2), 65.6 (C-3), 63.4 (C-6´), 62.6 (C-1), 34.1 and 
34.0 (CH2α), 31.8 (CH2CH2CH3), 30.1-28.8 (CH2), 24.81 (CH2β), 22.5 (CH2CH3), 13.8 
(CH3); HRMS(ESI) m/z calcd. for [C49H94NaO10]
+
: 865.6744, found: 865.6744. 
3-O-(β-D-Galactofuranosyl)-1,2-di-O-behenyl-sn-glycerol 
(sn-3-2c). Subjection of sn-3-6c (20.4 mg, 0.015 mmol) to the global desilylation 
procedure gave the title compound sn-3-2c as a colourless oil (13.5 mg, 0.015 mmol, 
quant.), (Rf = 0.55, MeOH/DCM, 1/6, v/v); []D
26
 = -10.0 (c = 0.1, Pyridine); IR (film) 
3450, 2917, 2849, 1736, 1466, 1265, 1108, 758, 732, 704, 634 cm
-1
; 
1
H NMR (600 
MHz, CDCl3/CD3OD, 2/1, v/v)  5.17 (m, 1H, H-2), 4.88 (s, 1H, H-1´), 4.32 (m, 1H, H-
1a), 4.11 (m, 1H, H-1b), 3.98-3.91 (m, 3H, H-4´, H-3´ and H-2´), 3.77-3.68 (m, 2H, H-
5´ and H-3a), 3.64-3.53 (m, 3H, H-3b, H6´a and H6´b), 2.27 (m, 4H, Hα), 1.55 (m, 4H, 
Hβ), 1.35-1.12 (m, 72H, CH2), 0.82 (m, 6H, CH3); 
13
C NMR (151 MHz, 
CDCl3/CD3OD, 2/1, v/v)  174.0 (C-1), 173.6 (C-2), 108.3 (C-1´), 84.8 (C-4´), 80.7 (C-
2´), 77.7 (C-3´), 71.1 (C-5´), 70.0 (C-2), 65.6 (C-3), 63.4 (C6´), 62.6 (C-1), 34.1 and 
33.9 (CH2α), 31.8 (CH2CH2CH3), 30.2-28.5 (CH2), 24.80 and 24.76 (CH2β), 22.5 
(CH2CH3), 13.8 (CH3); HRMS(ESI) m/z calcd. for [C53H102NaO10]
+
: 921.7365, found: 
921.7381. 
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3-O-(β-D-Galactofuranosyl)-1,2-di-O-cerotoyl-sn-glycerol 
(sn-3-2d). Subjection of sn-3-6d (3.0 mg, 0.002 mmol) to the global desilylation 
procedure gave the title compound sn-3-2d as a colourless oil (2.1 mg, 0.002 mmol, 
quant.), (Rf = 0.56, MeOH/DCM, 1/6, v/v); []D
26
 = -15.0 (c = 0.1, Pyridine); IR (film) 
3562, 2955, 2917, 2849, 1740, 1462, 1377, 1164, 719, 633 cm
-1
; 
1
H NMR (600 MHz, 
CD3OD/CDCl3, 1/2, v/v)  5.19 (m, 1H, H-2), 4.89 (s, 1H, H-1´), 4.34 (ABX, JH-1a, H-2 = 
3.4 Hz, JH-1a, H-1b = 12.2 Hz, 1H, H-1a), 4.12 (ABX, JH-1b, H-2 = 6.5 Hz, JH-1a, H-1b = 12.2 
Hz, 1H, H-1b), 3.99-3.93 (m, 3H, H-4´, H-3´and H-2´), 3.76 (ABX, JH-3a, H-2 = 5.7 Hz, 
JH-3a, H-3b = 11.0 Hz, 1H, H-3a), 3.73 (m, 1H, H-5´), 3.64-3.60 (m, 2H, H-6´a and b), 
3.58 (ABX, JH-3b, H-2 = 5.8 Hz, JH-3b, H-3a = 11.5 Hz, 1H, H-3b), 2.26 (m, 4H, CH2α), 1.56 
(m, 4H, CH2β), 1.37-1.09 (m, 88H, CH2), 0.83 (m, 6H, CH3); 
13
C NMR (151 MHz, 
CDCl3/CD3OD, 2/1, v/v)  174.0 (C-1), 173.6 (C-2), 108.4 (C-1´), 84.7 (C-4´), 80.7 (C-
2´), 77.7 (C-3´), 71.1 (C-5´), 70.0 (C-2), 65.6 (C-3), 63.4 (C-6´), 62.7 (C-1), 34.0 and 
34.2 (CH2α), 31.8 (CH2CH2CH3), 29.9-28.8 (CH2), 24.81 and 24.78 (CH2β), 22.5 
(CH2CH3), 13.8 (CH3); HRMS(ESI) m/z calcd. for [C61H118NaO10]
+
: 1033.8617, found: 
1033.8634. 
   3-O-(2,3,5-Tri-O-tert-butyldimethylsilyl-
β-D-galactofuranosyl)-1,2-di-O-stearoyl-sn-glycerol (sn-3-7a). A solution of sn-3-6a 
(150 mg, 0.12 mmol) in THF/TFA/H2O (95/2.5/2.5, v/v/v, 4.2 mL) was stirred at 0 °C 
for 48 h. The reaction mixture was then diluted with EtOAc, washed with NaHCO3 (sat. 
aq.) and brine, dried (MgSO4), filtered and concentrated. Following silica gel flash 
column chromatography (EtOAc/PE, 4/96, v/v), pure sn-3-7a was obtained as a 
colourless oil (97 mg, 0.086 mmol, 72% yield), (Rf = 0.38, EtOAc/PE, 1/9, v/v); []D
20
 
= -20.0 (c = 1.0, CHCl3); IR (film) 2924, 2854, 1743, 1463, 1361, 1252, 1113, 1054, 
1006, 940, 836, 776, 739, 670 cm
-1
. 
1
H NMR (500 MHz, CDCl3)  5.20 (m, 1H, H-2), 
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4.81 (s, 1H, H-1´), 4.35 (ABX, JH-1a, H-2 = 3.7 Hz, JH-1a, H-1b = 11.9 Hz, 1H, H-1a), 4.18 
(ABX, JH-1b, H-2 = 6.6 Hz, JH-1a, H-1b = 12.0 Hz, 1H, H-1b), 4.05 (m, JH-3´, H-2´ = 1.8 Hz, 
JH-3´, H-4´ = 4.5 Hz 1H, H-3´), 4.00 (dd, JH-2´, H-3´ = 1.8 Hz, JH-2´, H-1´ = 0.9 Hz, 1H, H-2´), 
3.99 (dd, JH-4´, H-3´ = 4.7 Hz, JH-4´, H-5´ = 3.3 Hz, 1H, H-4´), 3.86 (m, 1H, H-5´), 3.78 
(ABX, JH-3a, H-2 = 4.6 Hz, JH-3a, H-3b = 10.8 Hz, 1H, H-3a), 3.67 (ABX, JH-6´a, H-5´ = 5.6 
Hz, JH-6’a, H-6’b = 11.8 Hz, 1H, H-6´a), 3.61 (ABX, JH-6´b, H-5´ = 3.9 Hz, JH-6´b, H-6´a = 11.8 
Hz, 1H, H-6´b), 3.56 (ABX, JH-3b, H-2 = 5.6 Hz, JH-3b, H-3a = 10.8 Hz, 1H, H-3b), 2.40 (s, 
1H, OH), 2.30 (m, 4H, Hα), 1.61 (m, 4H, Hβ), 1.26 (m, 56H, CH2), 0.93-0.87 (m, 51H, 
CH3), 0.14-0.07 (m, 18H, SiCH3); 
13
C NMR (75 MHz, CDCl3)  173.4 (C(O)1), 173.0 
(C(O)2), 108.2 (C-1´), 87.2 (C-4´), 83.5 (C-2´), 79.1 (C-3´), 72.4 (C-5´), 65.1 (C-2), 
64.1 (C-6´), 62.6 (C-1); 34.3 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 
26.0 (C(CH3)3), 25.70 (C(CH3)3), 25.66 (C(CH3)3), 24.94 and 24.90 (CH2β), 22.5 (CH2), 
18.4 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 14.1 (CH3), -4.2 (SiCH3), -4.3 
(SiCH3), -4.4 (SiCH3), -4.5 SiCH3), -4.6 (SiCH3), -4.8 (SiCH3); HRMS(ESI) m/z calcd. 
for [C63H128NaO10Si3]
+
: 1151.8708, found: 1151.8713. 
   3-O-(6-O-Stearoyl-2,3,5-Tri-O-
tert-butyldimethylsilyl-β-D-galactofuranosyl)-1,2-di-O-stearoyl-sn-glycerol (sn-3-
22a). To a solution of sn-3-7a (16 mg, 0.014 mmol) and stearic acid (173 mg, 0.61 
mmol, recrystalised from MeCN and acetone) in dry toluene (1.0 mL) at 40 °C was 
added EDCI (116 mg, 0.61 mmol) and DMAP (2.5 mg, 0.020 mmol). The reaction 
mixture was stirred for 12 h and then diluted with EtOAc, washed with NaHCO3 (sat. 
aq.) and brine, dried (MgSO4), filtered and concentrated. Following purification by 
silica gel flash column chromatography (EtOAc/PE, 2/98, v/v), pure sn-3-22a was 
obtained as a colourless oil (19 mg, 0.014 mmol, quant.), (Rf = 0.76, EtOAc/PE, 1/9, 
v/v); []D
25
 = -11.8 (c = 0.1, CHCl3); IR (film) 3500, 2920, 2851, 1742, 1463, 1219, 
1115, 837, 773, 668 cm
-1
. 
1
H NMR (500 MHz, CDCl3)  5.21 (m, 1H, H-2), 4.81 (s, 1H, 
H-1´), 4.34 (ABX, JH-1a, H-1b = 11.9 Hz, JH-1b, H-2 = 3.6 Hz, 1H, H-1a), 4.19 (m, 2H, H-1b 
and H-6´a), 4.02 (ABX, JH-6´a, H-6´b = 11.4 Hz, JH-6’b, H-2 = 7.0 Hz 1H, H-6´b), 4.06 (dd, 
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JH-4´, H-3´ = 4.7 Hz, JH-4´, H-5´ = 2.3 Hz, 1H, H-4´), 3.99 (m, 1H, H-2´), 3.95 (m, 1H, H-5´), 
3.86 (t, JH-3´, H-4´ = JH-3´, H-2´= 4.8 Hz, 1H, H-3´), 3.79 (ABX, JH-3a, H-2 = 4.6 Hz, JH-3a, H-3b 
= 10.9 Hz, 1H, H-3a), 3.54 (ABX, JH-3b, H-2 = 5.20 Hz, JH-3b, H-3a = 11.0 Hz, 1H, H-3b), 
2.30 (m, 4H, Hα), 1.61 (m, 4H, Hβ), 1.17-1.37 (m, 56H, CH2), 0.96-0.81 (m, 51H, 
CH3C and CH3), 0.15-0.00 (m, 18H, SiCH3); 
13
C NMR (126 MHz, CDCl3)  173.5 
(C(O)6´), 173.3 (C(O)1), 172.9 (C(O)2), 108.2 (C-1´), 85.9 (C-4´), 83.8 (C-2´), 79.2 (C-
3´), 70.8 (C-5´), 65.2 (C-2), 66.0 (C-6´), 62.5 (C-1); 34.4-34.0 (CH2α), 31.9 
(CH2CH2CH3), 29.9-29.0 (CH2), 25.9 (C(CH3)3), 25.72 (C(CH3)3), 25.68 (C(CH3)3), 
24.94 and 24.90 (CH2β), 22.7 (CH2), 18.3 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 
(SiC(CH3)3), 14.1 (CH3), -4.10 (SiCH3), -4.2 (SiCH3), -4.44 (SiCH3), -4.47 (SiCH3), -
4.6 (SiCH3), -4.8 (SiCH3); HRMS(ESI) m/z calcd. for [C81H162NaO11Si3]
+
: 1418.1317, 
found: 1418.1324.  
3-O-(6-O-Stearoyl-β-D-galactofuranosyl)-1,2-di-O-
stearoyl-sn-glycerol (sn-3-3a). To a solution of sn-3-22a (11 mg, 0.0080 mmol) in 
THF (900 μL) was added HF.Pyridine (100 μL) and the reaction stirred at RT for 12 h. 
After this time, the HF was quenched with NaHCO3 (sat aq.) and the compound 
extracted using EtOAc. The organic layer was washed with HCl (0.1 M), brine, and 
then dried (MgSO4), filtered and concentrated to give pure sn-3-3a as a colourless oil 
(8.4 mg, 0.008 mmol, 90%) after purification by silica gel flash column 
chromatography (Rf = 0.42, MeOH/DCM, 1/9, v/v); []D
20
 = -36.0 (c = 0.1, CHCl3); IR 
(film) 3461, 2919, 2850, 1733, 1466, 1215, 757, 668 cm
-1
. 
1
H NMR (500 MHz, CDCl3) 
 5.20 (m, 1H, H-2), 5.02 (s, 1H, H-1´), 4.35 (ABX, JH-1a, H-1b = 11.7 Hz, JH-1b, H-2 = 3.9 
Hz, 1H, H-1a), 4.32 (ABX, JH-6´a, H-6´b = 11.9 Hz, JH-6´a, H-5´ = 8.8 Hz, 1H, H-6´a), 4.21 
(ABX, JH-6´b, H-6´a = 11.7 Hz, JH-6´b, H-5´ = 3.1 Hz, 1H, H-6´b), 4.10 (m, 3H, H-4´, H-5´, 
H-1b), 4.07 (bs, 1H, H-2´), 4.01 (bs, 1H, H-3´), 3.82 (ABX, JH-3a, H-3b = 10.8 Hz, JH-3a, H-
2 = 5.8 Hz, 1H, H-3a), 3.61 (ABX, JH-3b, H-3a = 10.8 Hz, JH-3b, H-2 = 4.5 Hz, 1H, H-3b), 
2.83 (s, 1H, OH-H-5´), 2.81 (s, 1H, OH-H-2´), 2.36 (t, JHα, Hβ = 7.7 Hz, 2H, 
RCH2αCOOCH2-6´), 2.32 (m, 4H, JHα, Hβ = 7.9 Hz, RCH2αCOOCH2-1 and 3), 1.62 (m, 
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6H, Hβ), 1.26 (m, 84H, CH2), 0.89 (t, JCH3, CH2 = 7.0 Hz, 9H, CH3) 
13
C NMR (126 MHz, 
CD3OD/CDCl3, 1/2, v/v)  174.6 (C(O)6´), 173.4 and 173.1 (C(O)), 108.7 (C-1´), 87.5 
(C-4´), 78.2 (C-2´), 78.6 (C-3´), 70.3 (C-5´), 69.6 (C-2), 66.5 (C-6´), 65.8 (C-3), 62.1 
(C-1), 34.2 (RCH2αCOOCH2-6´), 34.12 and 34.08 (RCH2αCOOCH2-1 and 3), 29.5 and 
31.9 (CH2), 24.8 (CH2β), 22.7 (CH3); HRMS(ESI) m/z calcd. for [C81H162NaO11Si3]
+
: 
1075.8723, found: 1075.8730. 
3-O-(6-O-[Phosphate]-β-D-galactofuranosyl)-1,2-di-O-
stearoyl-sn-glycerol (sn-3-23a). To a solution of sn-3-7a (16.1 mg, 0.014 mmol) in dry 
pyridine (1 mL) was added POCl3 (3.7 mg, 0.028 mmol). After 1 h, H2O/TEA (1/1, v/v, 
2 mL) was added and the reaction stirred for 15 min. The reaction mixture was then 
diluted with EtOAc, washed with NaHCO3, HCl (0.1 M) and brine, dried (MgSO4), 
filtered and concentrated. Following purification by silica gel flash column 
chromatography (DCM/MeOH, 24/1, v/v), pure sn-3-23a was obtained as a colourless 
oil (16.9 mg, 0.014 mmol quant.), (Rf = 0.57, MeOH/DCM, 1/9, v/v); []D
22
 = -16.0 (c 
= 0.5, CHCl3); IR (film) 3540, 2923, 2853, 1742, 1464, 1361, 1251, 1114, 1046, 837, 
777, cm
-1
. 
1
H NMR (500 MHz, CDCl3)  5.19 (m, 1H, H-2), 4.80 (s, 1H, H-1´), 4.35 
(ABX, JH-1a, H-1b = 11.0 Hz, JH-1b, H-2 < 2 Hz, 1H, H-1a), 4.20 (ABX, JH-1a, H-1b = 11.8 
Hz, JH-1b, H-2 = 6.8 Hz, 1H, H-1b), 4.14 (bs, 1H, H-3´), 3.98 (m, 2H, H-2´ and H-5´), 
4.00 (m, 1H, H-6´a), 3.93 (m, 1H, H-6´b), 3.90, (m, 1H, H-4´), 3.80 (ABX, JH-3a, H-2 = 
3.6 Hz, JH-3a, H-3b = 10.4 Hz, 1H, H-3a), 3.54 (ABX, JH-3b, H-2 = 5.2 Hz, JH-3b, H-3a = 10.4 
Hz, 1H, H-3b), 2.29 (m, 4H, CH2α), 1.60 (m, 4H, CH2β), 1.17-1.48 (m, 56H, CH2), 
1.02-0.78 (m, 51H, (CH3)3C and CH3), 0.21-0.00 (m, 24H, Si(CH3)2); 
13
C NMR (126 
MHz, CDCl3)  173.8 and 173.3 (C(O)1 and C(O)2), 108.2 (C-1´), 84.3 (C-4´), 84.1 (C-
2´), 79.0 (C-3´), 71.4 (C-5´), 67.4 (C-6´), 65.5 (C-3), 62.7 (C-1), 34.2 and 34.0 (CH2α), 
31.8 (CH2CH2CH3), 30.5-28.7 (CH2), 26.0 (C(CH3)3), 25.8 (x2) (C(CH3)3), 24.93 and 
24.90 (CH2β), 22.7 (CH2CH3), 18.3 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 
14.0 (CH3), -3.73 (Si(CH3)2), -4.17 (Si(CH3)2), -4.37 (Si(CH3)2), -4.43 (Si(CH3)2), -4.7 
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(Si(CH3)2), -4.8 (Si(CH3)2); 
31
P NMR (121 MHz, CDCl3)  0.59 HRMS(ESI) m/z calcd. 
for [C63H128O13PSi3]
-
: 1207.8406, found: 1207.8384. 
3-O-(6-O-[Phosphate]-β-D-galactofuranosyl)-1,2-di-O-
stearoyl-sn-glycerol (sn-3-4a). To a solution of sn-3-23a (16.3 mg, 0.013 mmol) in 
DCM/MeOH (2/1, v/v) was added Dowex H
+ 
and the reaction mixture stirred at RT for 
two weeks. The solution was then filtered and concentrated in vacuo to give sn-3-4a as 
a colourless oil (9.3 mg, 0.011 mmol, 80%), (Rf = 0.15, DCM/MeOH, 8/2, v/v); []D
23
 = 
-18.0 (c = 0.5, Pyridine); IR (film) 3413, 2917, 2849, 1740, 1463, 1176, 1034 cm
-1
. 
1
H 
NMR (500 MHz, CDCl3/CD3OD/D2O, 70/40/6, v/v/v)  5.20 (m, 1H, H-2), 4.92 (s, 1H, 
H-1´), 4.35 (m, 1H, H-1a), 4.17 (m, 1H, H-1b), 4.08 (m, 2H, H-6´a and b), 4.03 (m, 1H, 
H-3´), 4.01 (m, 1H, H-4´), 3.97 (m, 1H, H-2´), 3.77 (m, 1H, H-3a), 3.60 (m, 1H, H-3b), 
2.17-2.00 (m, 4H, Hα), 1.44-1.28 (m, 4H, Hβ), 1.21-0.81 (m, 56H, CH2), 0.74-0.47 (m, 
6H, CH3); 
13
C NMR (126 MHz, CDCl3)  174.1 and 173.7 (C(O)), 108.6 (C-1´), 84.2 
(C-4´), 80.8 (C-2´), 77.6 (C-3´), 70.2 (C-2), 69.5 (C-5´), 66.4 (C-6´), 65.6 (C-3); 34.10-
34.09 (CH2α), 31.9 (CH2CH2CH3), 29.9-29.0 (CH2), 24.95 (CH2β), 22.6 (CH2), 13.9 
(CH3), 
31
P NMR (121 MHz, CDCl3)  4.09 HRMS(ESI) m/z calcd. for 
[C63H128O13PSi3]
-
: 865.5812, found: 865.5809. 
31
P NMR (121 MHz, CDCl3)  4.09 
HRMS(ESI) m/z calcd. for [C63H128O13PSi3]
-
: 865.5812, found: 865.5809. 
3-O-(6-O-[2,3-O-isopropylidene-sn-
glyceroloxy(trimethylsilylethyloxy)phosphoryl]-2, 3, 5-Tetra-O-tert-
butyldimethylsilyl-β-D galactofuranosyl)-1,2-di-O-stearyl-sn-glycerol (sn-3-30a). To 
a solution of sn-3-7a (56.7 mg, 0.050 mmol) in THF (0.5 mL) was added a solution of 
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29 (28.0 mg, 0.11 mmol) in anhydrous MeCN (0.5 mL) followed by 1H-tetrazole (10.6 
mg, 0.15 mmol). The reaction mixture was stirred for 4 h and then t-BuOOH (6 M in 
octane, 42 μL) was added and the solution stirred for another 15 min. The reaction 
mixture was then diluted with EtOAc, washed with NaHCO3 (sat. aq.) and brine, dried 
(MgSO4), filtered and concentrated. Purification of the residue by silica gel flash 
column chromatography (EtOAc/PE, 3/7, v/v) gave sn-3-30a as colourless oil (14.6 mg, 
0.013 mmol, 27%), (Rf = 0.65, EtOAc/PE, 3/7, v/v); []D
21
 = -12.0 (c = 0.1, CHCl3); IR 
(film) 2925, 2855, 1743, 1464, 1371, 1251, 1114, 1005, 838, 778, 668, 636 cm
1
;
 1
H 
NMR (500 MHz, CDCl3)  5.20 (m, 1H, H-2), 4.80 (d, JH-1´, H-2´ = 1.5 Hz, 1H, H-1´), 
4.33 (ABX, JH-1a, H-1b = 11.9 Hz, JH-1a, H-2 = 3.8 Hz, 1H, H-1a), 4.30 (m, 1H, H-2´´), 4.18 
(ABX, JH-1b, H-1a = 11.9 Hz, JH-1b, H-2 = 6.2 Hz, 1H, H-1b), 4.17 (m, 2H, POCH2CH2Si), 
4.12 (m, 1H, H-6´a), 4.07 (m, 1H, H-3´´a), 4.06 (m, 1H, H-3´), 4.04 (m, 1H, H-1´´a), 
4.00 (m, 1H, H-1´´b), 3.99 (m, 1H, H-2´), 3.98 (m, 1H, H-5´), 3.94 (m, 1H, H-6´b), 3.87 
(m, 1H, H-4´), 3.83 (m, 1H, H-3´´b), 3.79 (ABX, JH-3a, H-3b = 10.9 Hz, JH-3a, H-2 = 4.9 Hz, 
1H, H-3a), 3.55 (ABX, JH-3b, H-3a = 10.9 Hz, JH-3b, H-2 = 5.2 Hz, 1H, H-3b), 2.29 (t, JHα, 
Hβ = 7.7 Hz, 4H, CH2α), 1.61 (m, 4H, CH2β), 1.41 (s, 3H, C(CH3a)), 1.36 (s, 3H, 
C(CH3b)), 1.26 (m, 56H, CH2), 1.12 (m, 2H, CH2Si), 0.93-0.66 (m, 24H, CH3), 0.14-
0.03 (m, 36H, CH3Si); 
13
C NMR (125 MHz, CDCl3)  173.3 (C(O)1), 172.9 (C(O)2), 
109.8 (C), 108.3 (C-1´), 85.29 and 85.26 (C-4´), 83.8 (C-2´), 79.1 (C-3´), 74.07 and 
74.02 (C-2´´), 71.62 and 71.55 (C-5´), 69.9 (C-2), 68.95 and 68.89 (C-6´), 67.31 and 
67.26 (C-3´´), 66.67 and 66.62 (POCH2CH2Si), 66.26 and 66.27 (C-1´´), 65.5 (C-3), 
62.6 (C-1), 34.3 and 34.1 (CH2α), 31.9 (CH2CH2CH3), 29.8-29.6 (CH2), 26.7 (i-Pr(a)), 
25.8 (C(CH3)3), 25.2 (i-Pr(b)), 24.92 and 24.90 (CH2β), 22.7 (CH2), 19.67 and 19.63 
(CH2Si), 18.3 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 14.1 (CH3), -1.52 
(CH2Si), -4.02 (SiCH3), -4.08 (SiCH3), -4.43 (SiCH3), -4.48 (SiCH3), -4.50 (SiCH3), -
4.83 (SiCH3); 
31
P NMR (121 MHz, CDCl3)  -1.39; HRMS(ESI) m/z calcd. for 
[C74H151NaO15PSi4]
+
: 1445.9760, obsd.: 1445.9765. 
Synthesis of 1-O-(Benzyloxybis[diisopropylamino]phosphine)-2,3-isopropylidene-
sn-glycerol (8). Was performed according to the procedure of Hamamoto et al.
279
 with 
the following modifications. 
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Bis(diisopropylamino)chlorophosphine (25). To a 3 neck 1 L flask 
equipped with a mechanical stirrer and a condenser was added anhydrous 
diisopropylamine (80 mL, 0.56 mol) and hexanes (60 mL). The solution was cooled to 0 
°C and PCl3 (12.2 mL, 0.14 mol) was cannulated dropwise into the mixture. As gauged 
by 
31
P NMR [coaxial tube, (CD3)2CO] PCl3 (219 ppm) reacted almost immediately with 
diisopropyamine to form the diisopropylamino-dichlorophosphine (166 ppm) and the 
bis(diisopropylamino)chlorophosphine (128.8 ppm) 
31
P signal slowly increased over 
time. The reaction was found to be complete after 12 h at which point it was filtered and 
washed with hexanes. Concentration and crystallisation from hexanes then afforded the 
aminochlorophosphine (25.0 g, 9.4 mmol, 67%), (Rf = 0.4, EtOAc/PE, 8/2, v/v, co-
spotted using TEA); 
1
H NMR (500 MHz, CDCl3)  3.66 (m, 4H, CH), 1.3-1.1 (m, 24H, 
CH3); 
13
C NMR (125 MHz, CDCl3)  47.6-47.2 (CH), 24.9-22.1 (CH3); 
31
P NMR (121 
MHz, CDCl3)  128.8. 
Benzyloxybis(diisopropylamino)phosphine (32). To a solution of 
bisisopropylaminochlorophosphine (4.0 g, 15 mmol) in dry Et2O (80 mL) was added 
benzyl alcohol (1.65 mL, 16 mmol) and triethylamine (2.37 mL, 17 mmol). The 
reaction was monitored using 
31
P
 
NMR and upon complete consumtion of the starting 
material was filtered and concentrated in vacuo. Silica gel flash column chromatography 
(TEA/PE, 0.5/99.5, v/v) then gave the benzyloxybis(diisopropylamino)phosphine (4.91 
g, 14.5 mmol, 97%); (Rf = 0.88, EtOAc/PE, 3/7, v/v, co-spotted with TEA); IR (film) 
2996, 1496, 1454, 1362, 1184, 1156, 1126, 1079, 1023, 974, 953, 759, 730, 694, 642 
cm
-1
;
 1
H NMR (500 MHz, CDCl3)  7.47-7.20 (m, 5H, CHBn), 4.66 (s, 2H, CH2), 3.58 
(s, 4H, CH), 1.19 (m, 24H, CH3); 
13
C NMR (125 MHz, CDCl3)  128.5-126.5 (CHBn), 
140.5 and 140.4 (CBn), 66.2 and 66.0 (CH2), 44.5 and 44.4 (CH), 24.8-23.6 (CH3); 
31
P 
NMR (121 MHz, CDCl3)  123.4; HRMS(ESI) m/z calcd. for [C19H36N2OP]
+
: 
339.2560, Found: 339.2557. 
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1-O-(Benzyloxybis[diisopropylamino]phosphine)-2,3-isopropylidene-
sn-glycerol (8). A solution of (-)-10 (264 mg, 2.0 mmol) in anhydrous MeCN (20 mL) 
was stirred with 3Å mol. sieves for 30 min. and then cooled to 0 °C. To this was added 
diisopropylamine (400 mg, 4.0 mmol), tetrazole (280 mg, 4.0 mmol) and 
benzyloxybis(diisopropylamino)phosphine (1.0 g, 3.0 mmol) and the reaction monitored 
using 
31
P NMR. After 3 h, the reaction mixture was diluted with EtOAc, washed with 
brine and dried (MgSO4). Silica gel flash column chromatography (TEA/PE, 0.5/99.5, 
v/v) then gave 8 (686.7 mg, 1.86 mmol, 93%) as a colourless liquid, (Rf = 0.81, 
EtOAc/PE, 3/7, v/v); []D
16
 = -7.5 (c = 0.1, CHCl3); IR (film) 2967, 1455, 1370, 1201, 
1184, 1156, 1126, 1053, 1022, 974, 846, 770, 732, 695 cm
-1
;
 1
H NMR (500 MHz, 
CDCl3)  7.44-7.21 (m, 5H, CHBn), 4.76 and 4.79 (m, 1H, CH2Bnb), 4.26 (m, 1H, H-
2), 4.06 (m, 1H, H-3a), 3.87 (m, 1H, H-3b), 3.80 (m, 1H, H-1a), 3.71 (m, 1H, H-1a), 
3.64 (m, 2H, CH), 1.43 and 1.37 (m, 6H, C(CH3)2), 1.20 (m, 12H, CH3); 
13
C NMR (125 
MHz, CDCl3)  139.3 (CCHBn), 128.8-126.4 (CHBn), 109.3 and 109.2 (C(CH3)2), 75.2 
and 75.10 (m, C-2), 67.21 and 67.16 (C-3), 65.45 and 65.32 (m, CH2Bn), 64.1 (d, JH-1, 
31P = 3.44 Hz, C-1) and 64.0 (d, 2.0 Hz, C-1), 43.0 (CH), 26.82, 26.81 25.47 and 25.44 
(C(CH3)2), 24.8-24.5 (CH3); 
31
P NMR (121 MHz, CDCl3)  148.1; HRMS(ESI) m/z 
calcd. for [C19H33NO4P]
+
: 370.2142, Found: 370.2149. 
3-O-(6-O-[2,3-O-Isopropylidene-sn-glycerol-1-
O-phospho-O-benzyl]-2,3,5-Tetra-O-tert-butyldimethylsilyl-β-D-galactofuranosyl)-
1,2-di-O-stearoyl-sn-glycerol (sn-3-33a). To a solution of sn-3-7a (58.9 mg, 0.052 
mmol) in THF (0.5 mL) was added a solution of 8 (20.5 mg, 0.078 mmol) in anhydrous 
MeCN (0.5 mL) followed by tetrazole (10.9 mg, 0.16 mmol). The reaction mixture was 
stirred for 4 h and then t-BuOOH (6 M in octane, 70 μL) was added and the solution 
stirred for another 15 min. The reaction mixture was then diluted with EtOAc, washed 
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with NaHCO3 (sat. aq.) and brine, dried (MgSO4), filtered and concentrated. 
Purification of the residue by silica gel flash column chromatography (EtOAc/PE, 2/25, 
v/v) gave 33a as a colourless oil (52.5 mg, 0.037 mmol, 72%), (Rf = 0.53, EtOAc/PE, 
3/7, v/v); []D
18
 = -6.0 (c = 0.1, CHCl3); IR (film) 2925, 2854, 1743, 1463, 1253, 1113, 
1016, 837, 777 cm
1
;
 1
H NMR (600 MHz, CDCl3)  7.40-7.30 (m, 5H, CHBn), 5.19 (m, 
1H, H-2), 5.09 (m, 2H, CH2Bn), 4.79 (d, JH-1´, H-2´ = 1.3 Hz, 1H, H-1´), 4.34 (m, 1H, H-
1a), 4.23 (m, 1H, H-2´´), 4.18 (m, 1H, H-1b), 4.12 (m, 1H, H-6´a), 4.05 (dd, JH-3´, H-2´ = 
2.3 Hz, JH-3´, H-4´ = 4.0 Hz, 1H, H-3´), 4.01 (m, 1H, H-1´´a), 4.00 (m, 1H, H-3´´a), 3.98 
(m, 1H, H-2´), 3.97 (m, 1H, H-5´), 3.96 (m, 1H, H-6´b), 3.93 (m, 1H, H-1´´b), 3.87 (m, 
1H, H-4´), 3.77 (m, 1H, H-3a), 3.74 (m, 1H, H-3´´b), 3.53 (ABX, JH-3a, H-3b = 10.9 Hz, 
JH-3a, H-2 = 5.2 Hz, 1H, H-3b), 2.28 (t, JHα, Hβ = 7.3 Hz, 4H, CH2α), 1.60 (m, 4H, CH2β), 
1.39 (s, 3H, C(CH3a)), 1.33 (s, 3H, C(CH3b)), 1.26 (m, 56H, CH2), 0.95-0.80 (m, 33H, 
CH3), 0.15-0.00 (m, 18H, CH3Si); 
13
C NMR (151 MHz, CDCl3)  173.3 (C(O)1), 173.0 
(C(O)2), 109.8 (C), 108.3 (C-1´), 85.2 (C-4´), 83.8 (C-2´), 79.0 (C-3´), 73.95 and 73.88 
(C-2´´), 71.47 and 71.41 (C-5´), 69.9 (C-2), 69.42 and 69.38 (CH2Bn), 69.0 (C-6´), 
67.46 and 67.41 (d, JH-3´´, P = 6.0 Hz, C-1´´), 66.2 (C-3´´), 65.5 (C-3), 62.6 (C-1), 34.3 
and 34.1 (CH2α), 31.9 (CH2CH2CH3), 30.0-29.0 (CH2), 26.7 (i-Pr(a)), 26.0 (C(CH3)3), 
25.75 (C(CH3)3), 25.70 (C(CH3)3), 25.2 (i-Pr(b)), 24.92 and 24.90 (CH2β), 22.7 
(CH2CH3), 18.3 (SiC(CH3)3), 17.9 (SiC(CH3)3), 17.8 (SiC(CH3)3), 14.0 (CH3), -4.03 
(SiCH3), -4.08 (SiCH3), -4.44 (SiCH3), -4.50 (SiCH3), -4.52 (SiCH3), -4.8 (SiCH3); 
31
P 
NMR (121 MHz, CDCl3)  -0.95 and -0.97; HRMS(ESI) m/z calcd. for 
[C76H145NaO15PSi3]
+
: 1435.9521, found: 1435.9523.  
  3-O-(6-O-[1-O-phospho-sn-glycerol]-β-D-
galactofuranosyl)-1,2-di-O-stearoyl-sn-glycerol (sn-3-5a). To a solution of sn-3-33a 
(8.5 mg, 0.0060 mmol) in CHCl3/MeOH/H2O (70/40/6, v/v/v, 1 mL) was added 
Pd(OH)2C (5 mg) and the mixture stirred under an H2 atmosphere (using a balloon) for 
12 h at RT. The solution was then filtered through a glass fiber filter, Dowex-H
+
 (10%, 
0.8 mg) was added, and the reaction mixture stirred for two weeks at RT. The reaction 
mixture was then filtered and concentrated in vacuo to give pure sn-3-5a as a colourless 
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oil (5.2 mg, 0.0055 mmol, 92% yield), (Rf = 0.14, DCM/MeOH, 4/1, v/v); []D
26
 = 64.0 
(c = 0.5, Pyridine); IR (film) 3450, 2918, 2850, 1733, 1558, 1466, 1258, 1033, 804, 771, 
720, 668, 656 cm
1
;
 1
H NMR (600 MHz, CDCl3/CD3OD/D2O, 70/40/6, v/v/v)  5.21 (m, 
1H, H-2), 4.90 (s, 1H, H-1´), 4.34 (m, 1H, H-1a), 4.17 (ABX, JH-1a, H-1b = 12.1 Hz, JH-1b, 
H-2 = 7.3 Hz 1H, H-1b), 4.01 (m, 1H, H-3´), 3.96 (m, 1H, H-2´), 3.94 (m, 1H, H-4´), 
3.92 (m, 1H, H-6´a), 3.91 (m, 1H, H-6´b) 3.90 (m, 1H, H-5´), 3.88 (m, 1H, H-3´´a), 
3.86 (m, 1H, H-3´´a), 3.79 (m, 1H, H-3a), 3.59 (m, 1H, H-1´´a), 3.58 (m, 1H, H-3´´b), 
3.55 (m, 1H, H-1´´b), 3.53 (ABX, JH-3a, H-3b = 10.9 Hz, JH-3a, H-2 = 5.2 Hz, 1H, H-3b), 
2.30 (m, 4H, CH2α), 1.58 (m, 4H, CH2β), 1.24 (m, 56H, CH2), 0.85 (t, JCH3, CH2 = 7.0 
Hz, 6H, CH3); 
13
C NMR (151 MHz, CDCl3/CD3OD/D2O, 70/40/6, v/v/v)  174.2 
(C(O)1), 173.8(C(O)2), 108.2 (C-1´), 84.4 (C-4´), 81.1 (C-2´), 77.5 (C-3´), 71.01 and 
70.96 (C-2´´), 70.24 (C-5´a), 70.19 (C-5´b), 70.0 (C-2), 66.82 (C-6´a), 66.79 (C-6´b), 
66.26 and 66.22 (C-3´´), 65.5 (C-3), 62.8 (C-1), 62.2 (C-1´´), 34.2 and 34.0 (CH2α), 
31.8 (CH3CH2CH2), 24.85 and 24.79 (CH2β), 13.8 (CH3); 
31
P NMR (121 MHz, CDCl3) 
 3.98; HRMS(ESI) m/z calcd. for [C48H93NaO15P]
+
: 963.6149, found: 963.6144. 
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Chapter 5 
 
Future Prospects and Conclusion 
 
Reports concerning bacterial glycosyldiglycerides claim that glycosyldiglycerides have 
immunological properties
104
 while other publications reveal that synthesised glycolipid 
anchors show only weak activity. For example, Deiniger synthesised the LTA anchor 3-
O-(β-D-gentiobiosyl)-1,2-di-O-myristoyl-sn-glycerol and found that it only weakly 
activated whole blood cells compared to its synthesised LTAs.
81
 Furthermore, 
glycoglycerolipids with differing fatty acid chains seem to exhibit different 
immunological properties.
78
 Indeed, Kinjo et al. synthesised a number of α-D-Galp-
diglyceride analogues by varying the type of fatty acid on sn-1 and sn-2-position of the 
glycerol. They found that 3-O-(α-D-galactopyranosyl)-1-O-oleoyl-2-O-palmitoyl-sn-
glycerol was the most potent antigen as it induced the highest level of IL-2 production 
in iNKT cells compared to the other glycolipids (Chapter 1, Section 1.5.4). These 
seemingly contradictory results were intriguing and thus the aim of this thesis was to 
shed light on the confusion regarding glycosyldiglyceride activity by providing a 
detailed structural analysis of the glycolipids tested from gut commensal bacteria and 
synthesising defined glycolipid structures. First, glycolipids were extracted from a 
beneficial commensal present in the human gut (L. plantarum). Here, the anomeric 
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configuration of the residues was clarified and the compounds tested for their ability to 
activate macrophages. Although whole L. plantarum cells have been reported, in the 
literature, to activate macrophages, the purified glycolipids in this research 
demonstrated no significant activity (Chapter 2). After elucidating the structure of the 
glycolipids from L. plantarum the next step was to study the glycolipids from 
bifidobacteria to determine if glycolipids from different commensals activated 
macrophages to the same extent. Thus, the glycolipids from B. longum subs. infantis 
were purified and their structure elucidated. Interestingly, a novel glycolipid structure 
was found (GL5). Again, the glycolipids showed no significant macrophage activity 
(Chapter 3). Figure 5.1 shows the ability of glycolipids extracted from L. plantarum 
(GL1-GL3) to activate macrophages compared and the glycolipids extracted from B. 
longum subs. infantis (GL4 and GL5) compared to LPS. None of the isolated 
glycolipids induced significant NO production in BMM.
l
 
As glycolipids are generally considered as forming the anchor for LTAs, with LTAs 
shown to be active (Chapter 1, Section 1.5.5), the next logical step was to analyze LTAs 
for their biological activity. However, due to the difficulties of LTA purification, most 
of the activation observed in LTAs produced from extracted and purified LTAs 
preparations was attributed to lipoprotein contamination (Chapter 1, Section 1.4.4.3). 
55
 
Thus the best approach was to synthesise LTA analogues for comparison. Therefore, 
Chapter 4 illustrated the synthesis of LTA derivatives from Streptococcus 8747 which 
are also analogues of the novel glycolipid (GL5) found in Chapter 3. In Chapter 4, the 
synthesis of glycolipid anchors containing different fatty acid chain lengths with 
phosphated derivatives was achieved. The glycolipids were tested for their ability to 
activate BMM. The analyzes showed that most of the glycosyldiglycerides activated 
bone marrow macrophages only to a small extent. However, some compounds such as 
sn-3-2b (Figure 5.2), compared to other glycosyldiglycerides, significantly activated 
macrophages. The activity seem to be related to the type of fatty acid present on the 
sugar moiety, which is not surprising as the activity of other glycolipids have been 
found to correspond to lipid length.
82
 
                                                 
l
 Assay conducted by Ashna Khan and Stephanie Chee 
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Figure 5.1 Glycoglycerolipids NO production by BMMs. BMMs were stimulated 
with glycoglycerolipids (GL1, GL2a, GL2b, GL3, GL4 and GL5) (20 g/mL and 40 
g/mL), or LPS (100 ng/mL) and the supernatants were analyzed for NO after 48 h 
using the Griess assay. Mean and SD of triplicate samples from a representative 
experiment of two performed are indicated. 
 
Figure 5.2 sn-3-2b activates BMM. 
The biological studies conducted in this work are only a preliminary screening and 
additional testing is needed to assess the full biological potential of these glycolipids. At 
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first, as described in Chapter 2, the glycolipids are dissolved in a small amount of 
DMSO before being diluted in a buffer to obtain a suspension after multiple cooling 
down and heating up iterations. Due to the varying extents of solubility of these 
glycolipids, different amounts of glycolipid are dissolved using this standard 
solubilisation protocol. Thus, solubility studies need to be conducted using higher 
amounts of DMSO. Also, as Kinjo et al. found that glycolipids derived from B. 
burgdorferi, with varying chain lengths, induced IL-2 production in iNKT cells 
(Chapter 1, Section 1.5.4), such an assay might be interesting to pursue.
82
 
From the work presented in this thesis, preliminary studies were undertaken and a 
number of avenues arise for possible future research. Firstly, it would be of interest to 
analyze structurally and biologically the LTAs from bifidobacteria. Indeed, the presence 
of putative bifidobacterial LTAs responsible for the beneficial effects of bifidobacteria 
is a noteworthy subject. Secondly, identification of the stereochemistry of the three 
unknown stereocenters of GL5 would be required for further synthesis of analogues. 
Finally, synthetic analogues with defined stereocenters need to be made so that they can 
be compared with the extracted glycolipids. This will allow for the determination of all 
the stereocenters. Furthermore, the development of methodology for such a synthesis 
could lead to the synthesis of analogues with varying lipid chain lengths. These 
glycolipids analogues could then be tested for their biological activity (e.g. BMM assay) 
in order to better understand their structural activity relationship. In this chapter, 
preliminary studies and future work concerning these points will be discussed in more 
detail. 
5.1 Bifidobacteria LTA Extraction 
As alluded to in Chapter 1 (Section 1.4.4), LTAs are usually formed after multiple 
condensation steps with glycosyldiglycerides that elongate the phosphoglycerol chain. 
The glycosyldiglyceride is thus the anchor for this long chain and as they were found to 
be active in some cases, the bifidobacterial glycolipid structures were characterised in 
Chapter 3. In fact, a novel glycolipid (GL5) was extracted from bifidobacteria and is 
described in Chapter 3. At this point, it seemed likely that an LTA containing GL5 as an 
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anchor might exist. However, as isolated LTAs are contaminated with active 
lipoproteins, the most reliable way to assess their biological activity is via synthesis as 
synthetic LTAs have been shown to be immunologically active in multiple reports.
12,86
 
Thus in Chapter 4, analogues of GL5 were synthesised to assess their biological activity 
and the phosphated LTA analogues (sn-3-4a and sn-3-5a) showed no significant activity 
(Figure 5.3). 
To date, study of the biological activity of natural LTAs has been hampered by 
difficulties in obtaining pure LTAs (free from active lipoproteins) and by harsh 
extraction methods (hot-phenol) forming less active LTAs.
56
 The hot-phenol extraction 
method has been used by Fischer et al. and Iwasaki et al. to characterise the LTAs from 
bifidobacteria (Chapter 1, Section 1.6.6).
62,124,146
 However, under the harsh extraction 
conditions,
62
 a LTA possessing GL5 as an anchor might not have been detected due to 
degradation. Thus, to compare the LTA activity and structure produced by three 
different extraction methods, the bifidobacterial LTA was extracted using hot phenol, 
water or butanol. These crude extracts were compared in a macrophage assay with 
synthesised LTA analogues from Chapter 4.
m
 However, all three crude extracts were 
able to activate macrophages strongly and to a similar extent (Figure 5.3) and thus no 
differences were observed. These extraction methods thus do not seem to give different 
glycolipid activity, however as the LTAs were not purified, the presence of lipoprotein 
might explain this high activity. 
As the biological activity seemed similar in a BMM assay, another quick screening to 
observe the differences in the structures was performed. As MALDI has been 
successfully used as a screening method for glycoglycerolipid analysis in whole cells 
(Chapter 3), the crude extracts were subjected to MALDI analysis and the results were 
compared to obtain insights on the structures. Both positive and negative ion mode, as 
well as different matrices (e.g. DHB, α-cyano-4-hydroxycinnamic acid, proton 
sponge)
184,235,297
 were investigated and the results were inconclusive. In some cases, no 
signal was visible and in other cases already known compounds, such as 
glycoglycerolipids, DAG or impurities (such as polyethylene glycol), were detected. It 
                                                 
m
 This assay was conducted by Ashna Khan and Stephanie Chee. 
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was then concluded that the sample was not pure enough for analysis and would first 
need to be purified before subsequent MALDI analyzes. 
In order to effectively compare the LTAs extracted with the three methods, the LTA 
would need to be purified using Octyl-sepharose and DEAE (See Chapter 1, Section 
1.4.4.3). Also, another mild extraction method that could be investigated involves the 
use of Triton-X-114, a detergent, to dissolve the LTAs.
298
 From these extractions and 
purifications, it is expected that more conventional analytical methods might have to be 
used to determine the structure. Such methods would include NMR, constituent sugar 
analysis, linkage analysis and fatty acid analysis. 
 
Figure 5.3 BMM were stimulated with a LTA extract from Bifidobacteria, (20 
g/mL and 40 g/mL), or LPS (100 ng/mL) and the supernatants analyzed for NO using 
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the Griess assay after 48 h. Mean and SD of triplicate samples from a representative 
experiment of two performed are indicated. 
5.2 Stereochemistry of Novel Glycolipid (GL5) 
In Chapter 3, a novel glycolipid has been described (Chapter 3, Section 3.3.4). Figure 
5.4 depicts the novel glycolipid showing the three unknown stereocenters found in the 
molecule. In order to determine the stereochemistry of these three stereocenters, a 
number of methods were attempted. A first method that has been conducted to define 
the stereochemistry of some of the stereocenters is described in the seminal work of 
Rundlöf et al.
299
 
 
 
Figure 5.4 Structure of GL5 showing the 3 unknown stereocenters. 
In this work, Rundlöf et al. described a degradation method for the determination of the 
absolute configuration of the glycerol moiety. In Scheme 5.1, the polysaccharide 
containing glycerol moiety 1 is first oxidised using TEMPO to form acid 2. After this, 
the resulting mixture is hydrolysed to give the glyceric acid 3 and other products. Then 
the glyceric acid is esterified with (S)-(+)-2-butanol to give ester 4. A final acetylation 
leads to derivative 5. After this, the reaction mixture was analyzed by GC-MS and the 
traces obtained compared with derivatives of D- and L-glyceric acid. Even though this 
method is very elegant, it can be applied to find out the stereochemistry of only one 
stereocenter (#3). Therefore, the method was adapted to elucidate the stereochemistry of 
stereocenter #1. Scheme 5.2 depicts three different derivatisation methods that were 
employed to determine the stereochemistry of stereocenters #1 and #3. Due to small 
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amounts of extracted GL5, the three strategies were employed without monitoring and 
purification of the intermediates and every step was assumed to be sucessful. 
Derivatisation method 1, the same as Rundlöf et al., was expected to identify the 
stereochemistry of stereocenter #3. In this method, GL5 was first oxidised with TEMPO 
and it was assumed that diacid 6 was formed. Then hydrolysis of diacid 6 using TFA 
was intended to lead to glyceric acid 3 and other degradation products. Esterification of 
(S)-(+)-2-butanol with glyceric acid 3 was assumed to give diastereomer 4. Derivative 5 
was finally assumed to be obtained after acetylation.  
Derivatisation method 2 was intended to determine the configuration of stereocenter #1. 
Similarly to derivatisation method 1, it started with the oxidation of GL5 to form diacid 
6. Then the acetal was presumably cleaved using acetic acid to give alcohol 7. This 
compound was then subjected to an oxidation that was intended to yield to diacid 8. 
Finally, glyceric acid 3 was supposedly released using TFA and esterification of (S)-(+)-
2-butanol followed by an acetylation was intended to give derivative 5. 
 
Scheme 5.1 Degradation method for absolute configuration determination by Rundlöf 
et al.
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The derivatisation method #3 was designed to test if the other derivatisation methods 
worked properly. Indeed, the stereochemistry of stereocenter #3 should be inverted 
compared to the result obtained for derivatisation method #1. This is due to the fact that 
the TEMPO oxidation occurs at different primary alcohols on the glycerol bearing 
stereocenter #3 depending on the derivatisation method. Here, in contrast to 
derivatisation methods 1 and 2, an attempt was made to first acetylate GL5. Presumed 
peracetylated compound 9 was then subjected to hydrolysis using acetic acid and 
supposedly released alcohols 10 and 11. Acid 12 and 13 were then assumed to be 
obtained after TEMPO oxidation. Glyceric acid was then intended to be released from 
acid 12 using TFA. Esterification of (S)-(+)-2-butanol with the mixture of acid 12 and 
13 and acetylation was intended to give derivative 5. 
Having completed the three derivatisation protocols, the derivatisation products were 
analyzed by GC-MS and the results were compared with the GC-MS traces of D and L-
glyceric acid derivatives. The results obtained were very puzzling. Indeed, all three 
derivatisation methods produced D-glyceric acid. From these results, it seemed likely 
that the esterification with (S)-(+)-2-butanol was successful as well as the acetylation. 
This was assumed as D- and L-glyceric acids successfully gave the acetylated 
derivatives 5 as expected. It was then suspected that some of the intermediate reactions 
did not occur as planned. As a very small amount of material was used, it was not 
possible to follow the reactions using TLC, NMR and MS. Thus, the implementation of 
a simpler method which does not include oxidation might be more successful. 
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Scheme 5.2 Derivatisation methods adapted from Rundlöf et al. 
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A simpler method described by Meguro and co-workers involves the synthesis of a 
chiral derivatising reagent for HPLC.
300,301
 Scheme 5.3 depicts the degradation 
methodology from a glycosyldiglyceride containing an unknown stereocenter to form 
di-O-methyl-sn-glycerol. Here, the esters from glycosyldiglyceride 14 are first removed 
using sodium methoxide and the hydroxyls methylated. Finally the sugar residue is 
cleaved to give glycerol derivative 15. In Scheme 5.4, the condensation of pinacolone 
with 2,3-hydroxytoluene (16) to form acetal 17 is first achieved. Then oxidation of 17 
with KMnO4 gives acid 18. The S enantiomer 19 is next optically resolved using 
cinchonidine. After this, acid 19 is subjected to thionyl chloride to obtain the acyl 
chloride 20. Finally, the di-O-methyl-sn-glycerol 15 is esterified with the chiral reagent 
20 to form ester 21. 
 
Scheme 5.3 Degradation method to form di-O-methyl-sn-glycerol.
300
 
As 2-octanone was available in the lab, its use was preferred over pinacolone. Here, 
following the method of Nishida et al. 2,3-hydroxytoluene 16 was condensed with 2-
octanone to form acetal 22. Acid 23 was then obtained in good yields (60%) after the 
oxidation of acetal 22 (Scheme 5.5).
301
 However, the crystallisation attempts using 
cinchonidine were unsuccessful and failed to produce 24. Here, either no crystallisation 
occurred or only the cinchonidine precipitated out of solution even though many 
solvents and solvent mixtures were investigated (e.g. hexane, ethanol, acetone, 
methanol, water, acetone/methanol). It appeared that the long chain on the acetal moiety 
might have hindered the crystallisation and the use of pinacolone was then considered 
as the chain is shorter and it is more bulky. 
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Scheme 5.4 Synthesis of derivatisating agent for HPLC.
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Scheme 5.5 Attempt to synthesise enantiomerically pure 24. 
The use of pinacolone was indeed successful. Here, following again the procedure of 
Nishida et al. (Scheme 5.4), derivatised glycerol 21 was obtained uneventfully. After 
the investigation of a few solvents (e.g. ethanol, methanol, acetone) a mixture of 
methanol/acetone (1/1, v/v) proved fruitful and after six subsequent crystallisations, an 
enantiomeric excess of 66% was obtained. With these encouraging results, the need for 
glycerol standards to compare the unknown glycerol derivatives arose. Scheme 5.6 
shows the synthesis of the glycerol standard. Here, the isopropylidene protected racemic 
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glycerol ±25 was first acetylated. Deprotection of acetonide ±26 using AcOH/H2O 
followed by methylation of diol ±27 then gave glycerol derivative ±28. This compound 
was deacetylated to give alcohol ±29 and esterified with the derivatising agent 20, and 
a mixture of enantiomers and diastereoisomers ±21 was obtained in 31% overall yield.  
Preliminary HPLC investigations on ester ±21 failed to separate the diastereoisomers 
present in the mixture even though different type of columns (e.g. silica, two silica 
columns in series, C-18, Hilic) and solvent systems (e.g. n-hexane/tert-BuOH, different 
gradients) were used. Following these unsuccessful attempts, GC was then assayed. The 
diastereomeric mixture of ester ±21 was injected in a GC-MS, but here, again, even 
though different columns (HP-5ms and BPX70) and different temperature programs 
were used, only one signal was observed (Figure 5.5). From these results, NMR seemed 
to be the best option for the analysis of the diastereoisomers. As shown in Figure 5.6, 
the duplication of 
13
C NMR signals for C-2 indicates the presence of two diastereomers. 
However, greater quantity of GL5 is needed for NMR analysis. Moreover, a single 
diastereoisomer of ±21 starting from pure R or S-solketal 25 needs to be synthesised for 
comparison with derivatives of the isolated mixture of diastereoisomers. 
 
Scheme 5.6 Synthesis of glycerol standard. 
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Figure 5.5 GC-MS chromatogram of derivatised glycerol 21. 
 
Figure 5.6 
13
C NMR spectrum expansion of derivatised glycerol 21 showing the 
presence of diastreomers. 
 
C-1 
C-2 
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Scheme 5.7 shows the design for a degradation method to find the stereochemistry of 
stereocenters #1 and #3 preparatively. In derivatisation method 1 (to determine the 
stereochemistry of stereocenter #3), it is proposed that the methylation of GL5 would 
lead to permethylated compound 30. Hydrolysis of 30 with TFA/H2O would then give 
partially methylated glycerol 29. Finally, glycerol derivative 21 could be obtained by a 
final esterification using the derivatisating agent ((+)-20). The second derivatisation 
method (determine the stereochemistry of stereocenter #1) would involve first an acetal 
hydrolysis step to obtain pentaol 31 from GL5. Then permethylation of 31 would lead to 
methylated compound 32. After this, glycerol 29 could be obtained by cleaving the 
acetal. Then esterification with derivatising agent (+)-20 would give derivatised 
glycerol 21. 
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Scheme 5.7 Degradation method to form glycerol derivatives. 
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5.3 Synthesis of Novel Glycolipid (GL5) 
Attempts to unmask the relative stereochemistry of stereocenter #2 using NOE 
measurements were also unsuccessful as no NOE correlations were observed. In this 
case, it seemed likely that this part of the molecule is too flexible for any NOE 
observation. It is anticipated that the comparison of synthetic samples to extracted GL5 
will next be necessary for the determination of stereocenter #2. Furthermore, while it 
was shown in Chapter 4 that a chain length of C20 was optimal for macrophage activity, 
it will be interesting to probe the activity of analogues of GL5 with varying chain 
length. 
Scheme 5.8 shows the retrosynthetic pathway for the synthesis of GL5. Here, a 
convergent strategy is proposed whereby the three key intermediates, the protected 
galactofuranose derivative 33, fatty acid 34 and sugar derivative 35 could be coupled to 
obtain a synthetic intermediate which would need to undergo further modifications in 
order to form the acetal function. Then, it is envisioned that the coupling of solketal (+)-
25 to galactofuranoside iodide 36 followed by deprotection of the acetonide will 
proceed as covered in Chapter 4 to form galactofuranose intermediate 33. For the sake 
of simplification, it is assumed that stereocenter #1 has an R configuration which is the 
same as DAG found in nature (see Chapter 1, Section 1.4.4). 
For the determination of stereocenter #2, isomers with known stereochemistry are 
needed to compare the structural data of the synthesised compounds with the structural 
data of the extracted compound. Here, depending on if sugar derivative 35 is D- or L- 
and if it is linked through an α- or β-linkage to the glycerol, the stereochemistry of the 
stereocenters can be manipulated (Scheme 5.9). 
For example, for both stereocenter #2 and #3 to be S, a D-sugar linked in a β- fashion to 
the glycerol is required for the synthesis. Scheme 5.10 shows the synthetic plan to form 
the R,S,S isomer of GL5. In order to synthesise vic-diol 38, the galactofuranose donor 
33 would need to be coupled with the arabinopyranose acceptor 35 in order to form 
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coupled product 37, followed by deprotection of the benzoyl groups in order to liberate 
vic-diol 38. Periodate cleavage of the intermediate diol 38 and reduction of the resulting 
dialdehyde would lead to triol 39. Subjection of 39 to DDQ would form the p-
methoxybenzylidene acetal 40 in an intramolecular protection step. Ketone 41 would 
then be obtained via oxidation of the primary alcohol in 40 using mild conditions. The 
elongation of the fatty acetal using Wittig methodology would lead to alkene 42. 
Esterification of the secondary alcohol in 42 with stearic acid would lead to ester 43, 
followed by hydrogenation to yield to saturated diol 44. A final removal of the TBS 
groups using HF.pyridine would lead to target compound R,S,S-GL5 (Scheme 5.10). 
An attempt was made to form the D-arabinose building block for the synthesis of R,S,S,-
GL5 (Scheme 5.11). D-Arabinose was partially benzoylated to form alcohol 45 in 43% 
yield. As mono, di, tri and tetrabenzoylated products were obtained, repetitive column 
chromatography was needed to obtain pure 45, and hence the poor yield was not 
unexpected. Then, the next step, consisting of protecting the 4-position of the arabinose 
using PMBCl proved unsuccessful. Even with the use of good quality, distilled DMF, 
addition of TBAI as catalyst and varying reaction temperature, the reaction was 
unsuccessful and starting material degradation was observed. From these failed 
attempts, it was concluded that the reaction mixture was too basic and that another 
strategy should be used. Indeed, the use of a PMB imidate to couple the PMB group at 
the 4-position was successful and formed derivative 46 in 65% yield. After this, the 
deprotection of the anomeric benzoyl group using hydrazine failed, even though 
different temperature and reaction times were assayed. In this case, the starting material 
46 was always recovered. Other reagents were also investigated such as hydrazine 
acetate and diethylamine and, again, only the starting material was recovered. Finally, 
using different quantities of NH3, the anomeric benzoyl group was removed, but with 
poor selectivity. Both the anomeric benzoyl and the benzoyls at C-2 and C-3 were 
removed. From these results, it seemed likely that the activation of the anomeric 
benzoyl group might work better under acid conditions. 
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Scheme 5.8 Retrosynthetic pathway for four different diastereomers of GL5. 
 
Scheme 5.9 Analogues for varying the stereochemistry of stereocenter 2 and 3.  
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Scheme 5.10 Synthetic plan to form R,S,S isomer of GL5. 
257 
 
 
Scheme 5.11 Attempts to synthesise building block 34 to obtain a S, S configuration 
for GL5. 
A test reaction was next conducted using tetrabenzoyl arabinose 48 formed from the 
previous efforts. Here, using TMSTMS and I2 to form TMSI in situ, iodide 49 was 
obtained in excellent yields. Then, the coupling was attempted using NIS and zinc 
iodide and coupled compound 50 was successfully obtained in 40% yield without 
further attempts to improve the yield (Scheme 5.12). As TMSI is known to deprotect 
PMB groups,
302
 another protecting group was needed that would play the same role as 
PMB and protect the diol intramolecularly to form a compound analogous to 40. To this 
end, the use of a naphthalene ether was investigated,
303
 however, the coupling of the 
NAP imidate did not proceed as smoothly as the PMB imidate and even though 
different promoters (BF3.OEt, TMSOTf and TfOH) were used, the very stable NAP 
imidate was recovered after the reaction. At this point in time, it could be assumed that 
the PMB imidate could be installed later on in the synthesis and a per-acetylated lyxose 
building block 51 was investigated for coupling to galactofuranose derivative 33. This 
coupling however resulted in orthoester 53 (Scheme 5.13) with no desired product 52 
formed.  
Alternatively, it is envisioned that the use of benzoyls as protecting groups could reduce 
the amount of orthoester formed during the coupling of galactofuranose derivative 33 
and lyxose building block 54 and thus benzoylated compound 54 is proposed as a 
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potential building block for the synthesis of intermediate 39. Subsequent removal of 
benzoyl groups on coupled product 55 would give tetraol 56 and the selective protection 
of the 2- and 3-positions of the lyxose with an isopropylidene would give diol 57. Next, 
the protection of the 4-position with a PMB group would lead to alcohol 58, as 
described by Parhi et al.
304
 This compound could finally lead to the desired triol 39 after 
isopropylidene cleavage, oxidative cleavage of the diol and reduction of the formed 
diketone (Scheme 5.14). 
 
Scheme 5.12 Test reaction to form coupled product 50. 
 
Scheme 5.13 Attempted coupling to form coupled product 52. 
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Scheme 5.14 Plan for synthesising intermediate 39. 
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5.4 Concluding Remarks 
In this thesis, the characterisation, synthesis and biological testing of L. plantarum and 
Bifidobacterium longum subs. infantis glycolipids was achieved. Hence, for the first 
time, the full characterisation of the four principal glycolipids of the L. plantarum cell 
wall was reported and tested in a BMM assay. The major glycolipids were identified as: 
α-D-Glcp-diglyceride, α-D-Galp-(1→2)-α-D-Glcp-diglyceride, β-D-Glcp-(1→6)-α-D-
Galp-(1→2)-6-O-acyl-α-D-Glcp-diglyceride and β-D-Glcp-(1→6)-α-D-Galp-(1→2)-α-
D-Glcp-diglyceride and showed no significant activity in BMM (Chapter 2). Then, a 
novel glycolipid, containing an unprecedented mixed acetal moiety and a 
galactofuranose moiety as a head group was reported in Bifidobacterium longum subs. 
infantis (Chapter 3). Finally, analogues of GL5 were then synthesised and led to 
macrophage activation (Chapter 4).  
The results of these different studies led to preliminary work and future prospects that 
were covered in this present chapter (Chapter 5). Interesting future work that would be 
conducted would be the extraction of bifidobacteria LTAs and the stereochemical 
determination of GL5. The extraction of bifidobacteria LTA could shed light on the 
beneficial properties of bifidobacteria by using less harsh conditions for the extraction. 
As a LTA anchor consisting of GL5 is plausible and given that synthetic LTAs without 
active contamination are needed, the knowledge of the stereochemistry of the three 
unknown centers of GL5 would help in future bifidobacterial glycolipids syntheses for 
further biological studies. 
 
 
 
 
261 
 
Bibliography 
1. Nomenclature of Lipids. In Biochemical Nomenclature and Related Documents, 
2nd Edition, Liébecq, C., Ed. Portland Press: London, 1992; p 10. 
2. Microbial Glycobiology. Moran, A. P.; Holst, O.; Brennan, P. J.; von Itzstein, 
M., Eds. Academic Press: London, 2009. 
3. Lebeer, S.; Vanderleyden, J.; De Keersmaecker, S. C. J., Nat. Rev. Microbiol. 
2010, 8, 171-184. 
4. Bacterial Infections of Humans. Brachman, P. S.; Abrutyn, E., Eds. Springer 
Science: New York, 2009. 
5. Gram, H. C., Fortschr. Med. 1884, 2, 185-189. 
6. Costerton, J. W.; Ingram, J. M.; Cheng, K. J., Bacteriol. Rev. 1974, 38, 87-110. 
7. Holst, O.; Moran, A. P.; Brennan, P. J., Overview of the Glycosylated 
Components of the Bacterial Cell Envelope. In Microbial Glycobiology, Moran, 
A. P.; Holst, O.; Brennan, P. J.; von Itzstein, M., Eds. Elsevier: London, U.K., 
2009; pp 3-13. 
8. Decad, G. M.; Nikaido, H., J. Bacteriol. 1976, 128, 325-336. 
9. Lugtenberg, B.; van Alphen, L., Biochim. Biophys. Acta-Rev biomembranes 
1983, 737, 51-115. 
10. Typas, A.; Banzhaf, M.; Gross, C. A.; Vollmer, W., Nat. Rev. Microbiol. 2012, 
10, 123-136. 
11. Hanson, B. R.; Neely, M. N., Curr. Opin. Microbiol. 2012, 15, 204-210. 
12. Weidenmaier, C.; Peschel, A., Nat. Rev. Microbiol. 2008, 6, 276-287. 
13. Ruas-Madiedo, P.; Hugenholtz, J.; Zoon, P., Int. Dairy J. 2002, 12, 163-171. 
14. Seltmann, G.; Holst, O., The Bacterial Cell Wall. Springer: Berlin, Germany, 
2002. 
15. Yother, J., Annu. Rev. Microbiol. 2011, 65, 563-581. 
16. Looijesteijn, P. J.; Trapet, L.; de Vries, E.; Abee, T.; Hugenholtz, J., Int. J. Food 
Microbiol. 2001, 64, 71-80. 
17. Roberts, I. S., Annu. Rev. Microbiol. 1996, 50, 285-315. 
18. Ruas-Madiedo, P.; Salazar, N.; de los Reyes-Gavilán, C. G.; Schmidt, R. R., 
Exopolysaccharides produced by lactic acid bacteria in food and probiotic 
262 
 
applications. In Microbial Glycobiology, Moran, A. P.; Holst, O.; Brennan, P. J.; 
von Itzstein, M., Eds. Academic Press: London, 2009; pp 887-902. 
19. Wang, Y.; Li, C.; Liu, P.; Ahmed, Z.; Xiao, P.; Bai, X., Carbohydr. Polym. 
2010, 82, 895-903. 
20. Vanhaverbeke, C.; Bosso, C.; Colin-Morel, P.; Gey, C.; Gamar-Nourani, L.; 
Blondeau, K.; Simonet, J.-M.; Heyraud, A., Carbohydr. Res. 1998, 314, 211-
220. 
21. Xia, G.; Peschel, A., Chem. Biol. 2008, 15, 95-96. 
22. Brown, S.; Zhang, Y.-H.; Walker, S., Chem. Biol. 2008, 15, 12-21. 
23. Bhavsar, A. P.; Brown, E. D., Mol. Microbiol. 2006, 60, 1077-1090. 
24. Fischer, W.; Behr, T.; Hartmann, R.; Peter-Katalinić, J.; Egge, H., Eur. J. 
Biochem. 1993, 215, 851-857. 
25. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C., 
Nature 2009, 458, 83-86. 
26. Chan, D. I.; Vogel, H. J., Biochem. J. 2010, 430, 1-19. 
27. Schujman, G. E.; de Mendoza, D., Curr. Opin. Microbiol. 2008, 11, 148-152. 
28. Svetashev, V. I.; Vysotskii, M. V.; Ivanova, E. P.; Mikhailov, V. V., Syst. Appl. 
Microbiol. 1995, 18, 37-43. 
29. The Lipid Handbook with CD-ROM. Gunstone, F. D.; Harwood, J. L.; Dijkstra, 
A. J., Eds. CRC press: Boca Raton, FL, 2009. 
30. Fischer, W., Lipoteichoic Acids and Lipoglycans. In Bacterial Cell Wall, 
Hakenbeck, J.-M. G. a. R., Ed. Elsevier: Amsterdam, Netherlands, 1994; pp 
199-215. 
31. Delcour, J.; Ferain, T.; Deghorain, M.; Palumbo, E.; Hols, P., Anton. Leeuw. Int. 
J. G. 1999, 76, 159-184. 
32. Xia, G.; Kohler, T.; Peschel, A., Int. J. Med. Microbiol. 2010, 300, 148-154. 
33. Lu, D.; Woermann, M. E.; Zhang, X.; Schneewind, O.; Gruendling, A.; 
Freemont, P. S., PNAS 2009, 106, 1584-1589. 
34. Kohler, T.; Xia, G.; Kulauzovic, E.; Peschel, A., Teichoic Acids, Lipoteichoic 
Acids and Related Cell Wall Glycopolymers of Gram-Positive Bacteria. In 
Microbial Glycobiology, Moran, A. P.; Holst, O.; Brennan, P. J.; von Itzstein, 
M., Eds. Academic Press: London, 2009; pp 75-91. 
35. Kiriukhin, M. Y.; Neuhaus, F. C., J. Bacteriol. 2001, 183, 2051-2058. 
263 
 
36. Huijbregts, R. P. H.; de Kroon, A. I. P. M.; de Kruijff, B., Biochim. Biophys. 
Acta 2000, 1469, 43-61. 
37. Dowhan, W., Annu. Rev. Biochem. 1997, 66, 199-232. 
38. Goldfine, H., Curr.Top. in Membr. and Trans. 1982, 17, 1-43. 
39. Larsen, Å.; Hvattum, E., Analysis of Phospholipids by Liquid Chromatography 
Coupled with On-Line Electrospray Ionization Mass Spectrometry and Tandem 
Mass Spectrometry. In Modern Methods for Lipid Analysis by Liquid 
Chromatography/Mass Spectrometry and Related Techniques, Byrdwell, W. C., 
Ed. AOCS Press: Champaign, Ill, 2005; pp 19-60. 
40. Hӧlzl, G.; Dӧrmann, P., Prog. Lipid Res. 2007, 46, 225-243. 
41. Morrison, I. M., Carbohydr. Chem. 1986, 15, 578-617. 
42. Bligh, E. G.; Dyer, W. J., Can. J. Biochem. Physiol. 1959, 37, 911-917. 
43. Brundish, D. E.; Shaw, N.; Baddiley, J., Biochem. J. 1966, 99, 546-549. 
44. Veerkamp, J. H., Biochim. Biophys. Acta, Gen. Subj. 1972, 273, 359-367. 
45. Thompson, B. G.; Anderson, R.; Murray, R. G. E., Can. J. Microbiol. 1980, 26, 
1408-1411. 
46. Shaw, N., Bacteriol. Rev. 1970, 34, 365-377. 
47. Heinz, E., Biochim. Biophys. Acta 1967, 144, 333-343. 
48. Heinz, E., Z. Pflanzenphysiol. 1973, 69, 359-376. 
49. Blakeney, A. B.; Harris, P. J.; Henry, R. J.; Stone, B. A., Carbohydr. Res. 1983, 
113, 291-299. 
50. Ciucanu, I.; Kerek, F., Carbohydr. Res. 1984, 131, 209-217. 
51. Paściak, M.; Holst, O.; Lindner, B.; Mordarska, H.; Gamian, A., J. Biol. Chem. 
2003, 278, 3948-3956. 
52. Huang, Y.; Anderson, R., J. Bacteriol. 1995, 177, 2567-2571. 
53. Paściak, M.; Sanchez-Carballo, P.; Duda-Madej, A.; Lindner, B.; Gamian, A.; 
Holst, O., Carbohydr. Res. 2010, 345, 1497-1503. 
54. Rahman, O.; Dover, L. G.; Sutcliffe, I. C., Trends Microbiol. 2009, 17, 219-225. 
55. Deininger, S.; Traub, S.; Aichele, D.; Rupp, T.; Baris, T.; Moeller, H. M.; 
Hartung, T.; von Aulock, S., Immunobiology 2008, 213, 519-529. 
56. Morath, S.; Geyer, A.; Hartung, T., J. Exp. Med. 2001, 193, 393-397. 
57. Jang, K.-S.; Baik, J. E.; Han, S. H.; Chung, D. K.; Kim, B.-G., Biochem. 
Biophys. Res. Commun. 2011, 407, 823-830. 
58. Fischer, W.; Koch, H. U.; Haas, R., Eur. J. Biochem. 1983, 133, 523-530. 
264 
 
59. Greenberg, J. W.; Fischer, W.; Joiner, K. A., Infect. Immun. 1996, 64, 3318-
3325. 
60. Koch, H. U.; Haas, R.; Fischer, W., Eur. J. Biochem. 1984, 138, 357-363. 
61. Fischer, W., Microb. Drug Resist. 1997, 3, 309-325. 
62. Iwasaki, H.; Araki, Y.; Ito, E.; Nagaoka, M.; Yokokura, T., J. Bacteriol. 1990, 
172, 845-852. 
63. Khan, A. A.; Chee, S. H.; McLaughlin, R. J.; Harper, J. L.; Kamena, F.; 
Timmer, M. S. M.; Stocker, B. L., ChemBioChem 2011, 12, 2572-2576. 
64. Miles, E. A.; Calder, P. C., Br. J. Nutr. 2012, 107, S171-S184. 
65. Yudina, O. N.; Gening, M. L.; Tsvetkov, Y. E.; Grachev, A. A.; Pier, G. B.; 
Nifantiev, N. E., Carbohydr. Res. 2011, 346, 905-913. 
66. Srivastava, J.; Khare, A.; Khare, N. K., ARKIVOC 2009, 180-188. 
67. Knox, K. K.; Wicken, A. J., Bacteriol. Rev. 1973, 37, 215-257. 
68. Neuhaus, F. C.; Baddiley, J., Microbiol. Mol. Biol. Rev. 2003, 67, 686-723. 
69. Weidenmaier, C.; Kokai-Kun, J. F.; Kristian, S. A.; Chanturiya, T.; Kalbacher, 
H.; Gross, M.; Nicholson, G.; Neumeister, B.; Mond, J. J.; Peschel, A., Nat. 
Med. 2004, 10, 243-245. 
70. Hogendorf, W. F. J.; Van den Bos, L. J.; Overkleeft, H. S.; Codée, J. D. C.; Van 
der Marel, G. A., Bioorg. Med. Chem. 2010, 18, 3668-3678. 
71. Fogler, W., Immunologic Properties and Activities of Phospholipids. In 
Phospholipids Handbook, Cevc, G., Ed. Dekker: New York, 1993; pp 817-832. 
72. Dieudé, M.; Striegl, H.; Tyznik, A. J.; Wang, J.; Behar, S. M.; Piccirillo, C. A.; 
Levine, J. S.; Zajonc, D. M.; Rauch, J., J. Immunol. 2011, 186, 4771-4781. 
73. Torchilin, V. P., Nat. Rev. Drug Discovery 2005, 4, 145-160. 
74. Lie Ken Jie, M. S. F.; Harwood, J. L.; Gunstone, F. D.; Cheung, W. H.; Lam, C. 
N. W., Synthesis. In The Lipid Handbook with CD-ROM, Gunstone, F. D.; 
Harwood, J. L.; Dijkstra, A. J., Eds. CRC press: Boca Raton, FL, 2009. 
75. Cheng, J. M. H.; Chee, S. H.; Knight, D. A.; Acha-Orbea, H.; Hermans, I. F.; 
Timmer, M. S. M.; Stocker, B. L., Carbohydr. Res. 2011, 346, 914-926. 
76. de la Salle, H.; Mariotti, S.; Angenieux, C.; Gilleron, M.; Garcia-Alles, L.-F.; 
Malm, D.; Berg, T.; Paoletti, S.; Maître, B.; Mourey, L.; Salamero, J.; Cazenave, 
J. P.; Hanau, D.; Mori, L.; Puzo, G.; De Libero, G., Science 2005, 310, 1321-
1324. 
265 
 
77. Stadelmaier, A.; Figueroa-Perez, I.; Deininger, S.; von Aulock, S.; Hartung, T.; 
Schmidt, R. R., Bioorg. Med. Chem. 2006, 14, 6239-6254. 
78. Kinjo, Y.; Illarionov, P.; Vela, J. L.; Pei, B.; Girardi, E.; Li, X.; Li, Y.; Imamura, 
M.; Kaneko, Y.; Okawara, A.; Miyazaki, Y.; Gómez-Velasco, A.; Rogers, P.; 
Dahesh, S.; Uchiyama, S.; Khurana, A.; Kawahara, K.; Yesilkaya, H.; Andrew, 
P. W.; Wong, C.-H.; Kawakami, K.; Nizet, V.; Besra, G. S.; Tsuji, M.; Zajonc, 
D. M.; Kronenberg, M., Nat. Immunol. 2011, 12, 966-974. 
79. Kinjo, Y.; Ueno, K., Microbiol. Immunol. 2011, 55, 472-482. 
80. Naito, M.; Kudo, I.; Mukai-Sato, Y.; Tsushima, S.; Nomura, H.; Nojima, S.; 
Inoue, K., Cancer Immunol. Immunother. 1987, 24, 158-164. 
81. Deininger, S.; Stadelmaier, A.; von Aulock, S.; Morath, S.; Schmidt, R. R.; 
Hartung, T., J. Immunol. 2003, 170, 4134-4138. 
82. Kinjo, Y.; Tupin, E.; Wu, D.; Fujio, M.; Garcia-Navarro, R.; Benhnia, M. R.-E.-
I.; Zajonc, D. M.; Ben-Menachem, G.; Ainge, G. D.; Painter, G. F.; Khurana, A.; 
Hoebe, K.; Behar, S. M.; Beutler, B.; Wilson, I. A.; Tsuji, M.; Sellati, T. J.; 
Wong, C.-H.; Kronenberg, M., Nat. Immunol. 2006, 7, 978-986. 
83. Girardi, E.; Yu, E. D.; Li, Y.; Tarumoto, N.; Pei, B.; Wang, J.; Illarionov, P.; 
Kinjo, Y.; Kronenberg, M.; Zajonc, D. M., PLoS Biol. 2011, 9, e1001189. 
84. Amara, S.; Lafont, D.; Fiorentino, B.; Boullanger, P.; Carrière, F.; De Caro, A., 
Biochim. Biophys. Acta 2009, 1791, 983-990. 
85. Schombs, M.; Park, F. E.; Du, W.; Kulkarni, S. S.; Gervay-Hague, J., J. Org. 
Chem. 2010, 75, 4891-4898. 
86. Schmidt, R. R.; Pedersen, C. M.; Qiao, Y.; Zaehringer, U., Org. Biomol. Chem. 
2011, 9, 2040-2052. 
87. Keller, R.; Fischer, W.; Keist, R.; Bassetti, S., Infect. Immun. 1992, 60, 3664-
3672. 
88. Morath, S.; Geyer, A.; Spreitzer, I.; Hermann, C.; Hartung, T., Infect. Immun. 
2002, 70, 938-944. 
89. Stadelmaier, A.; Morath, S.; Hartung, T.; Schmidt, R. R., Angew. Chem. Int. Ed. 
2003, 42, 916-920. 
90. Morath, S.; Stadelmaier, A.; Geyer, A.; Schmidt, R. R.; Hartung, T., J. Exp. 
Med. 2002, 195, 1635-1640. 
91. Roethlisberger, P.; Iida-Tanaka, N.; Hollemeyer, K.; Heinzle, E.; Ishizuka, I.; 
Fischer, W., Eur. J. Biochem. 2000, 267, 5520-5530. 
266 
 
92. Qiao, Y.; Lindner, B.; Zäringer, U.; Truog, P.; Schmidt, R. R., Bioorg. Med. 
Chem. 2010, 18, 3696-3702. 
93. Tissier, H. Recherches sur la flore intestinale des nourrissons (Etat normal et 
pathologique). University of Paris (France), Paris, 1906. 
94. Weiss, J. E.; Rettger, L. F., J. Infect. Dis. 1938, 62, 115-120. 
95. Orla-Jensen, S., Lait 1924, 4, 468-474. 
96. Leahy, S. C.; Higgins, D. G.; Fitzgerald, G. F.; van Sinderen, D., J. Appl. 
Microbiol. 2005, 98, 1303-1315. 
97. Mayo, B.; van Sinderen, D., Bifidobacteria: Genomics and Molecular Aspects. 
Caister Academic Press: Norfolk, UK, 2010; p 259. 
98. Picard, C.; Fioramonti, J.; Francois, A.; Robinson, T.; Neant, F.; Matuchansky, 
C., Aliment Pharmacol. Ther. 2005, 22, 495-512. 
99. Zhu, J.; Zhao, L.; Guo, H.; Jiang, L.; Ren, F., Afr. J. Microbiol. Res. 2011, 5, 8-
15. 
100. López, P.; Gueimonde, M.; Margolles, A.; Suárez, A., Int. J. Food Microbiol. 
2010, 138, 157-165. 
101. Biavati, B.; Mattarelli, P., The family bifidobacteriaceae. In Prokaryotes, 
Dworkin, M.; Falkow, S.; Rosenberg, E.; Schleifer, K. H.; Stackebrandt, E., Eds. 
Springer: Singapore, 2006; pp 322-382. 
102. Op den Camp, H. J. M.; Peeters, P. A. M.; Oosterhof, A.; Veerkamp, J. H., J. 
Gen. Microbiol. 1985, 131, 661-668. 
103. Amrouche, T.; Boutin, Y.; Prioult, G.; Fliss, I., Int. Dairy J. 2006, 16, 70-80. 
104. Novik, G. I.; Astapovich, N. I.; Pastsyak, M.; Gamian, A., Microbiology 2005, 
74, 678-683. 
105. Tone-Shimokawa, Y.; Toida, T.; Kawashima, T., J. Bacteriol. 1996, 178, 317-
320. 
106. Habu, Y.; Nagaoka, M.; Yokokura, T.; Azuma, I., J. Biochem. 1987, 102, 1423-
1432. 
107. Nagaoka, M.; Muto, M.; Yokokura, T.; Mutai, M., J. Biochem. 1988, 103, 618-
621. 
108. Nagaoka, M.; Shibata, H.; Kimura, I.; Hashimoto, S.; Kimura, K.; Sawada, H.; 
Yokokura, T., Carbohydr. Res. 1995, 274, 245-249. 
109. Nagaoka, M.; Hashimoto, S.; Shibata, H.; Kimura, I.; Kimura, K.; Sawada, H.; 
Yokokura, T., Carbohydr. Res. 1996, 281, 285-291. 
267 
 
110. Zdorovenko, E. L.; Kachala, V. V.; Sidarenka, A. V.; Izhik, A. V.; Kisileva, E. 
P.; Shashkov, A. S.; Novik, G. I.; Knirel, Y. A., Carbohydr. Res. 2009, 344, 
2417-2420. 
111. Hosono, A.; Lee, J.; Ametani, A.; Natsume, M.; Hirayama, M.; Adachi, T.; 
Kaminogawa, S., Biosci. Biotechnol. Biochem. 1997, 61, 312-316. 
112. Hosono, A.; Lee, J.; Ametani, A.; Natsume, M.; Hirayama, M.; Adachi, T.; 
Kaminogawa, S., Biosci. Microflora 1998, 17, 97-104. 
113. Zhang, G.; Fu, M.; Ning, J., Tetrahedron Asymmetr. 2005, 16, 733-738. 
114. Veerkamp, J. H.; Hoelen, G. E. J. M.; Op Den Camp, H. J. M., Biochim. 
Biophys. Acta, Gen. Subj. 1983, 755, 439-451. 
115. Xu, R.; Shen, Q.; Ding, X.; Gao, W.; Li, P., Eur. Food Res. Technol. 2011, 232, 
231-240. 
116. Fanning, S.; Hall, L. J.; Cronin, M.; Zomer, A.; MacSharry, J.; Goulding, D.; 
Motherway, M. O. C.; Shanahan, F.; Nally, K.; Dougan, G.; van Sinderen, D., 
PNAS 2012, 109, 2108-2113. 
117. MacFarlane, S.; Blackett, K. E.; MacFarlane, G. T., Synthesis and utilization of 
exopolysaccharides and prebiotics. In Bifidobacteria, Mayo, B.; van Sinderen, 
D., Eds. Caister Academic Press: Norwich, UK, 2010; pp 175-193. 
118. Andaloussi, S. A.; Talbaoui, H.; Marczak, R.; Bonaly, R., Appl. Microbiol. 
Biotechnol. 1995, 43, 995-1000. 
119. Leivers, S.; Hidalgo-Cantabrana, C.; Robinson, G.; Margolles, A.; Ruas-
Madiedo, P.; Laws, A. P., Carbohydr. Res. 2011, 346, 2710-2717. 
120. You, H. J.; Oh, D.-K.; Ji, G. E., FEMS Microbiol. Lett. 2004, 240, 131-136. 
121. Kohno, M.; Suzuki, S.; Kanaya, T.; Yoshino, T.; Matsuura, Y.; Asada, M.; 
Kitamura, S., Carbohydr. Polym. 2009, 77, 351-357. 
122. Seltmann, G.; Holst, O., The outer membrane of the Gram-negative bacteria and 
their components. In The Bacterial Cell Wall, Seltmann, G.; Holst, O., Eds. 
Springer: Berlin, 2002; pp 9-102. 
123. Veerkamp, J. H., J. Bacteriol. 1971, 108, 861-867. 
124. Fischer, W., Eur. J. Biochem. 1987, 165, 639-646. 
125. Veerkamp, J. H.; Van Schaik, F. W., Biochim. Biophys. Acta, Lipids Lipid 
Metab. 1974, 348, 370-387. 
126. Veerkamp, J. H., Biochim. Biophys. Acta 1974, 348, 23-34. 
268 
 
127. Jun Bae, A.; Hwang, H.-J.; Park, J.-H., J. Microbiol. Biotechnol. 2001, 11, 443-
451. 
128. Ruiz, L.; Sánchez, B.; Ruas-Madiedo, P.; de los Reyes-Gavilan, C. G.; 
Margolles, A., FEMS Microbiol. Lett. 2007, 274, 316-322. 
129. Jung, H.-K.; Kim, E.-R.; Ji, G.-E.; Park, J.-H.; Cha, S.-K.; Juhn, S.-L., J. 
Microbiol. Biotechnol. 2000, 10, 143-146. 
130. Ryhage, R.; Stenhagen, E., Ark. Kemi 1959, 13, 523-542. 
131. Oberg, T. S.; Ward, R. E.; Steele, J. L.; Broadbent, J. R., Appl. Environ. 
Microbiol. 2012, 78, 880-884. 
132. Exterkate, F. A.; Veerkamp, J. H., Biochim. Biophys. Acta 1969, 176, 65-77. 
133. Exterkate, F. A.; Otten, B. J.; Wassenberg, H. W.; Veerkamp, J. H., J. Bacteriol. 
1971, 106, 824-829. 
134. Novik, G. I.; Astapovich, N. I.; Grzegorzewicz, A.; Gamian, A., Microbiology 
2005, 74, 670-677. 
135. Novik, G. I.; Astapovich, N. I.; Grzegorzewicz, A.; Gamian, A., Microbiology 
2006, 75, 29-34. 
136. Exterkate, F. A.; Veerkamp, J. H., Biochimica et Biophysica Acta (BBA)/Lipids 
and Lipid Metabolism 1971, 231, 545-549. 
137. Novik, G.; Gamian, A.; Francisco, J. D. C.; Dey, E. S., J. Biotechnol. 2006, 121, 
555-562. 
138. Izhyk, A.; Novik, G.; Szwajcer Dey, E., J. Supercrit. Fluids 2012, 62, 149-154. 
139. Op den Camp, H. J. M.; Oosterhof, A.; Veerkamp, J. H., Infect. Immun. 1985, 
47, 332-334. 
140. Jiang, H.; Hu, H.; Wei, Q., Mianyixue Zazhi 2000, 16, 429-431, 441. 
141. Wang, Y.; Zhang, J.; Liu, M., Zhongguo Weishengtaixue Zazhi 2008, 20, 454-
456. 
142. Chu, Q.; Zhang, D., Zhongguo Weishengtaixue Zazhi 2008, 20, 521-523. 
143. Miyauchi, E.; Tanabe, S., Kagaku to Seibutsu 2008, 46, 590-592. 
144. Op Den Camp, H. J. M.; Oosterhof, A.; Veerkamp, J. H., Biochem. J. 1985, 228, 
683-688. 
145. Veerkamp, J. H., Biochim. Biophys. Acta, Lipids Lipid Metab. 1976, 441, 403-
411. 
146. Fischer, W.; Bauer, W.; Feigel, M., Eur. J. Biochem. 1987, 165, 647-652. 
269 
 
147. Lukjancenko, O.; Ussery, D. W.; Wassenaar, T. M., Microb. Ecol. 2012, 63, 
651-673. 
148. Kleerebezem, M.; Vaughan, E. E., Annu. Rev. Microbiol. 2009, 63, 269-290. 
149. Mayo, B.; Aleksandrzak-Piekarczyk, T.; Fernández, M.; Kowalczyk, M.; 
Alvarez-Martin, P.; Bardowski, J., Updates in the metabolism of lactic acid 
bacteria. In Biotechnology Of Lactic Acid Bacteria: Novel Applications, Mozzi, 
F.; Raya, R. R.; Vignolo, G. M., Eds. Wiley-Blackwell: Ames, 2010; pp 3-32. 
150. Felis, G. E.; Dellaglio, F., Curr. Iss. Intest. Microbiol. 2007, 8, 44-61. 
151. Kleerebezem, M.; Hols, P.; Bernard, E.; Rolain, T.; Zhou, M.; Siezen, R. J.; 
Bron, P. A., FEMS Microbiol. Rev. 2010, 34, 199-230. 
152. Remus, D. M.; Kleerebezem, M.; Bron, P. A., Eur. J. Pharmacol. 2011, 668, 
S33-S42. 
153. Fred, E. B.; Peterson, W. H.; Anderson, J. A., J. Biol. Chem. 1921, 48, 385-412. 
154. Tallon, R.; Bressollier, P.; Urdaci, M. C., Res. Microbiol. 2003, 154, 705-712. 
155. Dong, H.; Rowland, I.; Yaqoob, P., Br. J. Nutr. 2012, 108, 459-470. 
156. Chiang, S.-S.; Liu, C.-F.; Tseng, K.-C.; Mau, J.-L.; Pan, T.-M., Food Agric. 
Immunol. 2012, 23, 183-202. 
157. Duary, R. K.; Bhausaheb, M. A.; Batish, V. K.; Grover, S., Mol. Biol. Rep. 
2012, 39, 4765-4775. 
158. Tomita, S.; Irisawa, T.; Tanaka, N.; Nukada, T.; Satoh, E.; Uchimura, T.; Okada, 
S., Biosci., Biotechnol., Biochem. 2010, 74, 928-933. 
159. Bron, P. A.; Tomita, S.; van Swam, I. I.; Remus, D. M.; Meijerink, M.; Wels, 
M.; Okada, S.; Wells, J. M.; Kleerebezem, M., Microb. Cell. Fact. 2012, 11, 
123. 
160. Wicken, A. J.; Evans, J. D.; Campbell, L. K.; Knox, K. W., Infect. Immun. 1982, 
38, 1-7. 
161. Archibald, A. R.; Baddiley, J.; Buchanan, J. G., Biochem. J. 1961, 81, 124-134. 
162. Archibald, A. R.; Armstrong, J. J.; Baddiley, J.; Hay, J. B., Nature 1961, 191, 
570-572. 
163. Adams, J. B.; Archibald, A. R.; Baddiley, J.; Coapes, H. E.; Davison, A. L., 
Biochem. J. 1969, 113, 191-193. 
164. Archibald, A. R.; Coapes, H. E., Biochem. J. 1971, 124, 449-460. 
165. Tomita, S.; Furihata, K.; Nukada, T.; Satoh, E.; Uchimura, T.; Okada, S., 
Biosci., Biotechnol., Biochem. 2009, 73, 530-535. 
270 
 
166. Tomita, S.; Furihata, K.; Tanaka, N.; Satoh, E.; Nukada, T.; Okada, S., 
Microbiology 2012, In press. 
167. Douglas, L. J.; Wolin, M. J., Biochemistry 1971, 10, 1551-1555. 
168. Ikawa, M.; Snell, E. E., J. Biol. Chem. 1960, 235, 1376-1382. 
169. Critchley, P.; Archibald, A. R.; Baddiley, J., Biochem. J. 1962, 85, 420-431. 
170. Sargent, L. J.; Buchanan, J. G.; Baddiley, J., J. Chem. Soc. 1962, 2184-2187. 
171. Feng, M.; Zhang, Q.; Mayinuo, M.; Huang, L.; Cao, L.; Dong, M., Shipin Kexue 
2011, 32, 107-111. 
172. Ismail, B.; Nampoothiri, K. M., Arch. Microbiol. 2010, 192, 1049-1057. 
173. Tsuda, H.; Miyamoto, T., Food Sci. Technol. Res. 2010, 16, 87-92. 
174. Liu, C.-F.; Tseng, K.-C.; Chiang, S.-S.; Lee, B.-H.; Hsu, W.-H.; Pan, T.-M., J. 
Sci. Food Agric. 2011, 91, 2284-2291. 
175. Blank, G.; Adejumo, A. A.; Zawistowski, J., Lebensm.-Wiss. Technol. 1991, 24, 
231-235. 
176. Henderson, T. O.; McNeill, J. J., Biochem. Biophys. Res. Commun. 1966, 25, 
662-669. 
177. Turujman, N.; Jabr, I.; Durr, I. F., Int. J. Biochem. 1974, 5, 791-793. 
178. Weeks, G.; Wakil, S. J., J. Biol. Chem. 1970, 245, 1913-1921. 
179. Smith, D. D., Jr.; Norton, S. J., Arch. Biochem. Biophys. 1980, 205, 564-570. 
180. Grogan, D. W.; Cronan, J. E., Jr., Microbiol. Mol. Biol. Rev. 1997, 61, 429-441. 
181. Buist, P. H.; MacLean, D. B., Can. J. Chem. 1981, 59, 828-838. 
182. Tocanne, J. F., Tetrahedron 1972, 28, 363-371. 
183. Drucker, D. B.; Megson, G.; Harty, D. W.; Riba, I.; Gaskell, S. J., J. Bacteriol. 
1995, 177, 6304-6308. 
184. Calvano, C. D.; Zambonin, C. G.; Palmisano, F., Rapid Commun. Mass 
Spectrom. 2011, 25, 1757-1764. 
185. Arbogast, L. Y.; Henderson, T. O., J. Bacteriol. 1975, 123, 962-971. 
186. Burritt, M. F.; Henderson, T. O., J. Bacteriol. 1975, 123, 972-977. 
187. Ikawa, M., J. Bacteriol. 1963, 85, 772-781. 
188. Nakano, M.; Fischer, W., Hoppe-Seyler's Z. Physiol. Chem. 1977, 358, 1439-
1453. 
189. Fischer, W.; Nakano, M.; Laine, R. A.; Bohrer, W., Biochim. Biophys. Acta 
1978, 528, 288-297. 
271 
 
190. Fischer, W.; Laine, R. A.; Nakano, M., Biochim. Biophys. Acta 1978, 528, 298-
318. 
191. Zeng, R.-Z.; Kim, H. G.; Kim, N. R.; Gim, M. G.; Ko, M. Y.; Lee, S. Y.; Kim, 
C. M.; Chung, D. K., J. Korean Soc. Appl. Biol. Chem. 2011, 54, 763-770. 
192. Kim, H.; Jung, B. J.; Jung, J. H.; Kim, J. Y.; Chung, S. K.; Chung, D. K., Mol. 
Cells 2012, 33, 479-486. 
193. Kang, S.-S.; Ryu, Y. H.; Baik, J. E.; Yun, C.-H.; Lee, K.; Chung, D. K.; Han, S. 
H., Mol. Immunol. 2011, 48, 2170-2177. 
194. Sauvageau, J.; Ryan, J.; Lagutin, K.; Sims, I. M.; Stocker, B. L.; Timmer, M. S. 
M., Carbohydr. Res. 2012, 357, 151-156. 
195. Molin, G., Am. J. Clin. Nutr. 2001, 73, 380S-385S. 
196. Ahrné, S.; Nobaek, S.; Jeppsson, B.; Adlerberth, I.; Wold, A. E.; Molin, G., J. 
Appl. Microbiol. 1998, 85, 88-94. 
197. Rigaux, P.; Daniel, C.; Hisbergues, M.; Muraille, E.; Hols, P.; Pot, B.; Pestel, J.; 
Jacquet, A., Allergy 2009, 64, 406-414. 
198. Ishikawa, E.; Ishikawa, T.; Morita, Y. S.; Toyonaga, K.; Yamada, H.; Takeuchi, 
O.; Kinoshita, T.; Akira, S.; Yoshikai, Y.; Yamasaki, S., J. Exp. Med. 2009, 206, 
2879-2888. 
199. Cheng, J. M. H.; Khan, A. A.; Timmer, M. S. M.; Stocker, B. L., Int. J. 
Carbohydr. Chem. 2011, Article ID 749591, 13. 
200. Iwamori, M.; Shibagaki, T.; Nakata, Y.; Adachi, S.; Nomura, T., J. Biochem. 
2009, 146, 185-191. 
201. Iwamori, M.; Sakai, A.; Minamimoto, N.; Iwamori, Y.; Tanaka, K.; Aioki, D.; 
Adachi, S.; Nomura, T., J. Biochem. 2011, 150, 515-523. 
202. Zähringer, U.; Lindner, B.; Inamura, S.; Heine, H.; Alexander, C., 
Immunobiology 2008, 213, 205-224. 
203. Shaw, N.; Heatherington, K.; Baddiley, J., Biochem. J. 1968, 107, 491-496. 
204. Wiegandt, H., Glycolipids. Eselvier: London, 1985. 
205. Dubois, M.; Gilles, K. A.; Hamilton, J. K.; Rebers, P. A.; Smith, F., Anal. Chem. 
1956, 28, 350-356. 
206. Dittmer, J. C.; Lester, R. L., J. Lipid Res. 1964, 5, 126-127. 
207. Vaskovsky, V. E.; Kostetsky, E. Y.; Vasendin, I. M., J. Chromatogr. 1975, 114, 
129-141. 
272 
 
208. Doares, S. H.; Albersheim, P.; Darvill, A. G., Carbohydr. Res. 1991, 210, 311-
317. 
209. Cases, M. R.; Cerezo, A. S.; Stortz, C. A., Carbohydr. Res. 1995, 269, 333-341. 
210. Stránský, K.; Jursík, T.; Vítek, A.; Skořepa, J., J. High Resolut. Chromatogr. 
1992, 15, 730-740. 
211. Miwa, T. K.; Mikolajczak, K. L.; Earle, F. R.; Wolff, I. A., Anal. Chem. 1960, 
32, 1739-1742. 
212. Jiang, H.; McGiff, J. C.; Quilley, J.; Sacerdoti, D.; Reddy, L. M.; Falck, J. R.; 
Zhang, F.; Lerea, K. M.; Wong, P. Y.-K., J. Biol. Chem. 2004, 279, 36412-
36418. 
213. McCloskey, J. A.; Law, J. H., Lipids 1967, 2, 225-230. 
214. Carballeira, N. M.; Shalabi, F., J. Nat. Prod. 1994, 57, 1152-1159. 
215. Andersson, B. Å.; Holman, R. T., Lipids 1974, 9, 185-190. 
216. Stuehr, D. J.; Nathan, C. F., J. Exp. Med. 1989, 169, 1543-1555. 
217. Gunstone, F. D.; Harwood, J. L.; Dijkstra, A. J., Nuclear Magnetic Resonnance 
Spectroscopy. In The Lipid Handbook with CD-ROM, CRC press: Boca Raton, 
FL, 2009; pp 455-465. 
218. Kerwin, J. L.; Torvik, J. J., Anal. Biochem. 1996, 237, 56-64. 
219. Kerwin, J. L.; Wiens, A. M.; Ericsson, L. H., J. Mass Spectrom. 1996, 31, 184-
192. 
220. Knothe, G., Lipids 2006, 41, 393-396. 
221. Christie, W. W.; Holman, R. T., Lipids 1966, 1, 176-182. 
222. Guella, G.; Frassanito, R.; Mancini, I., Rapid Commun. Mass Spectrom. 2003, 
17, 1982-1994. 
223. Grimmecke, H. D.; Knirel, Y. A.; Shashkov, A. S.; Kiesel, B.; Lauk, W.; Voges, 
M., Carbohydr. Res. 1994, 253, 277-282. 
224. van Leeuwen, S. S.; Leeflang, B. R.; Gerwig, G. J.; Kamerling, J. P., Carbohydr. 
Res. 2008, 343, 1114-1119. 
225. Bhunia, S. K.; Dey, B.; Maity, K. K.; Patra, S.; Mandal, S.; Maiti, S.; Maiti, T. 
K.; Sikdar, S. R.; Islam, S. S., Carbohydr. Res. 2010, 345, 2542-2549. 
226. Bogle, R. G.; Baydoun, A. R.; Pearson, J. D.; Moncada, S.; Mann, G. E., 
Biochem. J. 1992, 284, 15-18. 
227. Fang, F. C.; Vazquez-Torres, A., Am. J. Physiol. Lung. Mol. Physiol. 2002, 282, 
L941-L943. 
273 
 
228. Utgaard, J. O.; Jahnsen, F. L.; Bakka, A.; Brandtzaeg, P.; Haraldsen, G., J. Exp. 
Med. 1998, 188, 1751-1756. 
229. Reddy, B. S.; Rivenson, A., Cancer Res. 1993, 53, 3914-3418. 
230. Lee, J.-H.; O'Sullivan, D. J., Microbiol. Mol. Biol. Rev. 2010, 74, 378-416. 
231. Tupin, E.; Kinjo, Y.; Kronenberg, M., Nat. Rev. Micro. 2007, 5, 405-417. 
232. Moran, A. P.; Prendergast, M. M.; Appelmelk, B. J., FEMS Immunol. Med. 
Microbiol. 1996, 16, 105-115. 
233. Weintraub, A., Carbohydr. Res. 2003, 338, 2539-2547. 
234. Ho, Y.-P.; Reddy, P. M., Mass Spectrom. Rev. 2010, 30, 1203-1224. 
235. Evason, D. J.; Claydon, M. A.; Gordon, D. B., Rapid Commun. Mass Spectrom. 
2000, 14, 669-672. 
236. Madonna, A. J.; Basile, F.; Ferrer, I.; Meetani, M. A.; Rees, J. C.; Voorhees, K. 
J., Rapid Commun. Mass Spectrom. 2000, 14, 2220-2229. 
237. Claydon, M. A.; Davey, S. N.; Edwards-Jones, V.; Gordon, D. B., Nat. Biotech. 
1996, 14, 1584-1586. 
238. Gidden, J.; Denson, J.; Liyanage, R.; Ivey, D. M.; Lay Jr, J. O., Int. J. Mass 
spectrom. 2009, 283, 178-184. 
239. Fuchs, B.; Schiller, J., Eur. J. Lipid Sci. Technol. 2009, 111, 83-98. 
240. Shu, X.; Li, Y.; Liang, M.; Yang, B.; Liu, C.; Wang, Y.; Shu, J., Int. J. Mass 
Spectrom. 2012, 321-322, 71-76. 
241. Ishida, Y.; Kitagawa, K.; Nakayama, A.; Ohtani, H., Appl. Environ. Microbiol. 
2005, 71, 7539-7541. 
242. Ishida, Y.; Madonna, A. J.; Rees, J. C.; Meetani, M. A.; Voorhees, K. J., Rapid 
Commun. Mass Spectrom. 2002, 16, 1877-1882. 
243. Jones, J. J.; Stump, M. J.; Fleming, R. C.; Lay, J. O.; Wilkins, C. L., J. Am. Soc. 
Mass Spectrom. 2004, 15, 1665-1674. 
244. Jones, J. J.; Stump, M. J.; Fleming, R. C.; Lay, J. O. J.; Wilkins, C. L., Anal. 
Chem. 2003, 75, 1340-1347. 
245. Schumaker, S.; Borror, C. M.; Sandrin, T. R., Rapid Commun. in Mass 
Spectrom. 2011, 26, 243-253. 
246. Gheysen, K.; Mihai, C.; Conrath, K.; Martins, J. C., Chem. Eur. J. 2008, 14, 
8869-8878. 
247. Hoelzl, G.; Doermann, P., Prog. in Lipid Res. 2007, 46, 225-243. 
274 
 
248. Huang, Y.; Zhao, N.; He, L.; Wang, L.; Liu, Z.; You, M.; Guan, F., J. Clin. 
Microbiol. 2005, 43, 1451-1455. 
249. Marlow, A. L.; Kiessling, L. L., Org. Lett. 2001, 3, 2517-2519. 
250. McConville, M. J.; Thomas-Oates, J. E.; Ferguson, M. A. J.; Homans, S. W., J. 
Biol. Chem. 1990, 265, 19611-19623. 
251. Gorin, P. A. J.; Mazurek, M., Can. J. Chem. 1975, 53, 1212-1223. 
252. Sassaki, G. L.; Iacomini, M.; Gorin, P. A. J., An. Ac. Br. Cien. 2005, 77, 223-
234. 
253. Wieneke, R.; Klein, S.; Geyer, A.; Loos, E., Carbohydr. Res. 2007, 342, 2757-
2765. 
254. Caruso, U., Rapid Commun. Mass Spectrom. 1996, 10, 1283-1285. 
255. Yachida, Y.; Kashiwagi, M.; Mikami, T.; Tsuchihashi, K.; Daino, T.; Akino, T.; 
Gasa, S., J. Lipid Res. 1998, 39, 1039-1045. 
256. Yachida, Y.; Kashiwagi, M.; Mikami, T.; Tsuchihashi, K.; Daino, T.; Akino, T.; 
Gasa, S., J. Lipid Res. 1999, 40, 2271-2278. 
257. Hikita, T.; Tadano-Aritomi, K.; Iida-Tanaka, N.; Anand, J. K.; Ishizuka, I.; 
Hakomori, S. I., J. Biol. Chem. 2001, 276, 23084-23091. 
258. Matsumoto, M.; Tamiya, K.; Koizumi, K., J. Biochem. 1971, 69, 617-620. 
259. Johnston, N. C.; Goldfine, H., Eur. J. Biochem. 1994, 223, 957-963. 
260. Johnston, N. C.; Goldfine, H., Biochim. Biophys. Acta 1988, 961, 1-12. 
261. Lee, J.; Jung, S.; Lowe, S.; Zeikus, J. G.; Hollingsworth, R. I., J. Am. Chem. 
Soc. 1998, 120, 5855-5863. 
262. Fujiwara, Y., Biochim. Biophys. Acta 2008, 1781, 519-524. 
263. Goldfine, H., Prog. Lipid Res. 2010, 49, 493-498. 
264. Young, S. L.; Simon, M. A.; Baird, M. A.; Tannock, G. W.; Bibiloni, R.; 
Spencely, K.; Lane, J. M.; Fitzharris, P.; Crane, J.; Town, I.; Addo-Yobo, E.; 
Murray, C. S.; Woodcock, A., Clin. Diagn. Lab. Immunol. 2004, 11, 686-690. 
265. Gore, C.; Munro, K.; Lay, C.; Bibiloni, R.; Morris, J.; Woodcock, A.; Custovic, 
A.; Tannock, G. W., J. Allergy Clin. Immunol. 2008, 121, 135-140. 
266. Ouwehand, A. C., J. Nutr. 2007, 137, 794S-797S. 
267. Suzuki, S.; Shimojo, N.; Tajiri, Y.; Kumemura, M.; Kohno, Y., Clin. Exp. 
Allergy 2007, 37, 506-511. 
268. He, F.; Morita, H.; Ouwehand, A. C.; Hosoda, M.; Hiramatsu, M.; Kurisaki, J.-
I.; Isolauri, E.; Benno, Y.; Salminen, S., Microbiol. Immunol. 2002, 46, 781-785. 
275 
 
269. Sauvageau, J.; Foster, A. J.; Khan, A. A.; Chee, S. H.; Lagutin, K.; Ryan, J.; 
Sims, I. M.; Timmer, M. S. M.; Stocker, B. L., ChemBioChem 2012, 13, 2416-
2424. 
270. Dangerfield, E. M.; Cheng, J. M. H.; Knight, D. A.; Weinkove, R.; Dunbar, P. 
R.; Hermans, I. F.; Timmer, M. S. M.; Stocker, B. L., ChemBioChem 2012, 13, 
1349-1356. 
271. Morath, S.; von Aulock, S.; Hartung, T., J. Endotoxin Res. 2005, 11, 348-356. 
272. Westphal, O.; Luederitz, O.; Keiderling, W., Zentralbl. Bakteriol. Parasitenkd. 
Infektionskr. Hyg. 1952, 158, 152-160. 
273. Cuthbertson, L., Lipopolysaccharide biosynthesis. In Bacterial Glycomics: 
Current Research, Technology and Applications:, Reid, C. W.; Twine, S. M.; 
Reid, A. N., Eds. Caister Academic Press: Norwich, UK, 2012; pp 1-25. 
274. Jang, K.-S.; Baik, J. E.; Kang, S.-S.; Jeon, J. H.; Choi, S.; Yang, Y.-H.; Kim, B.-
G.; Yun, C.-H.; Han, S. H., Mol. Immunol. 2012, 50, 177-183. 
275. Kusumoto, S.; Fukase, K.; Suda, Y.; Oikawa, M., J. Synth. Org. Chem., Jpn. 
1996, 54, 976-987. 
276. Pedersen, C. M.; Figueroa-Perez, I.; Lindner, B.; Ulmer, A. J.; Zähringer, U.; 
Schmidt, R. R., Angew. Chem., Int. Ed. 2010, 49, 2585-2590. 
277. Op den Camp, H. J. M.; Veerkamp, J. H.; Oosterhof, A.; Van Halbeek, H., 
Biochim. Biophys. Acta 1984, 795, 301-313. 
278. Gein, S. V.; Kuyukina, M. S.; Ivshina, I. B.; Baeva, T. A.; Chereshnev, V. A., 
Cytotechnology 2011, 63, 559-566. 
279. Hamamoto, S.; Takaku, H., Chem. Lett. 1986, 15, 1401-1404. 
280. Baldoni, L.; Marino, C., J. Org. Chem. 2009, 74, 1994-2003. 
281. Hirth, G.; Walther, W., Helv. Chim. Acta. 1985, 68, 1863-1871. 
282. Eibl, H., Chem. Phys. Lipids 1981, 28, 1-5. 
283. Lok, C. M.; Ward, J. P.; van Dorp, D. A., Chem. Phys. Lipids 1976, 16, 115-
122. 
284. Gola, G.; Libenson, P.; Gandolfí-Donadio, L.; Gallo-Rodriguez, C., ARKIVOC 
2005, 12, 234-242. 
285. D'Accorso, N. B.; Thiel, I. M. E.; Schueller, M., Carbohydr. res. 1983, 124, 
177-184. 
286. Pathak, A. K.; El-Kattan, Y. A.; Bansal, N.; Maddry, J. A.; Reynolds, R. C., 
Tetrahedron Lett. 1998, 39, 1497-1500. 
276 
 
287. Marino, C.; Cancio, M. J.; Varela, O.; de Lederkremer, R. M., Carbohydr. res. 
1995, 276, 209-213. 
288. Olah, G. A.; Narang, S. C., Tetrahedron 1982, 38, 2225-2277. 
289. Bartolmäs, T.; Heyn, T.; Mickeleit, M.; Fischer, A.; Reutter, W.; Danker, K., J. 
Med. Chem. 2005, 48, 6750-6755. 
290. Petri, A. F.; Bayer, A.; Maier, M. E., Angew. Chem. Int. Ed. 2004, 43, 5821-
5823. 
291. Yang, W.-B.; Patil, S. S.; Tsai, C.-H.; Lin, C.-H.; Fang, J.-M., Tetrahedron 
2002, 58, 253-259. 
292. Krotz, A. H.; Wheeler, P.; Ravikumar, V. T., Angew. Chem., Int. Ed. 1995, 34, 
2406-2409. 
293. Guanti, G.; Banfi, L.; Basso, A.; Bondanza, L.; Guglieri, G.; Powles, K.; Riva, 
R., Amino Acids 2010, 39, 367-373. 
294. Sureshan, K. M.; Riley, A. M.; Potter, B. V. L., Tetrahedron Lett. 2007, 48, 
1923-1926. 
295. Chen, J.; Feng, L.; Prestwich, G. D., J. Org. Chem. 1998, 63, 6511-6522. 
296. Sen, A.; Williams, W. P.; Brain, A. P. R.; Dickens, M. J.; Quinn, P. J., Nature 
1981, 293, 488-490. 
297. Gibson, B. W.; Engstrom, J. J.; John, C. M.; Hines, W.; Falick, A. M., J. Am. 
Soc. Mass Spectrom. 1997, 8, 645-658. 
298. Sutcliffe, I. C.; Hogg, S. D., J. Microbiol. Methods 1993, 17, 215-225. 
299. Rundlöf, T.; Widmalm, G., Anal. Biochem. 1996, 243, 228-233. 
300. Kim, J.-H.; Nishida, Y.; Ohrui, H.; Meguro, H., J. Carbohydr. Chem. 1995, 14, 
889-893. 
301. Nishida, Y.; Ohrui, H.; Meguro, H., Tetrahedron Lett. 1989, 30, 5277-5280. 
302. Kadota, I.; Yamagami, Y.; Fujita, N.; Takamura, H., Tetrahedron Lett. 2009, 50, 
4552-4553. 
303. Borbás, A.; Szabó, Z. B.; Szilágyi, L.; Bényei, A.; Liptàk, A., Carbohydr. Res. 
2002, 337, 1941-1951. 
304. Parhi, A. K.; Mootoo, D. R.; Franck, R. W., Tetrahedron 2008, 64, 9821-9827. 
 
 
